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Summary 
 
Ero1α is a resident ER oxidase and is an important member of the oxidative protein folding 
machinery. It generates disulphide bonds de novo and donates them to protein disulphide 
isomerase (PDI), which in turn oxidises nascent substrate proteins within the ER. Ero1 
activity must be tightly regulated for two key reasons: (i) it must maintain the balance of 
oxidised PDI to ensure oxidative protein folding can occur, but cannot be so active that the 
ER becomes hyperoxidising and dysfunctional, and (ii) Ero1 activity must be regulated to 
prevent the accumulation of hydrogen peroxide, a reactive oxygen species (ROS), within 
the ER. The regulation of Ero1α comes principally from 3 intramolecular disulphide bonds 
which are reduced by substrate upon activation, and re-oxidised upon inactivation by an 
unknown mechanism. Using an SDS-PAGE based assay we tested three hypotheses: that 
sulphenylation by Ero1α-produced hydrogen peroxide could induce re-oxidation; that an 
internal disulphide exchange mechanism could generate and distribute disulphide bonds 
within Ero1α; and that ER oxidoreductases could act to inactivate Ero1α. Having 
successfully expressed, purified and characterised a recombinant version of Ero1α, this 
was tested in a number of assays to address the above hypotheses. 
In vitro findings show that Ero1α is specifically and rapidly oxidised by ERp46 and PDI. 
Sulphenylation and internal disulphide exchange-mediated oxidation of Ero1α provided a 
comparatively slow and incomplete method of re-oxidation. In vivo results suggest that 
ERp46 and PDI may have implications in Ero1α activity regulation. Overexpression of 
several ER oxidoreductases had no effect on Ero1α re-oxidation after DTT challenge, 
whereas Ero1α oxidation was impaired slightly in PDI- ERp46 double knockdown cells. 
Depletion of PDI from cells results in the DTT-resistance of Ero1α, suggesting that Ero1α, 
PDI and glutathione are involved in an intricate mechanism of sensing and reacting to ER 
redox conditions. 
Two key ER oxidoreductases, PDI and ERp57, are oxidised in semi-permeabilised cells. 
Oxidation coincides with permeabilisation of the plasma membrane and the removal of 
cytosolic glutathione, directly implicating glutathione in the maintainence of the redox 
states of ER oxidoreductases. Oxidation during the permeabilisation of cells is an 
enzymatic process which is mediated in part by Ero1α. Semi-permeabilised cells harbour a 
more oxidising environment than do microsomes.  
This study contributes significantly to the research field by complementing several 
previously reported findings, as well as providing a novel investigation into the molecular 
regulation of Ero1α and its relationship with PDI and glutathione in the cell.
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CHAPTER 1.0 
Introduction 
 
Proteins are essential to the workings of cells and biological processes. They perform a 
variety of functions and roles, from providing physical strength and support in the case of 
actin, myosin and tubulin, to carrying oxygen around the body in the case of haemoglobin. 
Integral to the functioning of a protein is its native three-dimensional structure – this must 
be adopted otherwise enzymatic activity is abolished. The primary structure of proteins 
initially has no defined secondary or tertiary structure and is deemed to be in a random coil 
state. Hydrogen bonding between amino acids in the polypeptide backbone is facilitated by 
multiple C=O and N-H groups and this form of bonding gives the primary sequence a 
degree of rigidity and stability. Hydrogen bonding in the backbone can result in α-helical 
(Pauling and Corey, 1951a), or β-sheet structure (Pauling and Corey, 1951b). These 
structures, termed secondary structure, contribute to the natively folded protein. A further 
driving force in protein folding is hydrophobicity. Hydrophobic amino acids favour an 
environment free of water and so tend to cluster together in the middle of the protein where 
hydrophobic interactions stabilise the conformation, allowing hydrophilic amino acids to 
interact with the water-based surrounding environment. These interactions drive the 
folding of proteins and allow the adoption of their unique tertiary and quaternary structure, 
thus facilitating functionality. 
Disulphide bonds provide an extra degree of structural stabilisation and form between the 
side chain sulphydryl groups of two cysteine residues. Disulphide bonds also help proteins 
form tertiary and quaternary structure, effectively pinning parts of the molecule together. 
Many disulphide-containing proteins will not function until the correct disulphide bonds 
are formed within the molecule; an indication of their importance. Furthermore, studies 
have shown that cells deficient in disulphide formation are sensitive to stresses. Disulphide 
bonds are formed in proteins destined for life in the extracellular environment or within the 
plasma membrane. Due to their covalent nature they have increased stability and 
specialised function compared to hydrogen bonding or hydrophobic interactions. 
Disulphides are introduced into proteins in a specific process called oxidative protein 
folding; a pathway involving many enzymes which are conserved in eukaryotes. A number 
of diseases, such as ischemia, Parkinson’s, Creutzfeldt-Jakob disease (CJD) and various 
forms of Alzheimer’s, are linked to the misfolding of proteins. It is therefore crucial that 
proteins are folded and function correctly to avoid these debilitating diseases. 
1.1 Oxidative protein folding 
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1.1.1 Disulphide bond formation. 
Disulphide bond formation in proteins was first discovered to be a product of air oxidation 
(Anfinsen et al., 1961). Anfinsen used the model protein ribonuclease to investigate 
disulphide bond formation after treatment with β-mercaptoethanol and urea. This treatment 
leaves the enzyme in a reduced and denatured state with no ribonuclease activity. After 
removal of the reducing and denaturation agents, activity of the enzyme was followed as 
an indication of the folding status. The study showed that ribonuclease activity returns 
slowly over the course of 10-20 hours, suggesting that the native disulphide bonds have re-
formed. Considering the kinetic data collected in this study, the authors concluded that 
disulphides can form by air oxidation and that the rearrangement of incorrectly formed, or 
non-native, disulphides is driven thermodynamically. However, in reality this mechanism 
of disulphide bond formation is too slow given the particular demands placed on the 
endoplasmic reticulum within secretory cells and tissues. The cell has therefore evolved a 
highly efficient and extremely specialised oxidative protein folding pathway which can 
provide the disulphide bonds, and proteins, required to allow the cell to survive and thrive 
in its environment, while at the same time maintaining fidelity. This function is provided 
by the endoplasmic reticulum (ER). 
1.1.2 Oxidative protein folding; the role of the ER. 
Secretory proteins differ from cytosolic proteins in that they need an extra degree of 
folding and stability to survive in the harsh extracellular environment. Secretory proteins 
usually contain an N-terminal signal sequence which directs them to the ER. This N-
terminal signal sequence is hydrophobic in nature and binds to the signal recognition 
particle (SRP). SRP stalls translation and chaperones the ribosome-mRNA complex to the 
ER membrane where it interacts with the Sec translocon. Here SRP dissociates, translation 
re-starts and the nascent protein is co-translationally translocated through the Sec 
translocon pore into the ER lumen (Swanton and Bulleid, 2003). The ER is a highly 
specialised compartment which promotes protein folding and ensures that proteins exiting 
this organelle are folded correctly and appropriately glycosylated before being released 
from the cell. 
One particular property of the ER that contributes significantly to the protein folding 
process and differentiates this compartment from the cytosol is the physico-chemical 
composition. The ER environment is considerably more oxidising due to the glutathione 
composition and contains a relatively high concentration of calcium. Calcium is known to 
be stored within the ER at high concentrations of up to 1mM (Somlyo et al., 1985, 
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Meldolesi and Pozzan, 1998), and is actively pumped into the ER by calcium ion pumps 
(reviewed by (Moller et al., 2010)). Calcium is essential for the correct folding of many 
proteins within the ER such as the asialoglycoprotein receptor (Lodish et al., 1992) and α-1 
antitrypsin (Cooper et al., 1997, Lodish and Kong, 1990). With a perturbed calcium 
content, these proteins are misfolded and do not move through the secretory pathway. 
Many of the resident chaperones and protein folding enzymes contained within the ER 
have been shown to bind calcium; GRP94 is thought to have 15 calcium binding sites (Van 
et al., 1989). The binding of calcium triggers a conformational change which is thought to 
regulate its activity (Van et al., 1989). Other ER resident proteins known to bind calcium 
include GRP78/BiP, p50, PDI, ERp72, and calreticulin (Nigam et al., 1994). In a low 
calcium environment calreticulin is susceptible to proteolysis which indicates that calcium 
is needed for the enzyme to fold correctly (Corbett et al., 2000). Furthermore, PDI was 
found to bind calreticulin at low calcium concentrations, resulting in impaired PDI activity 
(Baksh et al., 1995). This binding is reversible upon increasing calcium concentrations and 
is coupled to an increase in PDI activity. The binding of ERp57 to calreticulin enhances 
ERp57 activity (Zapun et al., 1998) and is mediated by the binding of calcium to 
calreticulin (Corbett et al., 1999). Calcium therefore plays an essential role with regards to 
mediating activity of the folding enzymes and molecular chaperones provided by the ER. 
Without the high concentrations of calcium many chaperones fail to function, leading to 
protein misfolding. This is one specific way in which the ER provides a highly specialised 
environment to catalyse protein folding. 
As well as providing a calcium rich environment, the ER also contains another protein 
folding aide – the tripeptide glutathione. Glutathione is present in the cytoplasm as well as 
the ER, although the ratios of the two redox forms of glutathione differ between the 
compartments. Glutathione contains a redox active cysteine residue which, in its free thiol 
state, classifies the reduced species (GSH). This free thiol can form a disulphide with the 
thiol of a cysteine within another glutathione molecule forming the oxidised species 
glutathione disulphide (GSSG). The cytoplasmic redox conditions are reducing 
(Ostergaard et al., 2004) compared to the ER and as a result disulphide formation generally 
does not occur here (Hwang et al., 1992). This is explained largely by the cytosolic 
glutathione ratio, the ratio of reduced to oxidised glutathione (GSH: GSSG), of between 
10:1 and 100:1 which creates a redox potential of around -220 mV (Hwang et al., 1992). 
By comaparison, the glutathione ratio in the ER is between 1:1 and 3:1 creating a redox 
potential of around -170 mV (Hwang et al., 1992). This low ratio of GSH: GSSG is very 
close to the optimal ratio for oxidative protein folding determined in vitro to be 5:1 (Lyles 
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and Gilbert, 1991). Glutathione was, therefore, thought to be the source of oxidising 
equivalents for disulphide formation (Hwang et al., 1992). However, evidence is mounting 
to suggest it actually balances the oxidative activity of Ero1 and has been shown to 
facilitate protein folding in a novel way. It creates the necessary reducing pathway to 
support isomerisation (Chakravarthi and Bulleid, 2004), and maintains some of the folding 
catalysts in the reduced state required for their roles in their respective pathways (Jessop 
and Bulleid, 2004) . What is less well known is how this ratio of glutathione is maintained 
within the ER. The enzymes involved in glutathione synthesis are located within the 
cytosol and so some mechanism of transport must exist to import it into the ER. GSH 
uptake across microsomal membranes has been shown, however the membrane was 
impermeable to GSSG (Banhegyi et al., 1999). Contradictory studies have shown that 
radiolabelled GSSG can cross the membrane in a seemingly selective manner (Hwang et 
al., 1992) and so there is still a debate as to the mechanism of glutathione transport into the 
ER and the creation of the glutathione-based oxidising redox environment. 
The ER provides a specialised environment in which secretory proteins can adopt their 
native conformation prior to secretion. The ER houses the folding factors such as PDI, 
calnexin and calreticulin and harbours a physico-chemical environment distinct from the 
cytosol as calcium and oxidised glutathione levels are elevated. While the glutathione 
transport mechanism is not well characterised, the mechanism of retention of the ER-
resident enzymes has been studied.  This mechanism retains the protein folding machinery 
in this organelle thus facilitating ER function. 
1.1.3 ER-resident proteins are retained within the compartment. 
As the ER forms part of the secretory system, it is a thoroughfare for each nascent protein 
destined either for plasma membrane incorporation or for secretion. As such, there is a net 
movement of proteins from the cytosol to the ER, Golgi and on to the respective 
destinations in an anterograde fashion. While this movement is necessary for cargo 
proteins, the ER-resident enzymes must be kept within the ER in order to function. An 
elegant mechanism of protein retrieval from the Golgi has evolved in order to facilitate 
ER-retention and is based on two essential components, the KDEL retrieval motif and the 
KDEL receptor (Erd2). The KDEL motif and receptor work together to provide retrograde 
movement, preventing ER-residents from travelling further along the secretory pathway. 
The KDEL motif is located at the C-terminus and without it bona-fide ER-resident proteins 
are no longer retained in the ER (Munro and Pelham, 1987). Similarly, incorporating the 
KDEL sequence into the C-terminus of non-ER resident proteins results in their retention 
(Munro and Pelham, 1987). The KDEL sequence is so called as it contains lysine-
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aspartate-glutamate-leucine although there are slight variations of the sequence that still 
facilitate retention; for example RDEL allows the localisation of  ERp44 to the ER (Anelli 
et al., 2003). The motif is charged and so is affected by pH which is central to the retention 
mechanism – the KDEL receptor binds the KDEL ligand under acidic conditions and 
releases it in neutral conditions (Wilson et al., 1993). The pH within the ER is thought to 
be approximately neutral while the Golgi is more acidic (Anderson and Pathak, 1985) thus 
a pH gradient is created (Wu et al., 2001). The KDEL receptor therefore binds its ligand in 
the relatively acidic Golgi before the complex associates with the retrograde transport 
machinery (Aoe et al., 1998) and is directed back towards the ER. Once the complex 
reaches the ER, the neutral pH causes its dissociation resulting in the release of the ligand-
containing ER-resident enzyme and the release of the receptor. The receptor then moves on 
in an anterograde fashion to the Golgi where it can associate once more with the KDEL 
ligand, completing the retrieval cycle (Figure 1.1). This provides an effective mechanism 
for the retention of essential ER-resident enzymes. 
Not all ER-resident proteins contain the KDEL sequence, however, and are retained within 
the ER by other mechanisms. One such process is the di-lysine and di-arginine mechanism 
that exists in ER integral membrane proteins. Type I integral membrane proteins, which 
have a luminal N-terminus, containing a C-terminal di-lysine motif are thought to be 
retrieved from the Golgi as they remain ER-localised with Golgi-modifications (Jackson et 
al., 1993, Nilsson et al., 1989). Type II integral membrane proteins, with a luminal C-
terminus, are thought to be retrieved and retained within the ER by an N-terminal di-
arginine motif (Schutze et al., 1994). The di-lysine and di-arginine motifs do not exist 
exclusively in type I and type II proteins respectively, as evidence suggests that some type 
I proteins may contain the di-arginine motif. Calnexin is an example of a type I protein 
retained by a C-terminal di-arginine motif (Rajagopalan et al., 1994). The di-lysine motif is 
known to interact with the coatomer complex present in COP I coated vesicles (Cosson and 
Letourneur, 1994) and so this provides a method to return ER resident proteins to the ER. 
One further mechanism of ER-retention is thought to involve the exclusion of ER-resident 
proteins from transport – where protein complexes or oligomers are thought to form a 
molecule too large to be physically incorporated in or transported into vesicles. This was 
shown to be the case with N-acetylglucosaminyltransferase I (GlcNAc-TI) when it was 
attached to an ER retention motif. ER-retained GlcNAc-TI bound to mannosidase II and 
mediated the retention of the heterodimeric complex within the ER (Nilsson et al., 1996). 
1.1.4 Quality control in the ER. 
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Figure 1.1 – The KDEL system retains ER residents within the ER. ER resident proteins 
containing the C-terminal KDEL signal are maintained within the ER via interaction with 
the KDEL receptor. At neutral pH the KDEL sequence and the receptor dissociate, allowing 
movement of ER residents alongside cargo proteins towards the Golgi in anterograde 
transport vesicles. The Golgi harbours a comparatively lower pH which favours re-
association of the KDEL sequence with its receptor. The re-associated complex then 
moves back towards the ER in retrograde transport vesicles before disassociating in the 
neutral pH. 
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An ER quality control (QC) mechanism exists to ensure that nascent proteins leave the ER 
in their native conformation. This is a highly specialised system which ensures that non-
native proteins do not escape the ER as they are non-functional, may provide a source of 
toxicity and are more prone to aggregation. The quality control system can differentiate 
between folded and unfolded proteins, and directs them for either further folding or 
degradation. Nascent proteins first of all bind ER chaperones, or folding factors, such as 
BiP. At this stage the folding factors collectively serve three purposes - they bind exposed 
hydrophobic patches and prevent unwanted hydrophobic interactions; they prevent the 
degradation of unfolded proteins; and due to their ER-retention motifs, interaction with 
them mediates retention in the ER thus preventing release of immature proteins (Bottomley 
et al., 2001). 
In the case of glycoproteins, the primary sequence is first of all scanned by the ER-luminal 
oligosaccharyltransferase (OST) which adds an N-glycan to asparagines in the consensus 
sequence Asn-X-Ser/Thr. The structure of the glycan initially linked to the asparagine 
residue has two N-acetylglucosamines, nine mannose residues and three glucose residues. 
Two of the glucose residues are removed by glycanases which then allows the binding of 
lectins calnexin and calreticulin, while removal of the third clears the protein for release 
from the ER as a fully folded and mature product. UDP-glucose:glycoprotein 
glucosyltransferase (UGGT) acts as a folding sensor and can add back the terminal glucose 
residue if the protein has been released by the lectins prematurely – promoting their re-
association (Solda et al., 2007). Thus, the glycan structure signifies the folding state of the 
protein and can recruit help if required. 
Terminally misfolded proteins are subject to the process of endoplasmic reticulum-
associated degradation (ERAD) (McCracken and Brodsky, 1996). It is thought that specific 
folding factors have a role in ERAD substrate recognition (Denic et al., 2006); without BiP 
ER quality control is compromised (Mimura et al., 2008). Other enzymes proposed to play 
a role in quality control and ERAD substrate recruitment are slow-working mannosidases, 
which are suggested to target terminally misfolded proteins to ERAD due to their increased 
time spent within the ER (Fagioli and Sitia, 2001). In addition to this, overexpression of 
ER mannosidase 1 enhances degradation of a misfolded antitrypsin (Hosokawa et al., 
2003). A similar effect is seen with the ER degradation enhancing α-mannosidase-like 
protein (EDEM1) (Hosokawa et al., 2001). It is thought that EDEM1 may bind terminally 
misfolded proteins in place of the UGGT/calnexin/calreticulin complex to direct the 
substrate to ERAD (Molinari et al., 2003). Although ERAD substrate recognition is 
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Figure 1.2 – Endoplasmic reticulum-associated degradation targets misfolded proteins for 
degradation. Misfolded proteins within the ER attract folding factors such as BiP to 
prevent aggregation. Terminally misfolded proteins interact with the ERAD targeting 
factors such as EDEM1 which binds and cleaves N-glycans. The cleaved glycan is thought 
to act as the signal which targets proteins to ERAD. ERdj5 is thought to reduce disuphides 
prior to retrotranslocation through the retrotranslocon to the cytosol. Once the ERAD 
substrate reaches the cytosol it is ubiquitinated before degradation in the proteasome. 
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incompletely understood, it is likely to involve a number of mechanisms due to the 
importance of preventing the build-up of misfolded proteins in the ER. This would provide 
a fail-safe recruitment mechanism where one system could intervene if another fails. 
Once targeted for ERAD, substrates must be retrotranslocated into the cytosol where 
degradation occurs via the 26S proteasome. Recent evidence has shown that the ER 
localised protein ERdj5 is required to reduce targeted substrates to facilitate passage 
through the ER membrane (Ushioda et al., 2008). To then target the ERAD substrate to the 
retrotranslocon, homoCys-responsive ER-resident protein (HERP) has been implicated. 
HERP is thought to form a complex with BiP, derlin-1 (a potential retrotranslocon 
component), non-glycosylated ERAD substrates and the proteasome (Okuda-Shimizu and 
Hendershot, 2007). EDEM1 is thought to interact with further possible retrotranslocon 
components derlin-2 and derlin-3, which provides a link between the ERAD targeting 
enzymes and the retrotranslocon (Oda et al., 2006). Once the misfolded proteins have been 
identified for ERAD and unfolded, they are translocated through the retrotranslocon for 
ubiquitination and degradation. The composition of the retrotranslocon itself remains 
undefined. There are several candidates, the membrane-associated ATPase enzyme p97 is 
thought to extract ER membrane proteins and target them for proteasome degradation (Ye 
et al., 2001), while derlin-1 (Lilley and Ploegh, 2004, Ye et al., 2004) and PA700, the 
proteasomal regulatory complex, both promote translocation of an ERAD substrate 
(Wahlman et al., 2007, Ye et al., 2005). Derlin-2 is also thought to form a part of the 
translocon as its absence prevents retrotranslocation (Dougan et al., 2011); absence of 
derlin-3 prevents degradation of substrates (Oda et al., 2006). There is also evidence to 
suggest that the Sec61 complex may be involved in this process as it has been implicated in 
retrotranslocation of MHC class I (Wiertz et al., 1996) and glycopeptides (Gillece et al., 
2000). 
Following retrotranslocation from the ER, ERAD substrates undergo polyubiquitination 
prior to degradation. Ubiquitination is thought to involve an E2/E3 ubiquitin ligase enzyme 
complex. This complex, in mammals, is thought to include Ube2g2, an E2 ubiquitin-
conjugating enzyme, and gp78, an E3 ubiquitin ligase (Chen et al., 2006). Disruption of the 
interaction between these two proteins results in the accumulation of substrates within the 
ER. Human Hrd1 has also been suggested to play the role of the E3 ligase (Kikkert et al., 
2004). Taken together, this evidence is suggestive of a complex of various proteins, both 
integral to the ER membrane and soluble, which works to carry out the function of ERAD; 
that is the targeting, unfolding, retrotranslocation and ubiquitinylation of misfolded 
proteins prior to degradation by the proteasome (Figure 1.2).  
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1.1.5 The protein disulphide isomerase family. 
In order to prevent the misfolding of client proteins and their degradation by ERAD, the 
ER contains a number of enzymes that carry out a range of functions all with the goal of 
promoting protein folding and introducing disulphide bonds. A subsection of these 
enzymes, named oxidoreductases or PDI family members, is illustrated in Figure 1.3A. 
There have been over 20 oxidoreductases identified so far, all with varying functions. They 
do all, however, have one property in common – they possess one or more thioredoxin-like 
motifs. These motifs are based on the structure of the small cytosolic redox-active protein 
thioredoxin, which contains a five-stranded β-sheet with four flanking α-helices (Holmgren 
et al., 1975). Thioredoxin itself is a relatively small protein of around 110 amino acids and 
is very highly conserved throughout archaea, prokaryotes and eukaryotes. It functions as a 
disulphide reductant within the cytosol as it has a redox-active CxxC motif which can exist 
in either the dithiol or disulphide state. Thioredoxin reductase maintains thioredoxin in the 
reduced state so that thioredoxin can act as a reductase and reduce interacting proteins 
(Holmgren and Morgan, 1976). The ER oxidoreductases contain a thioredoxin fold which 
is slightly smaller than the thioredoxin protein; it contains a four-stranded β-sheet with 
three flanking α-helices. These domains can be seen in Figure 1.3B. Other enzymes known 
to include this fold are redox active, including glutaredoxin, glutathione S-transferase, 
DsbA, and glutathione peroxidase. The ER oxidoreductases, however, are not exclusively 
redox active. There are members of the family which cannot participate in disulphide 
transfer as they do not have a CxxC motif. These enzymes are generally not well studied, 
however there are known roles for PDILT and ERp44. PDILT is known to be expressed 
only in the testes and contains two modified CxxC motifs; SKQS and SKKC (van Lith et 
al., 2005). PDILT interacts with substrate proteins and Ero1 via its only active site 
cysteine, and is essential for the correct folding of ADAM3 - a protein essential for sperm 
migration and binding of the zona pellucida (Tokuhiro et al., 2012). ERp44 is known to 
interact with Ero1α and substrate proteins to retain them in the ER (Anelli et al., 2003) via 
its CRFS motif cysteine. In other PDI family members the CxxC active site motif is intact 
and provides the characteristic redox functionality required by the ER. The PDI family 
members catalyse the oxidative folding of cargo protein by introducing native disulphides 
between proximal thiols within their primary structure via a dithiol disulphide exchange 
reaction. This function was first observed by experiments carried out in 1963 (Goldberger 
et al., 1963) which showed, in vitro, that ribonuclease A was oxidised and activated at an 
increased rate in the presence of microsomes. This finding led to the identification of PDI – 
an enzyme which catalysed the formation of disulphides within ribonuclease A as well as 
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the reduction and rearrangement of incorrect disulphides. This was the first evidence to 
suggest that disulphide formation within proteins was catalysed, rather than driven by the 
polypeptide primary sequence as suggested previously (Anfinsen et al., 1961). 
Characterisation of PDI followed these experiments and a large body of evidence was 
collected implicating this enzyme in thiol-disulphide exchange. A 1967 study showed that 
PDI, upon reduction and alkylation, was inactivated (Fuchs et al., 1967). This suggested 
that PDI contained redox-active cysteine residues which were blocked by thiol-reactive 
alkylating agents. Furthermore, incubation of purified PDI with Cd
2+
 ions also caused 
inhibition of enzymatic activity, consistent with proteins of similar activity (Hillson and 
Freedman, 1980). The primary sequence of PDI was finally elucidated in 1985 and was 
found two contain two domains homologous to thioredoxin. These two homologous 
domains contain the CGHC active site motifs which give PDI its redox activity (Edman et 
al., 1985). PDI was subsequently shown to catalyse disulphide formation and isomerisation 
of a wide range of substrates in vitro (Bulleid and Freedman, 1988, Freedman et al., 1989). 
In vivo evidence for the role of PDI in oxidative protein folding came in 1995 when a yeast 
knockout study revealed that the essential function of PDI is to isomerise non-native 
disulphides (Laboissiere et al., 1995). In this study the Δpdi1 S. cerevisiae mutant, first 
shown to be lethal by Scherens et al. (Scherens et al., 1991), was complemented with PDI 
cDNA constructs carrying mutations in the CGHC active site motifs to regain viability. 
Laboissiere et al. used a CGHS PDI mutant with impaired oxidase and reductase activity, 
and a SGHC mutant with impaired oxidase, reductase and isomerase activity. They found 
that the CGHS mutant restored viability in yeast, suggesting that the isomerase function of 
PDI is necessary for viability of S. cerevisiae. Mutations in the active sites also result in 
sensitivity to the reducing agent dithiothreitol (DTT) in yeast (Holst et al., 1997), 
suggesting that PDI is also important for disulphide formation. 
Evidence for the direct involvement of PDI in oxidative protein folding was found in 1999. 
The yeast form of PDI was found in disulphide linked heterodimers with the ER oxidase 
Ero1p in vivo, resulting in the oxidation of PDI. PDI was then found in a mixed-disulphide 
complex with carboxypeptidase Y (CPY) implying that PDI either oxidises or isomerises 
CPY. A PDI knockout yeast mutant shows impaired CPY oxidation suggesting that PDI is 
important in the oxidative folding of this protein. This study concluded that there is a direct 
transfer of disulphide bonds from Ero1p to PDI and on to secretory proteins in the ER, for 
example CPY (Frand and Kaiser, 1999). In mammalian cells, Ero1α was shown to interact 
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Figure 1.3 – The PDI family are based on the thioredoxin motif. A – A small subsection of 
the PDI family is represented schematically. Each member has at least one domain 
homologous to the thioredoxin fold (blue box). The domain structures of PDI, ERp57, 
ERp46 and ERp44 are shown as are the active site sequences of each redox active 
domain. B – The structure of S. cerevisiae PDI illustrates the overall structure of the 
molecule and the four domains based on the thioredoxin motif. The domains are as 
follows: a (red), b (green), b′ (blue) and a′ (purple). The x-linker region is depicted in 
yellow. Note the classical V-shaped structure typical of the oxidoreductases. 
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with PDI and formed a disulphide linked complex (Benham et al., 2000) following the 
identification of Ero1α (Cabibbo et al., 2000). 
In addition to these oxidase and isomerase functions, PDI has since been shown to interact 
with and form mixed disulphides with PrxIV (Tavender et al., 2010) and VKOR (Wajih et 
al., 2007), while it is believed disulphides can be exchanged between PDI and Gpx7 and 
Gpx8 (Nguyen et al., 2011). This provides the link between de novo disulphide bond 
formation and disulphide introduction into nascent client proteins within the ER. In order 
to achieve this, however, the ER needs to generate a constant stream of disulphide bonds to 
supply PDI and ensure that the process of oxidative protein folding is not compromised. 
This stream originates from another subset of specialised ER-resident enzymes.  
1.1.6 De novo disulphide formation. 
The endoplasmic reticulum is a highly specialised protein-folding factory. As well as 
providing an environment conducive to protein folding, it must also ensure that disulphide 
bonds are introduced where required. It is estimated that in specialised secretory cells such 
as plasma cells or pancreatic β cells, around 3,000,000 disulphides are generated and 
introduced into immunoglobulin or insulin per minute (Scheuner and Kaufman, 2008). 
This figure gives some indication of the speed at which oxidative protein folding occurs 
and also gives an appreciation of the high fidelity to which the enzymes work. This large 
pool of disulphide bonds is thought to be generated by a small number of enzymes, namely 
quiescin sulphydryl oxidase (QSOX), and the ER-localised enzymes vitamin K epoxide 
reductase (VKOR), Endoplasmic reticulum oxidoreducxtase 1 (Ero1), the peroxidises 
peroxiredoxin IV (PrxIV), glutathione peroxidise 7 (Gpx7), glutathione peroxidise 8 
(Gpx8) and also by the oxidation and reduction of ascorbate (vitamin C). 
QSOX and Ero1 are thought to generate disulphide bonds via a similar mechanism, as both 
enzymes are flavoproteins; flavin adenine dinucleotide (FAD) is bound and essential for 
function (Hoober et al., 1996, Tu et al., 2000). FAD acts as an electron acceptor and 
facilitates the flow of electrons required to produce disulphide bonds within the associated 
enzymes. This mechanism relies principally on two sulphydryl groups of conserved 
cysteine residues, which exist as –SH groups in their reduced, electron rich form. In order 
to generate a disulphide bond, the electrons from these two sulphydryl groups are passed 
on to the FAD molecule and as a result become oxidised thus forming a covalent link 
between the two sulphur atoms. This is the newly generated disulphide bond. Other 
mechanisms of disulphide bond generation include VKOR, an ER localised enzyme 
(Schulman et al., 2010) which catalyses the reduction of vitamin K to vitamin K 
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hydroquinone (Jin et al., 2007). This results in the oxidation of the VKOR CxxC active site 
and the generation of a disulphide bond. Ascorbate is an indirect source of disulphide 
bonds, being oxidised to dehydroascorbate. Dehydroascorbate can be reduced by PDI 
(Saaranen et al., 2010), a key member of the oxidative protein folding machinery, resulting 
in the oxidation of PDI and the formation of a new disulphide bond. 
The other major method of disulphide bond generation comes from the recycling of 
hydrogen peroxide – a reactive oxygen species (ROS) which can be broken down into 
water by enzymes with a peroxidase function, of which there are three known to exist 
within the ER. The glutathione peroxidases (Gpx7 and Gpx8) enzymes and peroxiredoxin 
IV (PrxIV) all react with hydrogen peroxide to form cysteine sulphenic acid groups which 
are extremely reactive. These groups can react with proximal cysteine sulphydryl groups to 
form a disulphide bond between the sulphur atoms, coupled to the release of a water 
molecule.  
1.2 Ero1 structure and regulation. 
The Ero1 family of proteins provide a means of generating disulphide bonds within the ER 
and are well conserved amongst eukaryotes. In humans two forms of Ero1 exist, each 
exhibiting different mechanisms of regulation and tissue specific expression. Ero1α, the 
most widely expressed isoform, exists in most cells and tissues whereas Ero1β is expressed 
only in certain cells and tissues such as the pancreatic islets of Langerhans (Dias-
Gunasekara et al., 2005). Ero1α is upregulated by the Hypoxia-inducible factor (HIF-1α) in 
times of low oxygen (May et al., 2005), whereas Ero1β expression is stimulated by an ER 
stress response - the unfolded protein response (UPR) (Pagani et al., 2000). Comparatively 
little is known about the Ero1β structure and regulatory mechanisms and so the main focus 
and comparison will be made between Ero1α and the yeast Ero1p, both of which have 
been much more widely studied. Ero1p was first identified in 1998 in two separate studies 
(Frand and Kaiser, 1998, Pollard et al., 1998) and has since been the focus of further work 
due to its requirement for viability in Saccharomyces cerevisiae.  
1.2.1 The unique structure of Ero1p. 
The properties of yeast Ero1p have been intensely studied in the last few years. It is a 
65kDa glycosylated (Frand and Kaiser, 1998), flavin-adenine dinucleotide (FAD) binding 
protein (Tu and Weissman, 2002) that is localised to the luminal face of the ER membrane 
via a 127 amino acid C-terminal tail (Pagani et al., 2001). Interestingly, this tail sequence 
is absent in the human isoforms, Ero1α and Ero1β. A thermosensitive yeast ero1-1 mutant 
gave insight into the functions of the C-terminal region of Ero1p. The ero1-1 strain is non-
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viable at temperatures over 36°C but is rescued by both Ero1α and a truncated Ero1p 
missing the 127 amino acid C-terminal domain (Cabibbo et al., 2000). The C-terminal 
domain, therefore, is not essential for viability but is necessary for Ero1p localisation to the 
ER membrane. Furthermore, the tail region is required to rescue an Ero1p deletion strain 
(Pagani et al., 2001). Interestingly, Ero1p is a globular protein which is rich in α-helical 
structure with short connecting loops between helices, and an additional lengthy loop with 
no secondary structure (Gross et al., 2004). While the C-terminus is important for Ero1p 
localisation, there are important structural, catalytic and regulatory features found 
elsewhere within the molecule. 
10 cysteines within Ero1p are known to form intramolecular disulphide bonds (Figure 
1.4A), including four which form the catalytically active disulphides; Cys352-Cys355 and 
Cys100-Cys105. Cys352 and Cys355 are known as the active site cysteines, whereas the 
Cys100-Cys105 pairing is known as the shuttle cysteines (Sevier and Kaiser, 2008). The 
active site cysteines are positioned adjacent to the FAD cofactor, and transfer electrons 
from the shuttle cysteines to FAD (Tu et al., 2000, Tu and Weissman, 2002). The electrons 
are then passed on to molecular oxygen, producing hydrogen peroxide – a reactive oxygen 
species and potential source of cellular stress (Gross et al., 2006). This is thought to be one 
reason for the tight regulation of Ero1. The shuttle cysteines are so called as they pass 
electrons from protein disulphide isomerase (PDI), the partner of Ero1 in the disulphide 
bond formation pathway, to the active site cysteines (Figure 1.5A). This is done via 
intramolecular dithiol-disulphide exchange (Sevier and Kaiser, 2006). With PDI in an 
oxidised state, it can then act upon its substrate proteins by oxidising cysteine pairs thus 
donating its disulphide bonds (Figure 1.5B). The shuttle cysteines are positioned on a long, 
flexible loop which allows movement of the cysteines between the active site cysteines and 
PDI. The loop lacks secondary structure, which is thought to increase the affinity of PDI 
for the shuttle-containing loop as PDI substrates tend to be in unfolded conformations 
(Sevier and Kaiser, 2008). The cysteine residues of Ero1p also have another role to play in 
addition to disulphide bond transfer; they provide a crucial method of regulation of Ero1p 
activity. 
1.2.2 Regulation of Ero1p. 
A further significant role of the cysteines in Ero1p is their formation of two regulatory 
disulphides, Cys150-Cys295 and Cys90-Cys349. These disulphides are thought to sense 
the ER oxidation state and modulate Ero1p activity accordingly. The positioning of the 
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Figure 1.4 – Ero1p intramolecular disulphide connectivity. Schematic diagram of the 
Ero1p primary structure with cysteines numbered and in yellow. Native disulphides are 
shown connected by black lines, active site and shuttle cysteines are labelled. 
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regulatory disulphides is crucial; they control the flexibility of the shuttle cysteine loop, 
directly influencing its ability to pass electrons from PDI to the active site. The Cys143-
Cys166 disulphide is thought to be structurally important as an Ero1p-c-C143A-C166A 
double mutant has a lower activity compared to the wild type in activity assays (Sevier et 
al., 2007). This is thought to result from a loss of structure rather than regulation of 
activity. A further interesting property of Ero1p is that the initial activation lag phase in 
Ero1p-c activity is shortened significantly in the case of the C150A-C295A mutant (Gross 
et al., 2006). The C90A-C349A mutant also showed a moderate reduction in the lag phase, 
which was confirmed to be due to the reduction of these disulphides before Ero1p is 
activated suggesting that these disulphides are inhibitory. Sevier et al show that Ero1p can 
be completely deregulated by introducing the C150A-C295A mutant into yeast, as this 
mutation destabilises the Cys90-Cys349 disulphide and creates a constitutively active form 
of the enzyme (Sevier et al., 2007). This disulphide bond system forms an effective 
regulatory mechanism; when the ER environment is reducing the regulatory disulphides 
will be broken and Ero1p will be activated. It can then work to raise the oxidation potential 
of the ER. However, in oxidising conditions, the regulatory disulphides will re-form and 
Ero1p will become inactivated.  
A more recent study shed further light on the regulation of Ero1p, specifically the 
molecular steps required to reduce and activate the enzyme. This study built upon the 
previous knowledge on the electrophoretic mobility of the various redox forms of Ero1p. 
Heldman et al. used thiol alkylating agents, either N-ethyl maleimide (NEM) or 4-
acetamido-4’-maleimidylstilbene-2,2’-disulfonic acid (AMS), to trap the redox form of 
Ero1p at various stages of reaction with substrate. This approach confirmed that the 
C150A/C295A mutant Ero1p reached its fully reduced, active form more quickly when 
compared to the wild type enzyme (Heldman et al., 2010) which would explain why the 
mutant has a reduced lag phase. This approach also showed that upon completion of 
substrate oxidation Ero1p returned to its oxidised form, with the C150A/C295A mutant 
again reaching this form faster than the wild type. Together, these findings suggest that the 
breaking of the C150-C295 disulphide is one of the early events in the activation as well as 
being one of the initial events of the re-oxidation of Ero1p. Mass spectrometry 
investigations, however, showed that the C143-C166 disulphide is broken first of all during 
reduction of Ero1p, with the C150-C295 disulphide only being broken later in the process 
(Heldman et al., 2010). Interestingly, these results were observed using the non- 
physiological substrate thioredoxin and were different to those observed when using PDIp 
as a substrate. With PDIp as a substrate, Ero1p never reaches the reduced state that it does 
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Figure 1.5 – Disulphide bond transfer from Ero1 to PDI occurs via dithiol-disulphide 
exchange prior to client oxidation by PDI. A - The Ero1 active site disulphide, adjacent to 
the FAD cofactor is passed on to the Ero1 shuttle cysteines in a dithiol-disulphide 
exchange where the active site disulphide is attacked by the thiolate anion of a shuttle 
cysteine. This creates a disulphide linking the two active sites. This disulphide is attacked 
by the second shuttle cysteine to form the shuttle disulphide. A thiolate anion from PDI 
then attacks the shuttle disulphide, forming a mixed disulphide between the two 
enzymes. This is resolved within the PDI molecule by the second active site cysteine 
resulting in the oxidation of the PDI active site and reduction of the Ero1 shuttle 
disulphide. B – Oxidised PDI introduces disulphides into client proteins within the ER via a 
similar dithiol-disulphide exchange mechanism resulting in the oxidation of the client and 
the reduction of the PDI active site. 
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with thioredoxin. The reason for this observation is as yet unknown and may have 
implications for many studies which have investigated the activation and inactivation of 
Ero1p using thioredoxin. 
1.2.3 Discovery of Ero1α and its function. 
While there are similarities between the structure and regulatory mechanisms of the human 
and yeast forms of Ero1, there are many more distinguishing features. Following the 
discovery of Ero1p in 1998, (Frand and Kaiser, 1998, Pollard et al., 1998) the search for 
the human homologue resulted in the discovery of Ero1α (Cabibbo et al., 2000). A BLAST 
search using the yeast ERO1 nucleotide sequence found a human homologue with 49% 
similarity and 37% identity to the yeast Ero1p. Further bioinformatical analysis of this 
gene suggested an N-terminal ER-signal sequence with a cleavage site between residues 23 
and 24 as well as two N-glycosylation sites, both suggestive of an ER protein. 
Furthermore, the sequence was predicted to contain a CxxCxxC motif – important for 
Ero1p activity (Frand and Kaiser, 1998, Pollard et al., 1998). Follow up experiments 
confirmed a myc-tagged Ero1α gene product co-localised with ER proteins and that Ero1α 
is sensitive to EndoF and EndoH treatment, suggestive of a glycosylated ER protein 
(Cabibbo et al., 2000). In vitro translation assays confirmed microsome localisation and 
glycosylation of Ero1α. Solubility assays suggested that Ero1α is associated to the 
membrane either directly or through interactions with an integral membrane protein, 
similar to Ero1p. Ero1α is able to rescue viability of the yeast ero1-1 mutant strain and 
alleviated DTT sensitivity (Cabibbo et al., 2000); proof that Ero1α has a similar function to 
Ero1p. Mutation of the second and third cysteines in the CxxCxxC motif diminished the 
ability of the enzyme to complement the ero1-1 strain suggesting that these residues are 
crucial to the functioning of Ero1α. Cabibbo et al. also explored the function of Ero1α with 
respect to oxidative protein folding. Ero1p or Ero1α are required for CPY to reach its 
mature form in yeast. Taken together, this evidence suggests that Ero1α is an ER protein, 
possibly associated with the ER membrane, it is glycosylated, can functionally 
complement Ero1p in yeast, contains an essential CxxC motif and is important in the 
oxidative folding and maturation of substrates within the ER in vivo. 
In addition to this work by Cabibbo et al., a further study was published in 2000 by 
Benham et al. on the function of Ero1α. The study shed insight on the oxidative folding 
state of the enzyme in the ER and the involvement of the CxxCxxC motif in this. Benham 
et al. set out to determine the extent of disulphide bond formation within Ero1α as it 
contains 15 cysteine residues within its primary structure. In vitro translation assays in 
semi-permeabilised (SP) cells (treated with the detergent digitonin and washed to remove 
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the cytosol and leave an intact ER system) produced Ero1α which was taken up by a 
functional ER system. The group found that Ero1α was glycosylated and that the majority 
of the enzyme was bound to the membrane, in agreement with Cabibbo et al. Under 
reducing SDS-PAGE conditions Ero1α was found to exist in two forms – either 
glycosylated or non-glycosylated. Under non-reducing SDS-PAGE Ero1α formed two 
distinct bands of increased mobility, termed OX1 and OX2, indicating the formation of 
disulphide bonds within the molecule. The glycosylation state of these Ero1α forms was 
confirmed by using lectin binding ConA-beads which pulled down the OX2, OX1 and 
reduced forms of Ero1α. These bands all presented as a single reduced and glycosylated 
form after treatment with DTT and were all sensitive to glycosidase treatment. This 
experiment also showed that Ero1α was present in a complex with molecular weight of 
120kDa which was subsequently shown to be an Ero1α-PDI disulphide linked complex. 
This was the first evidence to suggest Ero1α-PDI interactions. 
To investigate the involvement of the CxxCxxC motif in the structure and function of the 
enzyme, Benham et al. created cysteine to alanine mutants of the three cysteines (C391A, 
C394A, and C397A). These were again translated in the presence of SP cells and their 
folding states analysed via reducing and non-reducing SDS-PAGE. The results led Benham 
et al. to conclude that Cys391 and Cys397 contribute to the oxidative folding of Ero1α but 
that Cys394 does not. Benham et al. then confirmed that the OX2 form is the native and 
most stable form found in cells. Investigation of the CxxCxxC mutants showed that the 
C391A and C394A mutants were either unstable and degraded or secreted. C391A showed 
a decreased ability to interact with PDI and ran as a diffuse smear after SDS-PAGE; it was 
unable to form the OX2 state suggesting this residue may play a role in the formation of 
the most oxidised state of Ero1α. C394A achieved the OX1 and OX2 forms and 
maintained its interaction with PDI, suggesting that PDI prefers to interact with correctly 
folded Ero1α. C397A was eventually able to reach the OX2 state, unlike during the in vitro 
translations, and interacted with PDI in both its OX1and OX2 states. Taken together, this 
data suggests that each of the cysteine residues investigated did not play a direct role in the 
interaction with PDI but that they are crucial for the folding and stability of the protein. As 
the Ero1α-PDI interaction is strongest with wild type Ero1α and with non-reduced and 
folded forms of Ero1, the data from this study suggests that PDI does not act as a 
chaperone. 
Further information can be drawn from data provided by both Benham et al. and Cabibbo 
et al. The C394A and C397A Ero1α mutants cannot complement the ero1-1 yeast mutant 
strain, whereas C391A can. Interestingly, Benham et al. showed that the C394A and 
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C397A mutants can interact with PDI which would suggest that interaction with PDI is not 
sufficient for the functioning of Ero1α and that the C394 and C397 residues play an 
important role in Ero1α function. This is consistent with the now-established mechanism of 
Ero1α function, thus providing the first real insight into the way in which this complicated 
and fascinating enzyme functions. It also raised a number of questions that would be 
subsequently studied and prompted further investigation to find out exactly how Ero1α 
works, the function of the cysteine residues, the significance and the features of the 
reduced, OX1 and OX2 forms and the role of Ero1α within the ER. 
1.2.4 Ero1α drives disulphide formation in substrates via oxidation of PDI. 
With the capability of Ero1α to complement the yeast ero1-1 mutant, it was hypothesised 
that this enzyme could act in a similar manner to yeast Ero1p, mediating disulphide bond 
formation within the ER. Following on from the discovery that Ero1p transfers electrons 
from an active site disulphide to its FAD cofactor (Tu et al., 2000, Tu and Weissman, 
2002), investigations began on Ero1α to elucidate the potential de novo disulphide 
generation mechanism in the human ER. Confirmation of disulphide generation came from 
a 2001 study by Mezghrani et al. by monitoring the oxidative folding of immunoglobulin 
in cells overexpressing Ero1α and Ero1β (Mezghrani et al., 2001). This group carried out a 
pulse chase experiment and analysed the folding states of immunoglobulin by SDS-PAGE. 
They found that overexpression of Ero1α and Ero1β led to the oxidation of the murine J 
chain (JcM) at an increased rate as seen by the formation of oxidised monomers, dimers 
and higher molecular weight complexes. The group confirmed that the Ero1s had no direct 
oxidative effect on the JcM as no JcM-Ero1 complexes were visible. A PDI-JcM complex 
was detected however, suggesting that the JcM oxidation is PDI-mediated. PDI-JcM mixed 
disulphides decreased with time, coupled to the increase in oxidised JcM, again suggesting 
that PDI is the oxidant required for disulphide formation in the JcM. 
Mezghrani et al. then confirmed that PDI and Ero1 could form mixed disulphides, seen in 
previous studies (Benham et al., 2000). In Ero1α overexpressing cell lines, PDI was found 
in high-molecular weight complexes as well as in a fast-migrating monomer species. This 
was not the case in control cells or cells expressing the C391A, C394A or C397A Ero1α 
mutant as the majority of PDI was found in the reduced monomeric state. Furthermore, 
after brief treatment with DTT during a pulse labelling period, the more oxidised form of 
monomeric PDI formed quickly in Ero1α overexpressing cells but not in control cells as 
seen from the chase samples. This suggests that Ero1α is driving PDI oxidation in vivo. To 
investigate the ability of the CxxCxxC motif mutants to drive disulphide formation in the 
JcM, JcM folding was monitored in cells via SDS-PAGE and was impaired in the C394A 
22 
 
and C397A mutants. The C391A mutant accelerated folding when compared to control 
cells but this acceleration was less than in wild type Ero1α expressing cells. The 
Mezghrani et al. study therefore showed for the first time that Ero1α could drive disulphide 
bond generation for ER-targeted substrates by oxidising PDI. This was a pivotal finding in 
itself, however the finding that mutating cysteines C394A and C397A disrupted Ero1α 
activity, in addition to the Benham et al. study. This again raised questions of the specific 
function of these critical residues, and how the Ero1α-PDI interaction is mediated. 
1.2.5 The Ero1α cysteines create two active sites and a regulatory mechanism at the 
molecular level. 
With the discovery of the disulphide bond generating and PDI-oxidising abilities of Ero1α, 
attentions then turned to determining the precise mechanisms by which these abilities are 
mediated. These issues were investigated by a study in 2004 by Bertoli et al. who 
generated a number of Ero1α cysteine mutants and tested their capability to carry out four 
functions: to complement the ero1-1 yeast mutant; to accelerate oxidative protein folding 
in cells; to form mixed disulphides with known interaction partners PDI and ERp44; and to 
form the characteristic redox isoforms seen previously (Benham et al., 2000). A Δ86-95 
mutant showed impaired activity in a folding assay as well as being unable to complement 
the ero1-1 mutant. This suggested an important role for the region of the enzyme 
containing cysteine 94. 
Bertoli et al. found that cells expressing C85S, C94S and C99A Ero1α mutants all 
displayed impaired JcM folding compared to the wild type and suffered from reduced 
growth during complementation assays. C394A and C397A mutants did not grow at all, 
thus suggesting that cysteines 85, 94 and 99 are important for functionality and that 
cysteines 394 and 397 are indispensible. This is similar to the properties of Ero1p (Frand 
and Kaiser, 2000). Cysteine 94, 166, 208 and 241 mutants all displayed impaired binding 
of PDI, and considering that only the C94S mutant is inactive in activity assays then this 
would imply that the Ero1α-PDI interaction may not exclusively transfer oxidising 
equivalents to PDI. Interestingly, these four mutants bound ERp44 as well as the wild type 
enzyme suggesting a different mechanism of interaction  which has since determined to be 
a multivalent interaction between Ero1α cysteines and ERp44 (Anelli et al., 2003). 
To determine the redox isoforms formed by the cysteine mutants, reducing and non-
reducing SDS-PAGE was performed to separate the reduced, OX1 and OX2 forms. The 
results suggested that cysteines 85 and 391 are required for OX2 formation. The JcM 
folding activity of two double mutants were tested and concluded that the two primary 
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residues of the CxxCxxC motifs in Ero1α, C85 and C391, are important for function as 
their absence results in a less active Ero1α. Taken together with the data showing that 
cysteines 94, 394 and 397 are essential to complement the ero1-1 mutant, and that 
cysteines 94, 99, 394 and 397 are important or essential for binding of PDI and oxidative 
folding of the JcM, this suggests that cysteines 85 and 391 coordinate the cooperation of 
the two CxxC motifs to allow the functioning of Ero1α possibly by forming a disulphide. 
This study therefore provided the first evidence that Ero1α contains two active sites and 
proposed that electron transfer occurs from PDI, through these Ero1α active sites and on to 
an upstream electron acceptor; resulting in a net transfer of disulphides in the opposite 
direction. This mechanism is similar to that found in Ero1p (Sevier and Kaiser, 2006). 
While this evidence provided a function for the CxxCxxC motif cysteines, there remained 
ambiguity over the role of the remaining Ero1α cysteines. These were dispensible for 
functioning of Ero1α but did influence the folding state of the enzyme (Bertoli et al., 
2004). Insight into the specific functions of these cysteines then came from two studies in 
2008 which showed that these residues are essential for regulation of Ero1α activity, 
following on from studies in Ero1p (Sevier et al., 2007). Baker et al. approached the 
investigation using a purified recombinant Ero1α and several mutants in order to 
characterise activity towards substrates and the influence of the cysteines on this activity. 
Biophysical studies confirmed that Ero1α contains a number of intramolecular disulphides. 
Ero1α activity towards the non-physiological substrate thioredoxin was characterised using 
a gel-based assay to distinguish between the reduced and oxidised forms of thioredoxin 
and Ero1α. Analysis of the redox states revealed that reduction of Ero1α coincides with 
activity, suggesting that reduction of disulphides within the molecule may allow its 
activation. There was a distinct lag between the completion of thioredoxin oxidation and 
the re-oxidation of Ero1α – something witnessed previously in Ero1p (Sevier et al., 2007). 
This, therefore, implies that Ero1p and Ero1α have similar regulatory mechanisms in place 
and provides further evidence that Ero1α has the ability to generate disulphides and oxidise 
substrate proteins. 
Baker et al. also investigated Ero1α-mediated oxidation of PDI by measuring oxygen 
concentration in solution as an indication of Ero1α activity. This approach had been used 
previously to determine Ero1p activity (Sevier et al., 2007) and works on the principle that 
oxygen is depleted as disulphide bonds are formed. This assay revealed that PDI oxidation 
is more efficient in the presence of reduced glutathione than in its absence, and that Ero1α 
activity turned over three disulphides per minute per molecule. This is comparable to 
activity witnessed with Ero1p (Sevier et al., 2007). Baker et al. also showed that PDI is 
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able to reduce the regulatory disulphides within Ero1α using a gel shift assay. Interestingly, 
the partially reduced form of Ero1α remained visible for much longer in the presence of 
PDI and GSH than with PDI alone. It was hypothesised that GSH maintained PDI in a 
reduced state enabling PDI to reduce the Ero1α regulatory disulphides – hinting that 
glutathione could play an indirect role in regulating the Ero1α redox state. 
In order to identify the regulatory disulphides within Ero1α, Baker et al. created a number 
of cysteine mutants and analysed any resultant changes in SDS-PAGE mobility or redox 
state. It was concluded that the absence of cysteines 85, 94, 131 or 104 all prevented the 
formation of disulphide bonds which contribute to the fully oxidised form of Ero1α. From 
this assay, Baker et al. were able to deduce that a disulphide exists between C94 and C131. 
Interestingly, a C85/131A double mutant ran with further decreased mobility compared to 
the C85A and C131A single mutants – indicating that perhaps two disulphides could not be 
formed and this has a cumulative effect on the mobility of this mutant. 
To investigate the effects of the absence of these disulphides on Ero1α activity, the abilities 
of the Ero1α mutants to oxidise thioredoxin and PDI were tested. Using thioredoxin as a 
substrate, C99A and C94/99A mutants showed complete inactivity while the C94A mutant 
showed weak activity. This complements previous data which suggested that these residues 
constitute an active site. Using PDI as a substrate, Baker et al. discovered that the C131A 
Ero1α mutant showed increased activity towards PDI and lacked the initial lag phase that 
is seen with the wild type enzyme. The C85/131A double mutant showed an even greater 
activity towards PDI. This data suggests that the proposed C94-C131 and C85-C391 
disulphides are regulatory in nature and that reduction of these disulphides results in a 
cumulative increase in activity towards PDI. The possibility of a C99-C104 disulphide was 
investigated as the C104A mutant displays a slight decrease in SDS-PAGE mobility. A 
C104/131A double mutant was produced and found to have a further increased activity 
towards PDI when compared to the C85/131A double mutant. This suggests that two 
regulatory disulphides play a critical role in Ero1α regulation – C94-C131 and C99-C104 
and that their reduction results in an activated enzyme. The Baker et al. study therefore 
shed light on the function of the cysteine residues that are not involved in the active sites. 
They provided evidence that Ero1α activity is strictly governed by a set of regulatory 
disulphides that inhibit activity when oxidised and permit activity upon their reduction. 
This regulatory mechanism was confirmed by a parallel study in 2008 by Appenzeller-
Herzog et al. This group tackled the question of regulatory disulphide formation from a 
different angle and used a mass spectrometry approach. This approach, combined with the 
Baker et al. study, provided complementary evidence that Ero1α activity is controlled by  
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Figure 1.6 – Disulphide bonding pattern within Ero1α. The primary sequence of Ero1α 
(light blue) contains 15 cysteine residues (red). The inner active site cysteines 391, 394 
and 397 are positioned adjacent to the bound FAD cofactor (yellow).  The shuttle 
cysteines, 94 and 99, are positioned on a flexible loop region (dark blue). In the Ox1 form, 
all of the intramolecular disulphides are formed. These disulphides exist between 
cysteines 35-48, 37-46, 85-391, 94-131, 99-104, 208-241 and 394-397. In the Ox1 form, 
the disulphide between cysteines 94-131 is broken allowing formation of the shuttle 
cysteine active site disulphide (cysteines 94 and 99). In the R form, all of the disulphides 
are broken although the two active site disulphides, between cysteines 94-99 and 394-
397, can still form. 
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intramolecular disulphide bonds. Both studies were able to map disulphide connectivity 
and each provided unique insights which contributed greatly to the wider understanding of 
Ero1α activity and regulation. Appenzeller-Herzog et al. overexpressed and purified Ero1α 
from cells and used it for mass spectrometry analysis. Analysis of the mass spectrometry 
data revealed that disulphide bonds were present between cys85 and one of 
cys391/394/397, and cys94-cys131. Further analysis via SDS-PAGE led to the conclusion 
that disulphides exist between cys85-cys391 and cys94-cys131, both of which define the 
OX2 form of Ero1α. Three further disulphides were detected; two between the N-terminal 
cluster of four cysteines, and one between cys208 and cys241. Armed with this 
information on the intramolecular disulphides, Appenzeller-Herzog et al. moved on to 
investigate how these influence Ero1α interactions with PDI. 
PDI had been shown to interact with cysteine 94 in the Ero1α ‘shuttle’ active site. An inter-
molecular disulphide between a PDI active site cysteine and Ero1α forms due to the 
nucleophilic attack on the Ero1α cys94-99 active site disulphide. The new data proposed 
by Appenzeller-Herzog et al. and Baker et al. suggest that there may be competition for 
this reaction from Ero1α cysteine 131 which would form a regulatory disulphide. To 
investigate this possibility, Appenzeller-Herzog et al. devised an assay which would 
determine whether the availability of PDI had an effect on the redox state of Ero1α. Using 
shRNA to knock down expression of PDI resulted in an increase in OX2 formation 
compared to OX1. Furthermore, Ero1α formed more OX1 relative to the OX2 form when 
PDI was overexpressed. Taken together this data suggests that lowering levels of PDI 
increased formation of the cys94-131 disulphide, or conversely, increasing PDI availability 
prevents formation of the cys94-131 disulphide. PDI therefore competes with Ero1α 
cysteine 131 for the nucleophilic attack of the Ero1α active site. This provides an insight 
into the regulatory mechanism – when PDI exists in a reduced state it will reduce the 
cys94-131 disulphide and activate Ero1α, thus generating disulphide bonds. With PDI in 
an oxidised state, for example during hyperoxidising conditions, it will no longer reduce 
this regulatory disulphide and Ero1α will remain oxidised and inactive. 
The evidence provided in these studies from Bertoli et al., Baker et al. and Appenzeller-
Herzog et al. suggests that the Ero1α molecule contains a network of conserved cysteine 
residues which are involved in an intricate and elegant mechanism of catalytic activity and 
regulation (Figure 1.6). Two separate CxxC motifs are proposed to work together and 
transfer electrons from PDI and onto an Ero1α-bound FAD cofactor. Adjacent to each 
active site are cysteine residues which are thought to bring into close proximity these 
active sites. Furthermore, two regulatory cysteines provide a means of modulating activity 
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by preventing the ‘shuttle’ disulphide from forming by occupying the active site cysteines 
in non-catalytic disulphides. Cysteine 94 is thought to be attacked by electron rich PDI but 
can also be attacked by cysteine 131 thus forming a regulatory disulphide and the OX2 
conformation. Cysteine 99 can form a regulatory disulphide with cysteine 104, providing 
an extra degree of regulation. Without this regulatory mechanism Ero1α could potentially 
generate disulphide bonds in a futile manner which has the potential to upset the delicate 
redox balance within the ER, and consequently preventing oxidative protein folding and 
isomerisation, essential for the health of the cell. 
1.2.6 Ero1α crystal structure. 
The crystal structure of Ero1α was solved in 2010 by Inaba et al. which provided insight 
into the structure-function relationship and validated previous work carried out on the 
enzyme. The crystal structures of two mutants were determined – the hyperactive 
C104/131A mutant and the C99/104A mutant (Inaba et al., 2010). These allowed 
homogenous populations of Ero1α to form by ensuring that only the C94-99 and C94-131 
disulphides could form, respectively, in addition to the surrounding structural disulphides. 
In the case of the hyperactive mutant, disulphides were subsequently identified between 
residues 35-48, 37-46, 85-391, 208-241 and 394-397, thus confirming previous work on 
disulphide connectivity (Appenzeller-Herzog et al., 2008, Baker et al., 2008). Ero1α has a 
globular structure which is rich in α-helical content (Figure 1.7), similar to Ero1p. The N-
terminal sequence, absent in the Ero1p study (Gross et al., 2004), creates an anti-parallel β-
hairpin structure stabilised by two disulphides, C35-48 and C37-46. The function of this 
structure remains unknown as it is dispensable; Ero1α activity is unaffected without it. 
Another difference between Ero1p and Ero1α is the elongation of the loop regions between 
α-helices. This discrepancy may help accommodate the additional regulatory disulphide 
that Ero1α possesses as both the regulatory cysteine residues, C104 and C131, are 
positioned within an extended loop lacking structure. Inaba et al. also propose that this may 
be to facilitate electron shuttling between PDI and the Ero1α FAD active site. One 
interesting feature of the Ero1α structure is that the catalytic core region is nearly identical 
to that of Ero1p and consists of four closely packed helices adjacent to the bound FAD 
cofactor. The sulphur atom of cysteine 397 is positioned 3.3Å from the C4a atom of the 
flavin cofactor thus facilitating electron transport between the two. FAD binds to Ero1α via 
interactions with conserved residues tryptophan 200 and histidine 255 which secure the 
isoalloxazine ring and adenine moiety. The oxygen group of arginine 287 is proposed to 
interact with the pyrophosphate group thus further stabilising the FAD cofactor. These 
residues are conserved across flavoenzymes indicating their importance (Fass, 2008). 
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One further interesting observation made by Inaba et al. concerns the apparent lack of a 
channel through which molecular oxygen can pass to come into the proximity of the flavin  
group. However, an extended loop region containing residues 183-194 is suggested to 
cover the isoalloxazine ring and could potentially move during interactions with PDI to 
facilitate access for oxygen. While the structure of the hyperactive Ero1α produced some 
interesting observations regarding activity and FAD binding, the structure of the inactive 
C99/104A mutant revealed more details concerning regulation and the governing 
disulphides. This structure showed no gross conformational changes compared to the 
hyperactive form suggesting that formation of the regulatory disulphides does not alter the 
overall structure of the molecule. There was, however, one major difference between the 
two structures – the loop containing residues 89-132 is structured in the inactive mutant 
due to the formation of the C94-131 regulatory disulphide, compared to the same 
unstructured region in the hyperactive mutant. Taken together, this study therefore builds 
upon knowledge drawn from 10 years of study on Ero1α. 
1.2.7 Correct regulation of Ero1p and Ero1α activity is essential for homeostasis in 
the ER. 
The ER environment is delicately balanced to ensure that nascent proteins undergo 
oxidative protein folding, but can also undergo disulphide isomerisation to correct non- 
native disulphide formation. The balance therefore must prevent the ER from becoming 
either hyper- or hypo-oxidising; a hyperoxidising environment will prevent isomerisation 
while a hypo-oxidising environment will impair disulphide formation. While glutathione is 
the major redox buffer in the ER, it is not always sufficient to prevent the upset of the 
redox balance and as a result there are mechanisms to combat this. The unfolded protein 
response (UPR) is one such mechanism that can help alleviate stress or can induce cell 
death if necessary (Haynes et al., 2004). This highlights the fact that it is imperative to 
maintain the correct ER oxidative balance. Hyper- and hypo-oxidising states are therefore 
an established source of cellular stress and have been studied in detail to determine the 
mechanism whereby these conditions come to exist. As a major contributor to oxidative 
protein folding, Ero1α is central to this balance. It can generate disulphide bonds as well as 
hydrogen peroxide as a by-product of its activity. Therefore Ero1α, without the appropriate 
regulation, can lead to the hyperoxidation of the ER. This source of ER stress has been 
investigated by a number of groups. 
In 1999, Cuozzo & Kaiser showed that Ero1p was a major source of oxidised glutathione 
as overexpression of Ero1p perturbed the glutathione balance (Cuozzo and Kaiser, 1999). 
Harding et al. then suggested that the oxidase activity of Ero1 could contribute to 
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Figure 1.7 – Overall molecular structure of Ero1α and the FAD binding region. A Ribbon 
diagram showinh the structure of Ero1α showing FAD as orange sticks, the conserved 
four-alpha helical core in cyan, β-sheet structures in blue, visible cysteine residues 
disulphide bonded and in red and the remaining structure in green. The loop region 
containing the shuttle disulphide and cysteines 104 and 131 is not shown due to poor 
electron density. The structure highlights the conserved alpha helical core which is crucial 
to the binding of FAD and for catalytic activity. B – Close up view of the FAD binding site 
within Ero1α. Sidechain atoms of labelled residues are represented as sticks with carbon 
atoms in green, nitrogen in blue, oxygen in red and sulphur in yellow. Tyr191, His255, 
Arg287 and Arg300 all contribute to the stabilisation of FAD (orange) allowing the 
adjacent positioning of Cys394 and Cys397. Adapted from Inaba et. al. (2010). 
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oxidative stress by showing that induced ER stress resulted in an accumulation of reactive 
oxygen species, but that this could be negated by the silencing of Ero1 by RNAi (Harding 
et al., 2003). These studies provided indirect evidence that Ero1 was a source of ROS and 
ER stress, however direct evidence of Ero1p involvement in ER stress and ROS came from 
a 2007 study which characterised deregulated mutants and highlighted the necessity for 
regulation of activity. 
Having determined that mutating regulatory cysteines to alanines resulted in an increased 
activity of Ero1p in vitro, and that reduction of Ero1p was coupled to activity, Sevier et al. 
investigated the implications of this on cell growth. A C150/295A mutant defective in 
regulatory disulphide formation was overexpressed and was shown to be detrimental to 
growth in yeast. Mutants unable to form the C90-C349 or C134-C166 disulphides grew as 
well as a control strain, suggesting that deregulation of Ero1p by preventing the C150-
C295 disulphide from forming causes cell stress. This effect was negated in the 
C150/295A-C100/105A mutant, unable to form the regulatory disulphide or the shuttle 
disulphide, suggesting the decreased viability was linked to catalytic activity. Cells 
deficient in UPR induction were more susceptible to defective growth, implicating ER 
stress in this observation and indicating that the stress response provided a compensatory 
mechanism. Sevier et al. also showed via SDS-PAGE analysis that the C150/295A mutant 
existed in the reduced form and that it exhibited increased activity in vivo; its 
overexpression was counteracted by the addition of the reducing agent DTT at 
concentrations previously shown to be toxic to cells. Furthermore, the GSH: GSSG ratio 
was disturbed by overexpression of this mutant as GSSG was generated in significant 
quantities. The evidence presented in this study therefore suggests that adequate regulation 
of Ero1p is essential for cell viability as its hyperactivity is detrimental to cell viability. 
Hyperactivity associated with mammalian Ero1α was investigated in 2008 by the parallel 
studies of Baker et al. and Appenzeller-Herzog et al., as both groups witnessed increased 
Ero1α activity in mutants. Baker et al. showed in vitro that preventing the C99-104 and 
C94-131 disulphides from forming resulted in a hyperactivity towards PDI, oxidising it 
more completely and at an increased rate when compared to the wild type enzyme (Baker 
et al., 2008). Appenzeller-Herzog et al. determined that hyperactive Ero1α can upset ER 
redox homeostasis in vivo. While overexpression of Ero1α did not alter the redox states of 
the ER oxidoreductases ERp57 or TMX3, overexpression of C131A Ero1α caused an 
increase in the relative oxidation of the two enzymes. In addition, depleting glutathione 
levels increased the level of oxidation of ERp57 and TMX3 suggesting that the effects of 
C131A Ero1α overexpression are masked by compensation from the redox buffer. 
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Overexpression of Ero1α C131A also caused an increase in oxidised glutathione, while no 
difference was witnessed with wild type Ero1α overexpression. The results presented by 
these studies therefore provide in vitro and in vivo evidence that deregulation or 
incomplete regulation by the Ero1α regulatory disulphides can affect the ER redox 
balance. The absence of the C94-131 disulphide in Ero1α results in an increase in 
oxidation of ER oxidoreductases and an increase in the ratio of oxidised to reduced 
glutathione – a shift towards a hyperoxidising environment. 
More recent work on a deregulated Ero1α mutant has shed yet more light on the resulting 
ER redox conditions, using a C104/131A double mutant which cannot form either of the 
regulatory disulphides that occupy the shuttle cysteine active site (Hansen et al., 2012). 
This study by Hansen et al. compared the effect of wild type and C104/131A Ero1α 
overexpression on the redox state of ERp57. They found that the double mutant produced a 
pronounced increase in ERp57 oxidation compared to the wild type, and more so than the 
effect of the C131A mutant Ero1α (Appenzeller-Herzog et al., 2008). They also 
investigated the effect of the expression of Ero1α or a deregulated mutant on the ERp57 
redox state in the presence of N-acetylcysteine (NAC). NAC is a reducing agent and 
glutathione precursor and therefore leads to increased production of GSH and a shift 
towards a more reducing environment. Treatment with NAC partially prevented the 
oxidative shift in ERp57 indicating that this effect is likely a result of the perturbed redox 
environment. NAC treatment also prevented the increase in BiP and HERP expression 
levels, upregulated during times of ER stress and part of the UPR, which was observed 
with overexpression of C104/131A Ero1α. To follow up further the compensatory effect of 
the glutathione redox buffer on C104/131A Ero1α overexpression, cells were treated with 
the glutathione synthesis inbibitor buthionine sulphoximine (BSO). In agreement with 
previous work with the C131A Ero1α mutant (Appenzeller-Herzog et al., 2008), 
decreasing the glutathione buffer available to the cells resulted in an aggravated phenotype 
when overexpressing the C104/131A mutant as ERp57 shifted further towards the oxidised 
form. An additional experiment using metabolic activity as a measure of cell viability 
revealed that cells overexpressing the double mutant had decreased viability when grown 
in the presence of BSO. Taken together, the data from the Hansen et al. study suggests that 
deregulated Ero1α can disturb the redox balance of the ER by causing a shift towards a 
more oxidising environment. This shift affects the ER oxidoreductase ERp57 as well as the 
glutathione ratio. Furthermore, this data reveals that without the glutathione redox buffer 
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the cells are much less viable and suggests therefore that the correct regulation of Ero1α 
activity is imperative for the health of the ER and the cell. 
As yet there have been no reported incidences of Ero1α interaction with ERp57, while 
reaction with GSH can be very slow. It is therefore thought that oxidation of these 
molecules is mediated by Ero1α interaction with PDI as PDI can oxidise GSH. Oxidation 
of ERp57 is also proposed to be glutathione mediated. In addition to the disulphide-
mediated oxidation of GSH, the glutathione balance is likely to be pushed further in the 
oxidising direction by the production of hydrogen peroxide by Ero1α. GSH is a known 
peroxide scavenger which can generate GSSG, while the peroxidase function of 
peroxiredoxin IV can also lead to the oxidation of ER oxidoreductases (Tavender et al., 
2010). Deregulation of Ero1α therefore has the potential to cause hyperoxidation of the ER 
in a variety of ways.  
1.2.8 Excessive hydrogen peroxide production is detrimental to ER function. 
Hydrogen peroxide production by a deregulated Ero1α has the potential to upset the redox 
balance within the ER. The above studies allow the conclusion that creating a more 
oxidising environment can be detrimental to the health of the cells. A study conducted in 
2012 aimed to investigate the physiological implications of excessive hydrogen peroxide 
production in the liver of mice and generated some interesting results. This Margittai et al. 
study created a hydrogen peroxide-producing system by administering gulonolactone 
which is metabolised in the ER lumen with the concomitant production of hydrogen 
peroxide. Administration of gulonolactone resulted in a swelling of the liver and increase 
in liver weight, while ER cisternae were also found to be dilated (Margittai et al., 2012). 
These effects could be reversed by the coadministration of DTT. Margittai et al. found that 
increased hydrogen peroxide production increased the oxidation of NADPH and NADH, 
the glutathione content within the ER and protein thiol content as ERp72, ERp46 and 
ERp5 all showed a shift towards the oxidised species. Furthermore, ER stress was induced 
as witnessed by the phosphorylation of the transcription factor eIF2α, a target of the UPR. 
The study also produced results to suggest that eliminating hydrogen peroxide can also 
have a detrimental effect on protein folding as evidenced by impaired immunoglobulin 
folding and secretion in cells expressing ER-localised catalase. In conclusion, this data 
suggests that the delicate balance of the ER must be maintained in order to facilitate 
oxidative protein folding. Hypo-oxidising conditions prevent effective oxidative protein 
folding while hyperoxidising conditions also prevent this process and can result in the 
induction of the UPR, raising the chances of cell death. 
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1.3 Sulphenylation: a significant redox-based post-translational modification. 
Sulphenylation is becoming an increasingly relevant and studied method of post-
translational modification. The investigation into the yeast Gpx3 and Yap1 system showed 
that this modification is crucial for the functioning of the Yap1 transcription factor 
(Paulsen and Carroll, 2009). It is also known that sulphenylation of catalytic cysteine 
residues can be detrimental to their function such as in the bacterial protein OhrR 
(Eiamphungporn et al., 2009) and so a protective mechanism exists within the bacterial 
periplasm to keep single cysteine residues in a reduced state (Depuydt et al., 2009). Recent 
results have therefore painted a very diverse picture concerning the function of cysteine 
oxidation; however it is clear that sulphenylation can have a critical impact upon the 
activity of enzymes and thus many cellular processes. 
1.3.1 Thiol sulphenylation is a potential method of reversibly modulating enzymatic 
activity. 
Sulphenylation of thiols occurs when the thiolate ion of a cysteine residue side chain (-S
-
) 
is reversibly oxidised by a ROS, such as a peroxide or superoxide, to form a sulphenic acid 
group (-SOH). Sulphenic acid is a highly reactive species and will react with proximal 
thiol-containing molecules such as proteins or glutathione, or with additional oxidants to 
form the hyperoxidised species - sulphinic (-SO2H) or sulphonic (-SO3H) acid. Recent 
evidence has shown that sulphenic acid groups can be protected from hyperoxidation by 
the local environment and may therefore provide a means of reversible activity 
modulation. This is thought to occur in peroxiredoxin IV where structuring of the local 
environment after sulphenylation of the peroxidatic cysteine prevents hyperoxidation and 
thus allows the protein to retain its activity (Cao et al., 2011). Another study investigating 
protein tyrosine phosphatase 1B showed that the active site cysteine undergoes 
sulphenylation which is stabilised by the formation of a sulphenyl amide, protecting it from 
further oxidation (van Montfort et al., 2003). Hyperoxidation was thought to be an 
irreversible modification however there is evidence to suggest that the sulfiredoxin family 
of enzymes can rescue proteins with this modification (Jeong et al., 2006) again suggesting 
a role for cysteine oxidation in reversible modulation. The van Montfort et al. and Cao et 
al. studies adopted a crystallographic approach to implicate cysteine sulphenic acid in the 
activity of protein tyrosine phosphatase 1B and peroxiredoxin IV respectively. However, a 
growing number of studies are adopting a chemical approach to identify cysteine sulphenic 
acid in enzyme activity. 
1.3.2 Detecting sulphenic acid in proteins using chemical probes. 
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The development of chemical probes to selectively react with cysteine sulphenic acid has 
provided a powerful means by which this modification can be investigated. A 1974 study 
by Benitez et al. first showed that sulphenic acid could react specifically and irreversibly 
with the chemical probe 5,5-dimethyl-1,3-cyclohexadione (dimedone). Dimedone was 
used to show that sulphenic acid formed in glyceraldehyde-3-phosphate dehydrogenase 
and that activity was subsequently abolished (Benitez and Allison, 1974). Dimedone is a 
cell permeable cyclic diketone which reacts with the electrophilic sulphur atom within 
cysteine sulphenic acid in a condensation reaction, covalently linking the chemical probe 
to the protein. This chemical probe was utilised in a 2009 study by Seo & Carroll where a 
means to visualise the dimedone-protein adduct was developed. A specific antibody was 
described which could bind the adduct and allow Western blotting and 
immunofluorescence techniques to provide a widely applicable method for sulphenic acid 
detection in vitro and in vivo (Seo and Carroll, 2009). 
In addition to the dimedone system, Carroll’s group developed a new probe, based on 
dimedone, in an attempt to improve the identification, enrichment and visualisation of 
labelled proteins (Reddie et al., 2008). Dimedone was used as a scaffold and modified to 
include an azide group attached to the 1,3-cyclohexadione via an amide link – allowing the 
addition of phosphine groups, for example pBiotin. The advantage of linking the chemical 
probe to pBiotin allows exploitation of the extremely specific and stable binding of biotin 
to avidin or streptavidin. Streptavidin can be coupled to agarose beads or conjugated to 
antibodies for purification or Western blotting techniques, respectively. These properties 
were subsequently confirmed using the newly created DAz-1 molecule and thus provide an 
additional method to detect sulphenic acid in proteins (Reddie et al., 2008). 
A 2009 study by Paulsen & Carroll utilised these chemical probes to investigate the role of 
cysteine sulphenic acid in the Yap1 transcription factor system in yeast, which is central to 
the oxidative stress response. The Yap1 system is essential for survival under conditions of 
oxidative stress and is known to upregulate over 100 genes including thioredoxin and 
glutathione biosynthesis genes. Yap1translocation to the nucleus under oxidative stress has 
been shown to be dependent on conserved cysteine residues (Kuge et al., 1997). Further 
work subsequently implicated disulphide formation in the regulation of the enzyme; a 
nuclear export signal is masked in the active, disulphide bonded state thus retaining the 
transcription factor in the nucleus (Wood et al., 2004). Gpx3, a glutathione peroxidase, was 
shown to have a role in Yap1 activation and implicated an essential Gpx3 cysteine in this 
activation. Furthermore, a cysteine to alanine mutation at residue 303 in Yap1 stabilised a 
Gpx3-Yap1 disulphide-linked complex, suggesting disulphide transfer to Yap1 (Delaunay 
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et al., 2002). Therefore the proposed mechanism of Yap1 activation is mediated by the 
peroxide-induced oxidation of Gpx3 which generates a disulphide bond. This disulphide is 
transferred to cysteine residues 303-598 of Yap1, masking the nuclear export signal and 
allowing the transcription factor activity of Yap1 to upregulate oxidative stress protection 
genes. 
The Paulsen & Carroll study confirmed that Yap1 accumulated in the cytosol in untreated 
cells and that peroxide treatment prevented nuclear export. However, peroxide treatment 
coupled with dimedone prevented Yap1 translocation from the nucleus, suggesting that 
sulphenic acid formation is essential for Yap1 accumulation in the nucleus (Paulsen and 
Carroll, 2009). To prove that this effect was as a result of Gpx3 sulphenylation and 
modification by dimedone, DAz-1 was used as an alternative sulphenic acid-reactive 
probe. Treatment with peroxide and DAz-1 again blocked Yap1 translocation from the 
nucleus. Immunoprecipitation of Gpx3 and subsequent ligation of p-Biotin then allowed 
detection of the DAz-1 labelling by a HRP Western blot. This confirmed that Gpx3 
selectively reacted with DAz-1 in the presence of hydrogen peroxide and thus DAz-1 traps 
Gpx3 in the sulphenylated state in vivo. This was also confirmed in vitro using 
recombinant protein. Paulsen & Carroll then provided evidence suggesting that dimedone 
could prevent formation of the Gpx3-Yap1 complex, confirming the hypothesis that 
dimedone modification of the sulphenylated Gpx3 cysteine would prevent mixed 
disulphide formation between the two enzymes. This study therefore provides clear 
evidence that oxidation of cysteine residues can play a critical role in the yeast oxidative 
stress response. It also shows that chemical probes can be used to detect sulphenic acid 
formation in vitro and in vivo, and provides a means of disrupting the system to determine 
the function of sulphenylation. 
1.3.3 The DsbG sulphenylation protection mechanism in gram negative bacteria. 
The Dsb system in bacteria provides an oxidative protein folding pathway within the 
periplasmic space. To balance the oxidative pathway, a reductive pathway exists and is 
mediated by the proteins DsbB and the periplasmic isomerases DsbC and DsbG. In 
addition to maintaining the isomerase machinery in a reduced state, the reductive pathway 
is now known to be important for other purposes.  For example, the discovery of a 
periplasmic peroxiredoxin enzyme and its reduction by the DsbB-like protein ScsB in 
Caulobacter crescentus prevents inactivation of the due to hyperoxidation (Cho et al., 
2012). This has implications in the scavenging of peroxides and the balancing of oxidative 
power in the periplasm. A novel PDI-like protein within the periplasm of the same 
organism, ScsC, and its ScsB-dependent reduction again demonstrates that this reductive 
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pathway is important for protein folding and is a widely adopted mechanism for electron 
transport (Cho et al., 2012). However, one particularly interesting and crucial function of 
the reductive pathway is the protective mechanism mediated by DsbG. While DsbG shares 
a certain level of identity and similarity with DsbC, one crucial difference between the two 
is the composition of the binding domains – DsbG is thought to bind larger, more fully-
folded proteins. 
As yet, no substrates have been found to be affected by the absence of DsbG in terms of 
folding; however a mutant of DsbG in which has the resolving cysteine of its active site 
mutated to alanine (CxxA) interacts with a host of substrates in a disulphide-dependent 
manner (Depuydt et al., 2009). This was shown in a 2009 study by Depuydt et al. which 
isolated and determined YbiS as an interacting factor; a transpeptidase involved in the 
crucial process of peptidoglycan synthesis. This protein contains a single cysteine residue 
which is essential for functioning (Mainardi et al., 2007). Depuydt et al. showed that, after 
reacting purified YbiS with the thiol-reactive 2-nitro-5-thiobenzoate (DTNB) to form 
YbiS-TNB, DsbG was able to reduce the YbiS cysteine. By spectrophotometrically 
following the reaction between these two reagents, the reduction of the YbiS cysteine 
residue is coupled to the release of the TNB moiety – which absorbs light at 412nm. The 
Depuydt et al. study showed that this reaction produced an increase in absorbance at 
412nm thus indicating the reduction of the YbiS cysteine. An in vivo disulphide-dependent 
interaction was confirmed between YbiS and DsbG when a dsbG null mutant was 
complemented with a DsbG containing the CxxA mutation in the active site. This mutant 
cannot resolve the mixed disulphide formed between the two molecules therefore the 
reaction intermediate is stabilised; the resultant complex was confirmed by Western 
blotting. Crucially, the equivalent experiments performed with DsbC showed no 
interaction, providing in vivo evidence for the distinctive substrate specificity of DsbG.  
Further in vivo studies by Depuydt et al. suggest that the cysteine thiol in YbiS is 
susceptible to oxidation or sulphenylation. This was shown by looking at the oxidation 
state of YbiS using a number of E. coli strains: dsbC, DsbG, dsbCdsbG and wild type. 
YbiS was found to be more oxidised in the dsbG null mutant compared to the dsbC null 
mutant, suggesting that it is preferentially reduced by DsbG. However, more oxidised YbiS 
was found in the dsbCdsbG mutant suggesting that DsbC may contribute slightly to the 
reduction of the thiol. Next, the study tested the YbiS oxidation state in a dsbB mutant 
which, as expected, resulted in an increased oxidation of the YbiS free thiol due to the 
absence of a reductive pathway. This oxidation was shown to be due to sulphenylation; 
incubating YbiS with hydrogen peroxide increased the cysteine sulphenic acid content. 
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This effect was confirmed both in vitro and in vivo. Further in vivo work subsequently 
showed that protein sulphenic acid content was elevated in dsbC and dsbG mutants, and 
was most prevalent in the dsbCdsbG double mutant. The conclusion from this study is that 
DsbG, with its increased affinity for folded proteins, is likely to reduce oxidised single 
cysteine residues and protect from sulphenylation and inactivation. DsbC is proposed to act 
as a backup for DsbG in this function so that proteins within the periplasm are protected 
from this unwanted modification. 
1.3.4 The peroxiredoxin family; protecting from and harnessing the oxidative power 
of hydrogen peroxide. 
While gram-negative bacteria possess the DsbG sulphenylation protection system, another 
conserved group of enzymes are widely adopted by prokaryotes and eukaryotes to prevent 
unwanted peroxide-mediated oxidation. The peroxiredoxin (Prx) group of enzymes, of 
which there are six in mammals (PrxI-VI), are all antioxidant enzymes with a high 
reactivity towards hydrogen peroxide. They have specific expression patterns: PrxI exists 
in the cytosol and nucleus (Immenschuh et al., 2003), PrxII in the nucleus, PrxIII in the 
mitochondria (Matsushima et al., 2006), PrxIV in the ER and potentially secreted 
(Tavender et al., 2008), PrxV in peroxisomes and PrxVI in the cytosol (Figure 1.8). The 
peroxiredoxins can be split into two main groups – the typical and the atypical 2-Cys Prxs. 
The typical 2-Cys peroxiredoxins are the most extensively studied group of peroxiredoxins 
with their general structures and catalytic mechanisms well established. PrxIV is a member 
of the typical 2-Cys family and is known to be directed to the ER by an N-terminal signal 
sequence and retained by an as yet unknown mechanism as it lacks the KDEL ER-retention 
motif (Tavender et al., 2008).  
The peroxiredoxins are characterised by a conserved redox active cysteine, termed the 
‘peroxidatic’ cysteine. The sulphydryl group of the residue attacks peroxides resulting in 
the formation of a cysteine sulphenic acid (-SOH) (Choi et al., 1998). The 2-Cys Prxs also 
have a C-terminal ‘resolving’ cysteine, which will then attack the sulphenic acid to form a 
disulphide with the concomitant release of water. PrxIV specifically exists as a 
homodecamer with the peroxidatic cysteine (C124) attacked by the resolving cysteine 
(C245) of another enzyme thus linking the two molecules together via a disulphide bond. 
This interaction arranges the dimer in such a way that the remaining free peroxidatic and 
resolving cysteines come into close proximity. Upon oxidation by further peroxide a 
disulphide can form between these residues resulting in the linking of the dimer by two 
disulphides rather than one (Figure 1.9). The remaining solvent accessible cysteine (C51) 
can then disulphide bond with adjacent C51 residues to build the homodecamer. The 
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reaction of Prx with peroxide is thought to be facilitated by the local environment of the 
peroxidatic cysteine. Thiols have a pKa of around 8, however the peroxidatic cysteine thiol 
is thought to have a pKa of around 5-6 (Nelson et al., 2008) allowing for a rate constant of 
around 10
7
 M
-1
 s
-1 
(Peskin et al., 2007). A conserved hydrogen bonding network present in 
the active site is also thought to activate peroxide to increase reactivity with the thiolate 
anion (Hall et al., 2011), resulting in the high rate constant.  
This high rate constant ensures that the peroxiredoxins are efficient peroxide scavengers 
and are sensitive to peroxide levels within the cell. However, they are susceptible to 
hyperoxidation by high concentrations of hydrogen peroxide (Wagner et al., 2002, 
Tavender and Bulleid, 2010). A sulphenic acid group can be oxidised further to create the 
hyperoxidised sulphinic (-SO2H) or sulphonic (-SO3H) acids. This effectively inactivates 
the enzyme as the hyperoxidised peroxidatic cysteine side chain cannot be resolved by the 
resolving cysteine and so cannot form the intramolecular disulphide bond. In the inactive 
form peroxiredoxin is thought to allow the accumulation of higher concentrations of 
hydrogen peroxide in order to propagate a signal, leading to cell cycle arrest for example 
(Phalen et al., 2006). They have also been suggested to provide a chaperone function when 
peroxidase activity is abolished (Lee et al., 2007). Hydrogen peroxide scavenging, 
chaperoning and signal propogation are therefore three functions carried out by the 
peroxiredoxins.  
One function particular to PrxIV was discovered recently relating to the specific 
localisation of PrxIV in the ER and its proximity to the oxidative protein folding 
machinery. The presence of the sulphydryl oxidase Ero1α within the ER leads to the 
production of hydrogen peroxide within the compartment. This hydrogen peroxide is now 
known to be not just mopped up by PrxIV but actually utilised in order to harness its 
oxidising power. Under steady state conditions oxidative stress is not induced within the 
ER, however when the UPR is induced Ero1β is upregulated, providing greater oxidising 
power (Harding et al., 2003). This in turn generates higher concentrations of reactive 
oxygen species and oxidative stress (Marciniak et al., 2004) which is exacerbated in a 
PrxIV knockdown cell line (Tavender and Bulleid, 2010). This suggests that PrxIV is the 
main peroxidase involved in the breakdown of Ero1α generated hydrogen peroxide. It is 
now known that the disulphide bonds generated by PrxIV can be passed on to PDI in a 
dithiol-disulphide exchange mechanism (Tavender et al., 2010, Zito et al., 2010) which, 
when coupled to the direct oxidation of PDI by Ero1α, results in the formation of two 
disulphides within PDI. The implications of this are that oxidative protein folding is more 
efficient and can be driven independently of the Ero1α-PDI mechanism and this  
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Figure 1.8 – Cellular and extracellular localisation of the peroxiredoxin peroxide 
scavangers. PrxI and PrxII are found in the nucleus, while PrxI, II and VI are found in the 
cytosol. PrxIII and V are localised to the mitochondria; PrxIV is found within the ER and is 
potentially secreted; PrxV is found in peroxisomes. 
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Figure 1.9 – Peroxiredoxin IV reacts with hydrogen peroxide which creates disulphide 
linked homodimers. Hydrogen peroxide reacts with cysteine 124, the ‘peroxidatic’ 
cysteine, of one molecule of PrxIV resulting in the sulphenylation of cysteine 124. The 
‘resolving’ cysteine, cysteine 245, of a second PrxIV molecule reacts with the cysteine 
sulphenic acid, releasing water and linking the two molecules via a disulphide. A second 
hydrogen peroxide molecule can then react with the second peroxidatic cysteine before 
resolution of the sulphenic acid by the second resolving cysteine. This links the dimer via 
a second disulphide. 
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observation has been confirmed in vivo (Zito et al., 2010). 
1.4 Aims of this study. 
The mechanism of reduction of the Ero1α regulatory disulphides has been well 
characterised. What is unclear is how these regulatory disulphides are re-formed. This is of 
significant interest as Ero1α hyperactivity, or deregulated activity, can have dire 
consequences for oxidative protein folding, the ER and the cell. Correct regulation of 
Ero1α activity is imperative to prevent hyperoxidation of the ER and the misfolding of 
client proteins. The Kim et al. study in 2012 highlighted the ability of Ero1p to regulate its 
own activity via autonomous oxidation, while PDI was also identified as a major source of 
disulphides for this purpose. Many studies have shown previously, however, that there are 
subtle differences between the Ero1p and Ero1α isoforms. This study aimed to investigate 
the regulation of Ero1α activity at the molecular level. 
Three hypotheses were proposed which could all feature in the mechanism of Ero1α re-
oxidation and inactivation, and could be tested experimentally. These were: 
 That Ero1α regulatory disulphide formation may be driven by hydrogen peroxide; 
creating a feedback loop that would ensure Ero1α activity would be regulated when 
hyperactivity generated excessive quantities of hydrogen peroxide. 
 That the flexible nature of the loop accommodating the Ero1α shuttle disulphide 
may provide a means of distributing disulphides within the Ero1α molecule itself, 
from the active site adjacent to the FAD cofactor to the regulatory cysteine 
residues. Autonomous Ero1α oxidation may also be feasible. 
 That PDI family members and ER residents may provide a means of oxidising 
Ero1α regulatory disulphides due to the propensity of PDIs to oxidise reduced 
substrates. This would also provide a feedback loop which would shut down Ero1α 
activity when the pool of oxidoreductases becomes overly oxidised, or when the ER 
glutathione balance is shifted towards a more oxidising ratio and prevents the 
reduction of the PDIs. 
Furthermore, the role of glutathione within the ER has been debated for a number of years. 
To further investigate the role of glutathione on the ER redox balance, this study aimed to: 
 Investigate role of glutathione in redox homeostasis in the ER 
 Investigate the impact of Ero1α on redox homeostasis in the ER in the absence of 
cytosolic glutathione 
 Compare the redox states of ER oxidoreductases in SP cells and microsomes 
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3. Oxidation by ER oxidoreductases?
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Figure 1.10 – Oxidation and inactivation of Ero1α may result from Sulphenylation, 
intramolecular disulphide exchange or by oxidation by ER oxidoreductases. Schematic 
diagram to depict the potential mechanisms of oxidation of Ero1α. 1 – Sulphenylation 
may drive oxidation of the regulatory disulphides. 2 – The disulphides generated by Ero1α 
may be distributed within the molecule to the regulatory cysteine residues. 3 – ER 
oxidoreductases, such as PDI, or the non-physiological substrate Trx, may provide a 
means of regulating Ero1α activity. 
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Chapter 2.0 
Materials and Methods 
 
2.1 Strains and plasmids. 
2.1.1 Bacterial strains. 
Escherichia coli XL1 blue cells (Invitrogen) were used for the replication of plasmid 
vectors. These cells are endonulease and recombinase deficient so inserts are more stable. 
For expression and purification of recombinant proteins, E. coli Origami B (DE3) pLysS 
cells were used (Novagen). These cells lack thioredoxin reductase and glutathione 
reductase; preventing reduction of thioredoxin and glutathione thus greatly enhancing 
disulphide bond formation within the cytoplasm. 
2.1.2 Plasmids used during this study. 
The human Ero1α expression vector was previously prepared as described (Baker et al., 
2008). A pET23a vector construct was used to express a His-tagged version of PDI. A 
pET28a vector was used to express a His-tagged version of E. coli thioredoxin. A pVD85 
construct expressing His-tagged PDI binding mutant (I272A, D346A, D348A) 
wasobtained from Lloyd Ruddock (University of Oulu). 
2.2 Growth of bacteria, culture media and general growth conditions. 
Unless stated, bacterial growth was carried out in Luria-Bertani (LB) medium (Tryptone 
10 g/l, yeast extract 5 g/l and NaCl 10 g/l in dH2O, pH 7). For LB-agar plates, 15 g/l agar 
was added to LB before autoclaving. All media was autoclaved immediately following 
preparation. 
Overnight cultures were grown in 5ml LB for 15 hr at 37 °C, shaking at 200 rpm. 
Inoculation was carried out using frozen glycerol stocks or a single colony grown on LB-
agar plates. Larger overnight cultures were grown in 50 ml volumes to be used in Midi-
prep plasmid purifications. 
Antibiotics were prepared by dissolving antibiotics in dH2O (ampicillin, kanamycin or 
tetracycline) or ethanol (chloramphenicol) before filter sterilising. Ampicillin was used at a 
final concentration of 100 μg/ml, chloramphenicol at 30 μg/ml, and kanamycin and 
tetracycline at 10 μg/ml. 
For LB-agar plates containing antibiotic, LB-agar was heated until liquid before cooling to 
42 °C before the addition of the appropriate antibiotic. 
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For short term storage, growth on LB-agar plates was stored at 4 °C for up to two weeks. 
For longer periods of storage, overnight cultures were grown and mixed with sterile 
glycerol (50% v/v) at a ratio of 4:1 of culture: 50% glycerol. The mix was then stored at -
80 °C. 
2.3 Transformations and extraction of plasmid DNA. 
2.3.1 Transformations. 
Approx. 1ng DNA was added to 50 l of competent cells (gifted by Dr. Jana Rudolf, 
University of Glasgow) and left on ice for 30 min after gently mixing. Cells were then heat 
shocked for 90 s at 42 °C before LB was added. Cells were incubated at 37 °C for 45 min, 
shaking at 200 rpm, before plating onto an LB-agar plate containing the appropriate 
antibiotics. Plates were left to dry then incubated at 37 °C overnight.  
2.3.2 DNA purification. 
DNA or shRNA was purified using a Qiagen Plasmid Midi Kit under the instructions 
recommended by the manufacturer. The final purified DNA was resuspended in dH2O. 
DNA was also purified by alkaline lysis. Using the alkaline lysis method, bacterial culture 
was spun at 14,000 x g before resuspending the pellet in chilled GTE solution (25 mM 
Tris-HCl, pH 8.0 containing 50 mM glucose, 10 mM EDTA; autoclaved). This was 
incubated for 2 min before adding NaOH/SDS solution (0.2 M NaOH and 1% (w/v) SDS) 
and inverting to mix. This was incubated on ice for 5 min then potassium acetate solution 
(5 M potassium acetate, pH 4.8) was added and mixed well. This mix was centrifuged at 
14,000 x g for 5 min then supernatant was moved to a fresh tube. 
Phenol:chloroform:isoamyl alcohol was added before centrifuging for 2 min at 14,000 x g. 
The resulting upper phase was moved to a new tube and choloform:isoamyl alcohol was 
added then mixed and centrifuged at 14,000 x g for 2 min. The upper phase was again 
moved to a fresh tube with 95% ethanol, mixed and centrifuged at 14,000 x g for 5 min. 
Supernatant was discarded and pellet was washed with 70% ethanol. The pellet was spun 
again, 95% ethanol removed and left to dry. The resulting dry pellet was resuspended in 
dH2O and used appropriately or frozen at -20 ºC. 
2.4 Recombinant protein expression and purification. 
2.4.1 Ero1α expression and purification. 
The Ero1α expression vector was transformed into Origami B (DE3) pLysS E. coli cells. A 
glycerol stock was used to inoculate 5 ml LB containing 100 µg/ml ampicillin, 30 µg/ml 
chloramphenicol, 10 µg/ml tetracycline and 10 µg/ml kanamycin. This culture was 
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incubated at 37 ºC overnight, shaking at 200 rpm. The 5 ml culture was used to inoculate 
500 ml LB containing the same antibiotics at the same concentrations, which was left to 
grow until the A600 reached between 0.5 and 1. At this point an additional 100 ml LB was 
added along with 0.4% glucose, 0.2 mM IPTG, 10 µM FAD and 20 µg/ml ampicillin. The 
culture was moved to a 16 ºC incubator where expression of Ero1α was induced for 24 hr. 
Cells were then pelleted by centrifugation at 8832 x g for 15 min before resuspending in 20 
ml ice-cold lysis buffer (50 mM Tris-HCl buffer, pH 7.5 containing 1 mg/ml chicken egg 
white lysozyme, 20 µg/ml DNase I, 2.5 µg/ml RNase A, two complete EDTA free protease 
cocktail inhibitor tablets, 1 mM EDTA and 0.1% v/v Triton X-100) per litre of culture. 
Cells were lysed by freeze-thawing in liquid nitrogen and a 37 ºC water bath then 
incubated at room temperature with gentle agitation for 10 min. Samples were centrifuged 
at 13,248 x g for 30 min and the supernatant was incubated with 1 ml glutathione 
sepharose beads (pre-equilibrated in 50 mM Tris-HCl buffer, pH 7.5, GE Healthcare). This 
was left for between 1 and 4 hr at 4 ºC with gentle agitation before washing with 50 ml 50 
mM Tris-HCl buffer, pH 7.5. Beads were then resuspended in 2.5 ml of 50 mM Tris-HCl 
buffer, pH 8 containing 2.5 mM CaCl2 and 100 units of thrombin. This was left at 4 ºC 
overnight with agitation. Supernatant was passed through a Nickel-affinity column (GE 
Healthcare, His-trap FF 1ml) pre-equilibrated with 50 mM Tris-HCl buffer, pH 7.5 
containing 5 mM imidazole. The column was then washed with wash buffer containing 50 
mM imidazole. Elution was carried out by gradually increasing the imidazole 
concentration up to 500 mM. 
The fractions containing Ero1α were then pooled and desalted in a PD10 column before 
buffer exchanged into 50 mM Tris-HCl buffer, pH 7.5 containing 1 mM EDTA and 
concentrated in a 10,000 Da Mw cut-off Vivaspin (GE Healthcare). Concentrations were 
determined via spectrophotometer using the bound FAD absorption coefficient of 12.9 
mM
-1
 cm
-1
at 280 nm. 
2.4.2 PDI wild type and binding mutant expression and purification. 
PDI wild type or binding mutant expression vectors were transformed into Origami B 
(DE3) pLysS E. coli cells. A single colony was used to inoculate a 5 ml overnight culture 
of LB containing 100 g/ml ampicillin. This was then used to inoculate 500 ml YT media 
(10 g/l tryptone, 5 g/l yeast extract, 25 mM Na2HPO4, 25 mM KH2PO4, 50 mM NH4Cl, 5 
mM Na2SO4, 2 mM MgSO4, 2 mM CaCl2, 0.5% glycerol, 2.5 mM glucose and 0.2% 
lactose in dH2O. This culture was grown for 30 hr at 30 °C before harvesting at 8832 x g 
for 15 min at 4 °C. Cells were lysed in 50 mM Tris-HCl buffer, pH 8 containing 300 mM 
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NaCl, 1 mg/ml chicken egg white lysozyme, 20 g/ml DNase I, 2.5 g/ml RNase A, two 
complete EDTA-free protease inhibitor cocktail tablets, 1 mM EDTA and 0.1% v/v Triton 
X-100. This was left at room temperature for 20 min then freeze/thawed three times. 
Samples were centrifuged at 13248 x g for 30 min and the supernatant was filtered through 
0.22 m filter then passed through a Nickel-affinity column (His-trap FF 1ml, GE 
Healthcare) pre-equilibrated with Buffer A (50 mM Tris-HCl buffer, pH 8 containing 300 
mM NaCl). Bound material was eluted over a linear concentration gradient from 0 – 500 
mM imidazole in Buffer A. Eluted material was concentrated and passed down a gel 
filtration column (Superdex 200 10/300 GL, GE Healthcare) pre-equilibrated in 50 mM 
Tris-HCl buffer, pH 7.5 containing 300 mM NaCl and 10% v/v glycerol. PDI-containing 
fractions, as determined by SDS-PAGE and Western blot, were either subject to further 
chromatography or pooled, concentrated, aliquoted and stored at -80 °C until needed. 
Protein concentration was determined as with Ero1α, using an absorption coefficient of 
45.8 mM
-1
 cm
-1
. 
2.4.3 Purification of thioredoxin. 
Purification of thioredoxin was carried out as for PDI but supplementing growth media 
with 10 µg/ml kanamycin in place of ampicillin. Protein concentration was calculated 
spectrophotometrically at 280 nm using an absorption coefficient of 14.1 mM
-1
 cm
-1
. 
2.4.4 Size-exclusion chromatography. 
Size exclusion chromatography was carried out using a Superdex 200 10/300 GL column 
(GE Healthcare). Samples were clarified by centrifugation at 13248 x g for 10 min and 
concentrated to 0.5 ml in a Vivaspin column (10,000 Da cut-off). Samples were loaded 
onto the column in a buffer of 50mM Tris-HCl, pH 7.5 containing 300mM NaCl and 
elution was carried out in the above buffer. 500 μl fractions were collected and analysed by 
SDS-PAGE where necessary. The elution volumes of proteins of interest were compared to 
that of known standards in order to calculate the molecular weights. 
2.4.5 Ion-exchange chromatography. 
Ion exchange chromatography was carried out using a HiTrap Q FF column (GE 
Healthcare). Samples were buffer exchanged to remove NaCl in a Vivaspin column 
(10,000 Da cut-off), clarified by centrifugation at 13248 x g for 10 min and loaded onto the 
column. After loading, the column was washed with 5 column volumes of buffer (50 mM 
Tris-HCl, pH 7.5). To elute proteins, a linear gradient elution was applied in the above 
buffer containing 0 – 1 M NaCl over 5 column volumes. 250 μl fractions were collected 
and samples from each analysed by SDS-PAGE. 
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2.5 SDS-PAGE, Western blotting and gel staining. 
Samples for sodium dodecyl-sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
analysis were resuspended in SDS sample buffer (25 mM Tris-HCl buffer, pH 6.8 
containing 2% w/v SDS, 2% v/v glycerol and 0.004% w/v bromophenol blue). Reduced 
samples contained 20 mM DTT or 10 mM TCEP. Gels were then Coomassie stained, silver 
stained or transferred onto a nitrocellulose membrane for Western blotting. For Western 
blots, membranes were blocked in 3% milk in TBST (Tris-buffered saline, 10 mM Tris-
HCl buffer, pH 7.5 containing 150 mM NaCl supplemented with 0.1% v/v Tween-20) for 1 
hr. Primary antibodies were used at 1:10,000 (α-GAPDH; Abcam), 1:2,000 (α-Ero1α, Cell 
Signalling Technologies; α-ERp46, Prof. Ellgaard, Univ. Copenhagen; and α-PrxSO2/3, 
Abcam), 1:1,000 (α-PDI, Prof. Freedman, Univ. Warwick; α-ERp57, Abcam; and α-PrxIV, 
Lab Frontier) or 1:500 (α-dimedone, Prof. Carroll, Scripps Institute) in TBST for 1 hr or 
overnight. Secondary antibodies (Thermo Scientific) were used at 1:2,500 for 1 hr, and 
blots were visualised using an Odyssey Imaging System (LI-COR Biosciences). α-mouse 
secondary antibody was used to bind α-GAPDH, α-PrxIV and α-PrxSO2/3 primary 
antibodies. α-rabbit secondary antibody was used to bind α-PDI, α-ERp46, α-ERp57 and α-
dimedone primary antibodies. α-goat secondary antibody was used to bind α-Ero1α 
primary antibody. 
SDS-PAGE gels were cast and run using Pharmacia Biotech mini VE Complete apparatus. 
The resolving gel with appropriate acrylamide content was poured using 30% ProtoGel 
(w/v) acrylamide (National Diagnostics), resolving buffer (1.5 M Tris-HCl, pH 8.8), 10% 
(w/v) ammonium persulphate in dH2O (APS), 10% SDS in dH2O and 25 μl N, N, N’, N’-
Tetramethylethylenediamine (TEMED) (Sigma). Once poured and before setting, the 
resolving gel was overlaid with 0.5 ml isopropanol. The isopropanol was removed once the 
gel was set. The resolving gel was poured using resolving buffer (0.5 M Tris-HCl, pH 6.8) 
in place of stacking buffer.  
Molecular weight markers used were either 10 μl 6H (Sigma) or 3 μl Prestained marker 
(New England Biolabs). 
Following electrophoresis, proteins were visualised by gently shaking in Coomassie blue 
staining solution (45% v/v methanol, 9% v/v glacial acetic acid, 0.1% w/v Sigma Brilliant 
Blue G-250) for a minimum of 1 hr. Excess stain was removed by washing with dH2O 
overnight. 
For silver staining, gels were fixed for a minimum of 2 hr in Fixer (50% methanol, 12% 
acetic acid, 0.05% formalin) and washed three times in 35% ethanol (20 min each). Gels 
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were sensitised in 0.02% sodium thiosulfate for 2 min before three 5 min washes in water. 
Gels were stained in 0.2% silver nitrate and 0.076% formalin for 20 min before two 1 min 
washes in water. Developer (6% sodium carbonate, 0.05% formalin and 0.0004% sodium 
thiosulfate) was added until bands were visible. Staining was stopped in 50% methanol; 
12% acetic acid. Gels were gently agitated throughout the silver staining protocol. 
2.6 In vitro assays. 
2.6.1 Ero1α – Thioredoxin assays. 
Thioredoxin was reduced with 10 mM DTT for 10 min at 4 °C and desalted on a PD10 
column (GE Healthcare). 2 M Ero1α was incubated with 100 M reduced thioredoxin. 
Assays were performed over 1200 s with samples taken at specific time points and the 
reactions were stopped in SDS sample buffer containing either 50 mM N-ethylmaleimide 
(NEM) or 20 mM 4-acetamido-4′-maleimidylstilbene-2,2′-disulfonic acid (AMS) to freeze 
the redox states. Samples were then analysed via 8% SDS-PAGE to visualise Ero1α redox 
state or 15% SDS-PAGE to visualise the Trx redox state. For anaerobic assays, all reagents 
and buffers were kept in an anaerobic chamber overnight to eliminate oxygen. Buffers 
were purged with nitrogen prior to incubation in anaerobic chamber. Reactions were 
carried out in 50 mM Tris buffer, pH 7.5 containing 1 mM EDTA. 200 M free FAD or 50 
mM dimedone were included in the reaction buffer as indicated. 
2.6.2 Oxygen electrode assays. 
Changes in oxygen concentration in solution were measured using a Clarke-type oxygraph 
instrument (Hansatech Instruments Ltd). Assays were carried out in 50 mM Tris-HCl 
buffer, pH 7.5 containing 300 mM NaCl; in a total volume of 500 µl. Ero1α was included 
at a concentration of 2 µM with DTT (10 or 20 mM). Measurement of the oxygen 
concentration was continued for 900 s or until the oxygen in the chamber had been 
completely consumed.  
For Ero1α-PDI oxidation assays using the oxygen electrode, reactions were carried out 
using 1µM Ero1α and 10µM PDI under the above conditions. Increasing concentrations of 
GSH (350µM, 1mM, 2mM or 10mM) were included to maintain PDI recycling. 
2.6.3 Ero1α re-oxidation assays. 
The redox state of Ero1α was determined using an SDS-PAGE based approach. For the 
oxygen titration assay, Ero1α was reduced with 10 mM DTT for 1 min before applying to a 
Micro Bio-Spin 6 Chromatography Column (Bio-Rad) which was pre-equilibrated in 
anaerobic buffer (50 mM Tris-HCl, pH 7.5 containing 1 mM EDTA) to remove DTT. 
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Aerobic buffer (50 mM Tris-HCl, pH 7.5 containing 1 mM EDTA and approximately 250 
M O2) was added to the reaction to increase the O2 concentration from 0 M to 50 M or 
225 M. Samples were taken at time points 0, 10, 30, 60 and 300 s and immediately 
alkylated in SDS sample buffer containing 25mM NEM. Samples were analysed by 8% 
SDS-PAGE and silver stained. 
For the ER oxidoreductase assays, Ero1α was reduced and DTT was removed as described 
above. Purified ER oxidoreductases were oxidised by incubation with 20 mM GSSG for 15 
min before applying to Micro Bio-Spin columns to remove GSSG. 2 M Ero1α was 
incubated with 10 M oxidoreductase in anaerobic buffer. Samples were taken at time 
points 0, 10, 30, 60 and 300 s and immediately alkylated in SDS sample buffer containing 
25 mM NEM. Samples were analysed by 8% SDS-PAGE and silver stained or Western 
blotted as required. 
For the hydrogen peroxide assays, Ero1α was reduced and DTT removed as above. 10 or 
100 μM hydrogen peroxide was added to 2 μM Ero1α then samples were taken at 0, 10, 30, 
60 and 300 s. Samples were immediately alkylated in SDS sample buffer containing 25 
mM NEM. Samples were analysed by 8% SDS-PAGE and silver staining. 
2.6.4 Dimedone labelling. 
To label recombinant, purified PrxIV with dimedone in order to identify sulphenic acid 
formation, 10 µM PrxIV was incubated with 5 mM dimedone and 60 µM hydrogen 
peroxide in 50 mM Tris-HCl buffer containing 300 mM NaCl. The reaction was titrated to 
pH 7.5 using sodium hydroxide prior to protein addition. After 10 min, reactions were 
quenched and dimedone removed by precipitation of protein in 500 µl 10% trichloroacetic 
acid (TCA). Samples were left on ice for 30 min before centrifucation at 16,000 x g. 
Precipitated protein was washed three times with 1 ml ice-cold acetone and resuspended in 
SDS sample buffer and analysed by SDS-PAGE under reducing conditions (50 mM DTT). 
Labelling of C245A PrxIV was carried out as above but using 0, 5 or 50 µM hydrogen 
peroxide during the incubation. Labelling of Ero1α was carried out in the presence of 0, 
10, 20 or 60 µM hydrogen peroxide. Samples were then analysed as above. All samples 
were Western blotted, probing with the α-dimedone antibody. 
Trapping Ero1α in its active, reduced form with dimedone during the Ero1α-Trx assay was 
carried out as in Chapter 2.6.1 but included 50 mM dimedone in the reaction mixture. The 
solution was titrated to pH 7.5 using sodium hydroxide.  
2.7 In vivo assays. 
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2.7.1 Semi-permeabilised cell preparation. 
HT1080 cells were grown to confluence in a T75 flask. Cells were washed with 10 ml PBS 
then trypsinized in 2 ml Trypsin solution (0.05% Trypsin – EDTA; Gibco) for 3 min at 37 
°C. Detached cells were resuspended in 8 ml KHM buffer (20 mM HEPES buffer, pH 7.2 
containing 110 mM KOAc and 2 mM MgOAc). Soybean trypsin inhibitor was added to a 
concentration of 100 μg/ml and the cell suspension moved to a 15 ml Falcon tube. Cells 
were pelleted at 250 x g for 5 min and resuspended in 6 ml ice cold KHM buffer. Digitonin 
was added to a final concentration of 40 μg/ml and the cells were incubated on ice for 5 
min. A further 6 ml KHM buffer was added and mixed before pelleting cells at 250 x g for 
5 min. Cells were resuspended in 14 ml HEPES buffer (90 mM HEPES buffer, pH 7.2 
containing 50 mM KOAc) and incubated on ice for 10 min before pelleting at 250 x g for 5 
min. Cells were resuspended in 1 ml KHM buffer and a 10 μl aliquot was taken in order to 
count cells and confirm their permeability using Trypan blue (0.4% in dH2O). Cells were 
transferred to a 1.5 ml Eppendorf, pelleted and resuspended in 100 μl KHM buffer. 
2.7.2 DTT-recovery. 
HT1080 cells were grown in 6cm dishes in Dulbecco’s Modified Eagle Medium (DMEM, 
Invitrogen) containing 10% FCS, 0.1 mg streptomycin and 100 units per ml penicillin 
(Sigma) and 2 mM glutamine. Cells were treated with 2 ml DMEM containing 10 mM 
DTT for 5 min before washing the cells in 4 ml fresh DMEM for up to 60 min. Cells were 
incubated in PBS containing 20 mM NEM for 10 min to freeze the redox status of ER 
proteins. PBS containing NEM was then removed and cells were lysed in 100 μl ice cold 
lysis buffer (50 mM Tris-HCl buffer, pH 8 containing 1% Triton X-100, 150 mM NaCl 
and 5 mM EDTA) and detached using a cell scraper. Lysates were incubated on ice for 20 
min before spinning at 16,000 x g for 10 min. The supernatant was transferred to a fresh 
tube and 20 μl of this was added to 5 μl 5x SDS PAGE sample buffer. Samples were 
analysed by 8% SDS-PAGE. The oxidised control sample was created by treating cells 
with 2 ml DMEM containing 1 mM DPS for 5 min before washing cells in PBS containing 
NEM and processing as above. 
2.7.3 shRNA knockdown assays. 
HT1080 cells were grown to 80% confluence in 15 cm dishes.12 μg of DNA constructs 
encoding shRNA against either PDI or ERp46 (or 10µg of each for the PDI-ERp46 double 
transfection) was mixed with 0.5 ml serum-free DMEM for 10 min at room temperature. 
360 μM polyethylenimine (PEI) was added and mixed by gently pipetting and left at room 
temperature for 20 min. 0.5 ml of this mixture was added drop by drop to 20 ml of 
51 
 
complete DMEM in each 15 cm dish. After gentle mixing, cells were returned to the 37 °C 
incubator for 6 hr. Media was aspirated and replaced with 20 ml complete DMEM. 
Selection media (1 μg/ml puromycin in complete DMEM) was added 16 hr post-
transfection and replenished 48 hr post transfection. Cells were used to complete DTT-
recovery assay, above, after 5 days. 
2.7.4 Determining the redox state of PDI and ERp57. 
Cells, SP cells or microsomes were treated with 10 mM DTT, 1 mM DPS or left untreated 
for 10 min on ice in KHM buffer. The redox states of the enzymes were frozen by adding 
20 mM NEM. Cells were centrifuged at 300 x g for 5 min before lysing in 10% TCA. 
Precipitated proteins were pelleted by centrifugation at 16,000 x g for 10 min and washed 
three times in ice-cold acetone. Samples were resuspended in SDS sample buffer. 10 mM 
TCEP was added and incubated at room temperature for 10 min before incubating with 20 
mM AMS. Samples were then analysed via 8% SDS-PAGE and Western blotted. 
2.7.5 Quantifying the glutathione content in cells and SP cells. 
Cells or SP cells were lysed in 400 µl 1% 5-sulfosalicyclic acid on ice for 1 hr. Precipitated 
proteins were removed by centrifugation at 16,000 x g for 10 min. 10 µl of supernatant was 
added to 150 mM sodium phosphate buffer, pH 7.5 containing 0.2 mM NADPH, 0.6 mM 
Ellman’s reagent and 1 unit of glutathione reductase in a total volume of 500 µl. The rate 
of change of absorption at 405 nm was monitored at 30 ºC and compared to that of 
glutathione standards to quantify glutathione content in cell or SP samples. 
Ero1α knockdown cells were created previously: HT1080 cells expressing roGFP-iL-
KDEL were transfected with and Ero1α shRNA construct. These cells were grown under 
selection and single colonies were tested for expression of Ero1α by Western blot (van Lith 
et al., 2011). 
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Chapter 3.0 
Characterisation of Ero1α and its chemically-mediated re-oxidation 
 
3.1 Introduction. 
3.1.1 Hydrogen peroxide production. 
Hydrogen peroxide is a reactive oxygen species (ROS) which is produced by a number of 
enzymes throughout the cell: (i) in the ER as a result of oxidative protein folding; (ii) in the 
mitochondria from electron transport chain enzymes; (iii) in the peroxisome to fight 
foreign bodies;(iv) throughout the cytosol and plasma membrane as a byproduct of 
enzymatic activity. These enzymes are generally involved in electron transfer and are 
bound to electron transfer-facilitating cofactors such as FAD or transition metals. Within 
the ER, Ero1α is known to produce one molecule of hydrogen peroxide per disulphide 
bond created (Gross et al., 2006). QSOX, an enzyme which traverses the ER prior to 
secretion is also known to generate hydrogen peroxide (Hoober et al., 1996). These two 
enzymes are linked to an FAD cofactor which, upon reduction, leads to hydrogen peroxide 
production. Within mitochondria, a number of proteins can generate hydrogen peroxide as 
a byproduct of activity. Respiratory complexes I and III are major producers of ROS as a 
result of their role in oxidative phosphorylation (Ksenzenko et al., 1983, Kussmaul and 
Hirst, 2006, Sun and Trumpower, 2003). Amine oxidases, involved in amino acid 
metabolism, also produce hydrogen peroxide as a byproduct (Cona et al., 2003), while 
superoxide dismutase (SOD) is another source. 
While many enzymes produce hydrogen peroxide and its precursors as byproducts of 
activity, there are a number of sources where peroxide is generated for a specific function. 
In peroxisomes there are a number of hydrogen peroxide producers including D-amino 
acid oxidase, Acyl CoA oxidase, and Xanthine oxidase. These enzymes produce hydrogen 
peroxide in order to combat foreign bodies; powerful oxidants damage the foreign bodies 
and eliminate potential threats. The hydrogen peroxide produced by the amine oxidases are 
proposed to contribute to defence and cell wall synthesis in plants (Cona et al., 2003). The 
NADPH oxidase (NOX) family of enzymes are thought to contribute significant quantities 
of hydrogen peroxide to the phagocyte-mediated killing of bacteria (Geiszt et al., 2003, 
Moore and MacKenzie, 2009). 
There are a variety of hydrogen peroxide sources within the cell, therefore, which provide 
potential sources of ROS which may result in the unwanted or debilitating oxidation of a 
host of molecules. 
3.1.2 PrxIV reduces hydrogen peroxide; increasing the oxidative power of the ER. 
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A number of peroxidase enzymes located within the ER possess the ability to eliminate 
excessive concentrations of hydrogen peroxide. PrxIV is able to protect cells from DTT or 
tunicamycin-induced ER stress (Tavender and Bulleid, 2010). Upon DTT treatment, Ero1α 
generates an increased concentration of hydrogen peroxide as the oxidative balance within 
the ER is restored. PrxIV is sensitive to increased hydrogen peroxide levels, implicating 
this enzyme in the elimination of Ero1α-generated hydrogen peroxide. 
Several members of the PDI family, such as ERp46, PDI and P5, are able to reduce the 
peroxidatic disulphide within PrxIV. Reduction of the peroxidatic disulphide is enhanced 
when PDI family members are reduced by glutathione, indicating that the recycling of the 
PDIs leads to increased recycling of PrxIV. In cells, overexpression or shRNA knockdown 
of P5, ERp46 and PDI leads to increased or decreased PrxIV recycling, respectively 
(Tavender et al., 2010). A PrxIV-PDI mixed disulphide has been isolated, confirming 
disulphide transfer between the two molecules (Zito et al., 2010). PrxIV is thought to 
provide an alternative source of disulphides in Ero1α deficient cells, as it can drive 
oxidative folding of RNase and supports collagen folding (Zito et al., 2010). PrxIV, 
therefore, has a cytoprotective role and its absence increases cellular sensitivity to 
oxidative stress. PrxIV also complements the disulphide generating ability of Ero1α and 
provides a novel mechanism of driving oxidative protein folding coupled to the elimination 
of hydrogen peroxide. The ER therefore generates two disulphides per molecule of 
hydrogen peroxide formed. 
3.1.3  The autonomous oxidation of Ero1p. 
Ero1p is capable of autonomous oxidation – where one molecule of Ero1p can oxidise 
another. Three Ero1p mutants, a C-terminal and N-terminal truncated form named Ero1pc, 
a shuttle-disulphide deficient mutant termed C100A-C105A, and a mutant unable to form 
the active site disulphide termed C355A-Ero1pc, were created and used in a number of 
assays to investigate their re-oxidation (Kim et al., 2012). The C100A-C105A Ero1p 
mutant is re-oxidised at a slower rate than the fully active Ero1pc. C355A-Ero1pc 
remained in the reduced form indicating that this mutant is incapable of autonomous 
oxidation. The ability of a maltose binding protein-Ero1pc fusion (MBP-Ero1pc) to oxidise 
C355A-Ero1pc was measured and shown to be able to oxidise both itself and the inactive 
mutant – indicative of intramolecular disulphide exchange between the two molecules. 
Further investigation using a MBP-ero1-C100A-C105A mutant, catalytically active but 
lacking a shuttle disulphide, proved that this mutant is incapable of disulphide transfer and 
prevented oxidation of both proteins when incubated with C355A-Ero1pc. Ero1p re-
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oxidation and inactivation can, therefore, occur by autonomous oxidation and is mediated 
by the shuttle disulphide (Kim et al., 2012). 
3.1.4  The Ero1α shuttle disulphide. 
The shuttle disulphide (C100-105 in Ero1p) plays a crucial role in the autonomous 
oxidation and inactivation of Ero1p (Kim et al., 2012). The shuttle disulphide within 
Ero1 (C94-99) may carry out a similar function. The Ero1α shuttle cysteine-containing 
loop is predicted to be extremely flexible and was unable to be mapped during 
crystallographic studies due to poor electron density (Inaba et al., 2010). Furthermore, the 
Ero1α loop regions are longer and more flexible than their Ero1p equivalents. This may 
therefore provide Ero1α with a means of distributing disulphide bonds inter- or intra-
molecularly. The flexible loop, between residues Asp90 and Cys131, may facilitate 
disulphide transfer between the shuttle disulphide and the two adjacent regulatory 
disulphides, thus inactivating Ero1α. 
3.2 Ero1α expression, purification and characterisation.  
In order to investigate the oxidation and inactivation of Ero1α, an in vitro approach was 
adopted as this facilitated control of several important variables that would have been 
difficult to control in vivo. With three possible mechanisms of Ero1α oxidation and 
inactivation (discussed in Chapter 1.4), it was important to assess the ability of each 
individually. Work was undertaken to express and purify recombinant Ero1α lacking the 
23 N-terminal residues thought to constitute the ER signal sequence which is cleaved in 
vivo.  
3.2.1  Ero1α expression and purification. 
Expression of GST and His-tagged Ero1α was carried out in Origami B (DE3) pLysS cells. 
Samples were taken before and after induction of Ero1α expression and analysed by SDS-
PAGE (Figure 3.1A). A band corresponding to a protein of approximately 80 kDa was less 
intense in the pre-induction sample (lane 2) than in the post-induction sample (lane 3). 
After lysis, glutathione-sepharose beads were used to purify the GST-His-Ero1α fusion 
protein. Unbound material from the supernatant was sampled and shows the disappearance 
of the 80 kDa band (lane 4). The beads were washed with buffer which also shows that the 
80 kDa band was absent (lane 5). A sample of bound material showed the reappearance of 
the 80 kDa band (lane 6). The GST moiety was cleaved with thrombin to leave GST bound 
to the beads, releasing His-tagged Ero1α into the supernatant. His-tagged Ero1α ran with a 
mobility corresponding to a molecular weight of approximately 50 kDa (lane 7). Elution of 
remaining bound material showed an intense band running at approximately 25 kDa with 
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Figure 3.1 – Recombinant Ero1α expression and three-step purification. A - Ero1α was 
expressed in E. coli DE3 pLysS Origami cells with samples taken before (lane 2) and after 
(lane 3) induction with IPTG. Lysate was incubated with glutathione sepharose (GS) beads, 
unbound material was sampled and run in lane 4. Beads were washed with buffer (lane 
5). Material bound to the beads (lane 6) was cleaved with thrombin and the supernatant 
collected (lane 7). Elution of material with reduced glutathione shows some Ero1α 
remained bound (lane 8). This material was loaded onto a HisTrap (HT) column; 
flowthrough (lane 9) and a protein-containing fraction (lane 10) shows an intense band 
around 50 kDa and some smaller, less intense bands. B – After concentration of the 
pooled HisTrap fractions containing Ero1α (lane 1), anion exchange was used to remove 
contaminants and degradation products. Lanes 2 – 5 represent the eluted Ero1α. Samples 
were run under reducing conditions and Coomassie stained. 
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a small amount of material running at approximately 50 kDa (lane 8). Further purification 
by nickel-affinity chromatography was carried out. Diluted unbound flowthrough from the 
column (lane 9) contained no Ero1α while the eluted and pooled material contained the 55 
kDa band (lane 10). 
The nickel affinity eluate was concentrated before applying to an anion exchange column 
to clean up the product (Figure 3.1B). The concentrated sample was analysed by SDS-
PAGE (lane 1) as were the eluted fractions (lanes 2-5) which revealed a cleaner product 
(lanes 3 and 4) which were pooled, aliquoted and kept at -80 °C until required. 
3.2.2 Further characterisation of purified Ero1α. 
Equipped with recombinant Ero1α, the next step was to determine its concentration. This 
was carried out as described previously (Baker et al., 2008). Spectrophotometric analysis 
revealed that Ero1α displays the characteristic spectra of an FAD-bound protein as 
absorption peaks at 454 nm and 280 nm (Figure 3.2A). This analysis reveals the 
concentration of Ero1α was 9.1 µM, while the concentration of FAD present was 7 μM. 
The ratio of FAD: Ero1α was 7: 9, therefore approximately 78% of Ero1α was natively 
folded and bound by FAD. 
To determine whether Ero1α had been successfully folded and adopted its oxidised redox 
state after expression and purification, a simple SDS-PAGE based assay was used as 
described previously (Baker et al., 2008). There was a large mobility shift between reduced 
and non-reduced samples; non-reduced Ero1α ran with a molecular weight of 
approximately 50 kDa compared to the reduced form which ran at approximately 60 kDa 
(Figure 3.2B). 
The oligomeric state of Ero1α was analysed by size-exlusion gel filtration chromatography 
(Figure 3.2C), as reported previously (Baker et al., 2008, Dias-Gunasekara et al., 2005). 
Several absorption peaks were observed at 280 nm, while two absorption peaks were 
observed at 454 nm, corresponding to elution volumes of approximately 10.6 ml and 14.45 
ml. These peaks correspond to molecular weights of approximately 41 kDa and 87 kDa, 
comparing the volume of elution to a calibration curve (Appendix 1). 
3.2.3  Measuring Ero1α activity with an oxygen electrode. 
Having shown that the purified Ero1α had bound FAD, was largely monomeric and had 
intramolecular disulphide bonds, enzymatic activity was characterised. To confirm that 
Ero1α was active towards select substrates, an oxygen electrode based assay was used as 
previously desctibed for Ero1p (Gross et al., 2006). This assay works on the principle that  
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Figure 3.2 – Further characterisation of Ero1α. A – The absorbance of purified 
recombinant Ero1α was measured between 260 and 600 nm. B – Ero1α was analysed by 
SDS-PAGE in the presence or absence of DTT. The gel was Coomassie stained to visualise. 
C – Ero1α was analysed by size exclusion gel filtration chromatography. The absorbance 
of eluted material was measured at 280 nm as a measure of protein content (blue trace), 
while the absorbance at 454 nm was monitored as a measure of FAD content. 
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oxygen acts as the terminal electron acceptor in the Ero1α activity cycle; electrons are 
passed from Ero1α to FAD and on to molecular oxygen with the resulting disulphide 
formation within the enzyme and the production of hydrogen peroxide. Therefore, 
enzymatic activity is coupled to oxygen depletion. DTT was used as a substrate as it is a 
strong reducing agent and is readily oxidised. It was oxidised by Ero1α as detected by a 
decrease in oxygen concentration (Figure 3.3A), however in the absence of Ero1α limited 
oxygen was consumed. Likewise, Ero1α incubated in the absence of DTT produced a 
limited depletion of oxygen without a reductant present. This confirmed that the purified 
Ero1α was redox active towards DTT. Further investigation revealed that oxygen 
consumption increased with increasing concentrations of DTT (Figure 3.3A). The reaction 
was limited by the availability of oxygen at DTT concentrations of 10 mM and 20 mM.  
Ero1α activity towards its physiological substrate PDI was tested using the oxygen 
electrode assay (Figure 3.3B). When Ero1α (1 μM) was incubated alone it consumed 
approximately 15 µM oxygen over 900 s. When Ero1α (1 µM) was incubated with reduced 
PDI (10 µM), consumption of 20 µM oxygen was observed. Including 350 µM GSH with 
Ero1 and PDI resulted in the consumption of 20 µM oxygen. This was somewhat 
unexpected because 350 µM GSH is theoretically sufficient to reduce 175 µM of 
disulphides within PDI and thus consume 175 µM oxygen (if two molecules of GSH are 
required to reduce a disulphide, per molecule of oxygen). Including 1 mM GSH resulted in 
a larger concentration of oxygen consumption; 50 µM oxygen was consumed under these 
conditions. Including 2 mM GSH in the chamber resulted in the consumption of 
approximately 90 µM oxygen. The inclusion of 10 mM GSH allowed complete 
consumption of the oxygen, approximately 220 µM, within 200 s. Interestingly, Ero1α 
displayed the characteristic lag- phase under these conditions, as seen by the slow initial 
consumption of oxygen in the presence of DTT (10 mM and 20 mM), and with GSH (1 
mM, 2 mM and 10 mM). Ero1α was active towards DTT and PDI thus was used to further 
investigate its activity using thioredoxin. 
3.2.4  Ero1α oxidises recombinant thioredoxin. 
Ero1α is able to oxidise thioredoxin (Trx) in vitro and displays characteristic redox patterns 
during a time course assay; an initially oxidised Ero1α is quickly reduced by thioredoxin 
before its subsequent re-oxidation at later time points (Baker et al., 2008). The equivalent 
assay was performed on Ero1p, obtaining similar results (Heldman et al., 2010, Sevier et 
al., 2007). To confirm that purified Ero1 could oxidise thioredoxin, displayed the lag-
phase and displayed the intermediate redox forms, an SDS-PAGE based assay was 
performed.  
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Figure 3.3 – Measuring oxygen consumption to characterise Ero1α activity. A – Using DTT 
as a substrate. 1 µM Ero1α alone (red line) and 20 mM DTT alone (blue line) were 
incubated in the oxygen electrode chamber as controls to show that oxygen consumption 
by these two molecules in isolation is minimal. Upon the addition of 10 mM (green line) 
or 20 mM (purple line) DTT to 1 µM Ero1α, oxygen is consumed as Ero1α oxidises DTT. B – 
Ero1α activity towards PDI was measured in the presence and absence of GSH. Assays 
with Ero1α only (dark blue), Ero1α with 10 µM PDI (green), and Ero1α with PDI and 350 
µM GSH (yellow) show minimal oxygen consumption. Including 1 mM (red), 2 mM (light 
blue) and 10 mM GSH (brown) increases oxygen consumption. Assays were carried out in 
50 mM Tris buffer, pH 7.5 containing EDTA and were monitored for 900 s or until the 
oxygen was completely consumed. 
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Figure 3.4 – Ero1α oxidises thioredoxin and displays the characteristic redox pattern. 2 
µM Ero1α was incubated with 100 µM Trx and the redox states of both enzymes were 
frozen using AMS (except the oxidised control) at the given time points. Samples were 
analysed via SDS-PAGE and stained to visualise the proteins. Reduced and oxidised 
controls are included for comparison. The assay is depicted schematically; an initially 
oxidised Ero1α is incubated in the presence of reduced Trx and, upon its reduction, 
oxidises Trx. 
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Purified Ero1 (2 µM) was incubated with purified and reduced Trx (100 µM), with 
samples taken at various time points (0, 10, 30, 60, 120, 600 and 1200 s) and alkylated 
with 4-acetamido-4'-maleimidylstilbene-2,2'-disulfonic acid (AMS) (Fig 3.4). AMS acts to 
freeze the redox state of free thiol groups and adds a mass of 510 Da per thiol modified, 
resulting in a decreased mobility of the modified protein during electrophoresis. Reduced 
proteins therefore run with slower mobility during SDS-PAGE compared to oxidised 
proteins due to their increased mass as well as the increase in hydrodynamic radius due to 
disulphide reduction.  
DTT-reduced and alkylated Ero1α (lane 1, upper panel) ran much more slowly through the 
gel than non-reduced and non-alkylated Ero1α (lane 2). Ero1α existed initially in the fully 
oxidised conformation which migrated quickly through the gel (lane 3) and likely 
corresponded to the OX2 conformation. Ero1α mobility rapidly decreased within 10 s, 
indicating the reduction of one or more disulphides and likely corresponded to the OX1 
form. By 30-120 s the fully reduced form was clearly seen, indicated by the further 
decrease in mobility. Ero1α then slowly shifted back towards, although did not form, the 
OX2 species, indicating incomplete re-oxidation of Ero1α at the later time points. 
The Trx redox state showed that it was initially fully reduced with very little oxidation 
witnessed before 30 s, but was fully oxidised between120-600 s; coinciding with the 
appearance of the fully reduced form of Ero1α. 
3.3 Using sulphenic acid-reactive molecular probes. 
Dimedone has been used previously in a number of studies and reacts specifically with 
cysteine sulphenic acid form. Dimedone was therefore used to determine whether a 
sulphenic acid intermediate is formed within Ero1α, which would indicate that re-oxidation 
and inactivation of Ero1α is mediated by sulphenylation. Dimedone reactivity and 
specificity towards sulphenic acid was initially characterised using peroxiredoxin IV as a 
model system, as sulphenic acid is known to drive PrxIV oxidation. 
3.3.1  Peroxiredoxin IV is sulphenylated and reacts with dimedone. 
To confirm that dimedone was selectively reactive with sulphenic acid, PrxIV (previously 
purified by Dr. Timothy Tavender, University of Glasgow) was treated with dimedone (5 
mM) in the presence or absence of hydrogen peroxide (60 µM). Samples were analysed via 
SDS-PAGE and Western blot using an α-dimedone antibody (Prof. K. Carroll, Scripps 
Research Institute, Florida). The results confirmed that PrxIV is sulphenylated and reacted 
with dimedone both in the presence and absence of hydrogen peroxide (Figure 3.5A).  In 
the absence of hydrogen peroxide, sulphenylation may occur due to the high affinity of  
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the peroxidatic cysteine for hydrogen peroxide which may be present in buffers in trace 
amounts. To prevent dimedone reactivity with the peroxidatic cysteine, and any solvent 
accessible cysteines within PrxIV, a PrxIV triple mutant (TM) was used. This mutant (a 
gift from Dr. Timothy Tavender) has all three solvent accessible cysteines mutated to 
alanines and has only one remaining cysteine buried within the hydrophobic core of the 
molecule. Dimedone reactivity with the PrxIV TM was undetectable, both in the presence 
and absence of hydrogen peroxide. In treating PrxIV TM with SDS, the sole cysteine is 
exposed as the molecule is denatured and is therefore solvent accessible. In the presence of 
hydrogen peroxide this cysteine reacts with dimedone, however in its absence no signal is 
visible. Taken together, this data suggested that the dimedone reaction is cysteine specific 
and is related to oxidation of the thiol sidechains by hydrogen peroxide. 
To show that dimedone reacts specifically with sulphenic acid rather than sulphinic or 
sulphonic acid groups, another PrxIV mutant was used. The PrxIV C245A mutant is a 
cysteine to alanine mutant at position 245 and so does not have a resolving cysteine. Any 
sulphenic acid formed by reaction of hydrogen peroxide with the peroxidatic cysteine will 
not be resolved thus the sulphenic acid will either react with dimedone or be further 
oxidised. C245A PrxIV was treated with dimedone (5 mM) and with increasing 
concentrations of hydrogen peroxide (0 to 50 µM). Samples were then analysed by SDS-
PAGE and Western blot, probing with the α-dimedone antibody. The results showed that in 
the absence of hydrogen peroxide, dimedone had not reacted (upper left panel). In the 
presence of hydrogen peroxide (5 µM) the C245A PrxIV mutant was modified with 
dimedone indicating the formation of sulphenic acid under these conditions. Increasing the 
concentration of hydrogen peroxide to 50 µM resulted in decreased dimedone 
modification. Using an antibody that recognises the hyperoxidised form of peroxiredoxin 
(α-Prx SO2/3) it was possible to see that decreased dimedone reactivity in the presence of 
50 µM hydrogen peroxide was due to the increased formation of hyperoxidised cysteine 
residues. Thus dimedone seemed to be reacting specifically with cysteine sulphenic acid. 
The absence of any band in the samples without dimedone also confirmed that this signal 
was specific to dimedone reactivity (upper right panel).  
3.3.2  Ero1α – dimedone reactivity. 
Having shown that dimedone reacts specifically with cysteine sulphenic acid, it was used 
to investigate the potential formation of sulphenic acid within Ero1α. Ero1α was treated 
with hydrogen peroxide (0-60 μM) and dimedone (5 mM) in an attempt to trap sulphenic 
acid (Figure 3.6A). Samples were analysed by SDS-PAGE and Western blotted using the 
α-dimedone antibody. In the absence of hydrogen peroxide, Ero1α reacted with  
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Figure 3.5 – Dimedone reacts specifically with cysteine sulphenic acid. A – Purified PrxIV 
was treated with 5 mM dimedone in the presence and absence of hydrogen peroxide (60 
µM). The same treatment was carried out on the PrxIV TM and the PrxIV TM in the 
presence of SDS. Samples were analysed by SDS-PAGE and Western blot, probing with the 
α-dimedone antibody. B – C245A PrxIV was treated with or without dimedone in the 
presence of increasing concentrations of hydrogen peroxide. The reaction was quenched 
by acidification in 10% TCA and samples were analysed via SDS-PAGE and Western blot, 
probing with α-dimedone or α-Prx SO3. 
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Figure 3.6 – Ero1α reacts with dimedone. Ero1α was incubated with 5 mM dimedone in 
the presence of increasing concentrations of hydrogen peroxide for 10 min. The reaction 
was quenched by acidification in 10% TCA and samples were analysed via SDS-PAGE 
before Western blotting with the α-dimedone antibody.  
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Figure 3.7 – Dimedone does not trap Ero1α in an active state. 2 μM Ero1α was incubated 
with 100 μM Trx in the presence of 50 mM dimedone and the redox state of both 
enzymes were monitored over 1200 s. Samples were alkylated with AMS at the stated 
time points, analysed by SDS-PAGE and stained to visualise. Reduced and non-reduced 
(ox) samples are included for comparison.  
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dimedone as it was recognised by the α-dimedone antibody. Concentrations of 10 and 20 
μM hydrogen peroxide caused similar levels of sulphenylation in Ero1α, however at 60 μM 
hydrogen peroxide the level of Ero1α recognised decreased. In the absence of dimedone 
there was no visible signal, again confirming that the signal was dimedone specific and 
that Ero1α was sulphenylated. 
3.3.3  Ero1α is not trapped in an active form by dimedone. 
To investigate the possibility of Ero1α re-oxidation and inactivation being induced by 
sulphenylation, the above Ero1α-Trx assay (Chapter 3.2.4) was repeated in the presence of 
dimedone (Figure 3.7). Sulphenic acid should rapidly react with dimedone and pin 
Ero1α in the reduced state rather than induce disulphide formation. This reduced state 
could then be visualised on a gel due to its decreased mobility. 50 mM dimedone was used 
in this assay rather than the 5 mM above to ensure that sulphenic acid formation would be 
quickly trapped to prevent disulphide formation. Ero1α was not trapped in this state as re-
oxidation was seen as an increase in mobility at the later time points (600-1200 s). 
Thioredoxin was oxidised completely by Ero1α, confirming that enzymatic activity had not 
been disturbed in the presence of dimedone. Furthermore, Ero1α showed the typical redox 
pattern witnessed previously (Figure 3.4) and in previous studies and, therefore, was not 
trapped in the reduced state by dimedone. 
3.4 Hydrogen peroxide induced oxidation of Ero1α.  
While dimedone was used to determine if sulphenic acid groups were formed within 
Ero1α, the ability of hydrogen peroxide to cause the direct oxidation of Ero1α was 
investigated using an SDS-PAGE based assay. Reduced Ero1α was incubated with 
hydrogen peroxide (0, 10 or 100 μM) under anaerobic conditions to prevent de novo 
disulphide generation by Ero1α. The sole source of disulphides, therefore, was 
sulphenylation of cysteine thiols. The redox state of Ero1α was monitored over the course 
of 300 s and samples were alkylated with N-ethylmaleimide (NEM) to freeze the redox 
state before SDS-PAGE analysis (Figure 3.8, upper panel). 
Under anaerobic conditions Ero1α existed in the Ox1 forrm for the duration of the assay. 
The inclusion of 10 μM hydrogen peroxide in the assay resulted in a band of increased 
mobility appearing after 10 s, and the disappearance of the reduced band. This showed that 
10 μM hydrogen peroxide caused a degree of Ero1α re-oxidation. In the presence of 100 
μM hydrogen peroxide, Ero1α was almost completely oxidised within 30 s as indicated by 
the disappearance of the reduced forms and the formation of the species with increased 
mobility.  Densitometry analysis was performed using the ImageJ software 
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Figure 3.8 – Hydrogen peroxide oxidises Ero1α. Ero1α was reduced with DTT before 
passing through a Spin Column with a molecular weight cut-off of 6 kDa to remove the 
reducing agent. The reduced Ero1α was incubated with increasing concentrations of 
hydrogen peroxide. Samples were taken at the given time points and the redox state was 
frozen with NEM.The whole assay was performed under anaerobic conditions. Samples 
were analysed via SDS-PAGE and silver stained to visualise Ero1α. The assay was repeated 
three times independently and densitometry analysis was performed to quantify the re-
oxidation of Ero1α. Representative values of Ero1α oxidation for each treatment are 
plotted against time. 
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(Schneider et al., 2012), with the proportion of oxidised Ero1α shown as a percentage of 
total Ero1α (Figure 3.8, lower panel). Hydrogen peroxide was able to directly oxidise 
approximately 70% of total Ero1α after 300 s. The assay was repeated a total of three times 
independently, with representative results shown.  
3.5 Ero1α inter- or intra-molecular disulphide exchange. 
One hypothesis for the mechanism of re-oxidation and inactivation of Ero1 is the inter- or 
intra-molecular disulphide exchange mechanism, where disulphides could be generated by 
and distributed within Ero1α, or between molecules, in order to regulate activity. This 
would be possible if a lack of reduced PDI was available and would prevent 
hyperoxidation of the ER. De novo disulphide formation at the C394-C397 active site 
provides a source of disulphides which could be distributed internally to the structural and 
regulatory disulphides via the shuttle disulphide positioned on the flexible loop region. By 
inhibiting the generation of disulphides under anaerobic conditions, the controlled addition 
of electron acceptors could re-start disulphide formation meaning the sole source of 
disulphides for the regulatory cysteines would be Ero1 itself.  
3.5.1 Ero1α cannot utilise exogenous FAD. 
Exogenous FAD has been shown to act in vitro as a terminal electron acceptor for yeast 
Ero1p in the absence of oxygen (Gross et al., 2006, Tu and Weissman, 2002). Ero1α has 
been reported to be unable to do this (Wang et al., 2009). To clarify this issue, Ero1α (2 
μM) was incubated with Trx under aerobic or anaerobic conditions, with samples removed 
at the given time points and alkylated immediately in AMS. Under aerobic conditions 
(Figure 3.9A) Ero1α was able to fully oxidise Trx. During the assay, Ero1α was reduced 
quickly by Trx, indicated by the decrease in mobility, before returning to its more oxidised 
forms at the later time points. Under anaerobic conditions (Figure 3.9B), Ero1α oxidised 
approximately 54% of the total Trx (quantified using ImageJ) and remained in a reduced 
state, seen from 10-1200 s. The assay was repeated in the presence of 200 μM free FAD. 
Under these conditions, Ero1α remained in a reduced state and Trx oxidation was 
approximately 45% of total Trx (Figure 3.9C). In the absence of Ero1α, Trx was stable in 
its reduced form (Figure 3.9D). Ero1α was unable to utilise exogenous FAD as a terminal 
electron acceptor. 
 3.5.2 Oxygen cannot fully re-oxidise Ero1α. 
With tissue oxygen concentrations around 3-6% it is possible that oxygen facilitates 
internal disulphide exchange within Ero1α itself. This potential mechanism of Ero1α re-
oxidation and inactivation was investigated using molecular oxygen as a terminal electron  
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Figure 3.9 – Exogenous FAD cannot act as a terminal electron acceptor for Ero1α. Ero1α 
was incubated under aerobic (A) or anaerobic (B) conditions with reduced thioredoxin. At 
each time point, the reaction was stopped by alkylation with AMS before analysis via SDS-
PAGE. Ero1α gels were silver stained, thioredoxin gels were Coomassie stained. C – Ero1α 
was incubated with thioredoxin under anaerobic conditions in the presence of FAD 
(200µM) before further analysis as above. D – The redox state of thioredoxin was 
monitored in the absence of Ero1α. E - Schematic diagram showing that the initially 
oxidised Ero1α is reduced by reduced thiredoxin. The thioredoxin present is completely 
oxidised by Ero1α.  
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Figure 3.10 – Oxygen drives incomplete intramolecular disulphide exchange within Ero1α. 
Ero1α was reduced with DTT before passing through a Spin Column with a molecular 
weight cut-off of 6 kDa to remove the reducing agent. Reduced Ero1α was incubated 
under anaerobic conditions before titrating increasing concentrations of oxygen into the 
assay mix. The redox state of Ero1α was frozen by alkylating with NEM, then analysed by 
SDS-PAGE in the absence of reducing agent. Ero1α was then visualised by silver staining. 
Densitometry analysis was performed on the results of three separate and independent 
experiments and mean oxidised Ero1α, as a percentage of total Ero1α per lane, is plotted 
against time. Error bars represent standard deviation. 
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acceptor. Reduced Ero1α was incubated with increasing concentrations of oxygen, from 
50-225 μM, for 300 s. Samples were taken at the given time points, alkylated with NEM, 
analysed by SDS-PAGE and silver stained. Ero1α existed in its reduced form under 
anaerobic conditions, however in the presence of oxygen (50 μM), thought to be 
approximately equal to the physiological oxygen tissue concentration, approximately 53 ± 
7.6% (standard deviation, n=3) of the Ero1α was oxidised after 300 s (Figure 3.10). 
Incubating Ero1α with 225 μM did not allow complete re-oxidation of Ero1α; indeed 
Ero1α oxidation after 300 s was approximately 47 ± 12% (standard deviation, n=3) 
oxidised. It can be concluded that internal disulphide exchange may play a role in the 
inactivation of Ero1α in vivo but is unlikely to be the main or sole mechanism. 
3.6 Discussion. 
During this study, a recombinant version of Ero1α containing an N-terminal GST and His-
tag was successfully expressed, purified and characterised. Previous studies have produced 
Ero1α with similar characteristics (Baker et al., 2008). Ero1α was successfully expressed 
in a bacterial expression system. Purification by nickel affinity and ion exchange 
chromatography yielded a clean product of approximately 55 kDa. An established method 
of confirming native folding of Ero1α is to measure the ratio of protein: bound FAD 
cofactor (Baker et al., 2008). This study produced a ratio of approximately 7:9, or 78% of 
bound FAD, hence natively folded Ero1α, and compares well to the ratio previously 
described (85%) (Baker et al., 2008). Another test of Ero1α folding is to compare the 
mobility of the reduced and oxidised forms during SDS-PAGE. In agreement with 
previous studies, a decrease in mobility was observed upon reduction of Ero1α with DTT, 
confirming the presence of disulphide bonds (Benham et al., 2000). One further test of 
folding was carried out using size-exclusion gel filtration chromatography. Ero1α exists 
mainly as a monomer of approximately 41 kDa with some dimer formation which elutes at 
approximately 87 kDa (Figure 3.2C, Appendix 1). This compares well with previous 
results(monomer: 44 kDa, dimer: 100 kDa) (Wang et al., 2009). The remaining absorbance 
peaks at 280 nm eluting at approximately 7.5 ml and 13.5 ml are most likely aggregates 
and preparation contaminants, respectively, as they do not absorb at 454 nm. 
Having confirmed that Ero1α had bound FAD, contained disulphides and existed at the 
correct size, it was possible to characterise its activity towards a number of substrates. 
Ero1α activity has previously been characterised towards DTT thus providing a 
comparison (Araki and Nagata, 2011, Wang et al., 2009). The Ero1α prepared during this 
study was comparatively active towards DTT. The results in Figure 3.3A highlight the 
necessity for Ero1α activity modulation as Ero1α activity can produce significant 
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concentrations of hydrogen peroxide in a short time. Interestingly, this hydrogen peroxide 
is unable to prevent further Ero1α activity and so does not provide a reliable regulatory 
mechanism. This lack of regulation may be as a result of using such a strong reducing 
agent as a substrate. DTT, therefore, is a good substrate to test activity of Ero1α but may 
mask any regulatory effects that are the focus of this study. 
Using PDI as a substrate for Ero1α, more information can be drawn on the regulation of 
Ero1α activity (Figure 3.3B). As expected, Ero1α shows limited activity towards PDI in 
the absence of GSH. This is consistent with previous findings (Baker et al., 2008) and is 
likely a result of available reduced substrate being consumed without regeneration of 
reduced PDI.  It is interesting that Ero1α shows limited activity towards PDI in the 
presence of 350 µM GSH. 350 µM GSH is theoretically enough to recycle the oxidised 
PDI, however the PDI redox state is sensitive to the ratio of reduced: oxidised glutathione 
(Chambers et al., 2010). This may provide an insight into the lack of recycling, hence 
Ero1α activity. The consumption of 20 µM oxygen may indicate that Ero1α is oxidising 
both active sites of 10 µM PDI and consuming 20 µM oxygen as a result, or 10 M of 
oxidised PDI may be turned over by GSH. This could potentially result in the oxidation of 
40 µM GSH, creating a GSH: GSSG ratio of approximately 16:1 (310 µM: 20 µM). In the 
presence of 1 mM GSH approximately 50 µM oxygen is consumed; theoretically 100 µM 
GSH would be required to recycle the substrate resulting in a GSH: GSSG ratio of 18:1 
(900 µM: 50 µM). Including 2 mM GSH in the chamber resulted in the consumption of 
approximately 90 µM oxygen or 180 µM GSH. This would create a GSH: GSSG ratio of 
approximately 20:1. Finally in the assay containing 10 mM GSH, the oxygen in the 
chamber was completely consumed within 200 s and so a GSH: GSSG equilibrium could 
not be established. This observation may reveal a regulatory mechanism – Ero1α activity 
may be stopped as the balance of glutathione is restored at a ratio of between 16:1 and 
20:1, or Ero1 is able to drive oxidation of glutathione until this ratio is reached. 
Furthermore, 1 mM or 2 mM GSH should provide enough reducing equivalents to 
completely consume the oxygen in the electrode. The fact that this does not occur indicates 
that glutathione is acting to shut down Ero1α activity. The glutathione ratio within the ER 
is thought to be around 10:1 and so perhaps Ero1α is responsible, in part, for this. Further 
contribution may come from other oxidative pathways such as that of PrxIV or VKOR. It 
is important to note, however, that equilibrium may not have been reached before 
completion of the assay at 900 s. This could potentially result in an underestimation of 
oxygen consumption and thus affect the glutathione ratios.  
An alternative source of Ero1α regulation in Figure 3.3B could potentially come from 
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hydrogen peroxide-mediated sulphenylation. Up to 20 M hydrogen peroxide would be 
produced in the Ero1 - PDI and assay and in the assay containing 350 M GSH; 50 M 
in the assay with 1 mM GSH; 90 M hydrogen peroxide in the assay with 2 mM GSH; and 
220 M hydrogen peroxide in the assay with 10 mM GSH. There is, therefore, the 
potential for the production of a large concentration of hydrogen peroxide within the 
chamber which may influence the redox state of PDI or Ero1, thus influencing activity 
and oxygen consumption. 
One further interesting observation is the apparent delay in reaching the maximum rate of 
oxygen consumption, or lag-phase, after initiating the reaction. This observation has been 
described previously as an Ero1 phenomenon; a consequence of regulatory disulphide 
reduction prior to enzyme activation (Araki and Nagata, 2011, Baker et al., 2008, Gross et 
al., 2006, Heldman et al., 2010, Wang et al., 2009). This lag-phase is present in assays 
using both DTT and PDI as substrates thus confirming observations in previous studies. 
The results from the thioredoxin assay in Figure 3.4 provide data in agreement with 
previous studies (Baker et al., 2008, Heldman et al., 2010). The characteristic lag phase is 
observed. Trx oxidation in this assay is quicker than in previous studies, likely due to the 
concentrations used (0.5 μM Ero1α was used previously compared to 2 μM in this study) 
(Baker et al., 2008). It is also interesting to note that Ero1α does not return to its fully re-
oxidised OX2 form in Figure 3.4, in contrast to previous studies with Ero1α (Baker et al., 
2008) and Ero1p (Heldman et al., 2010). The reasons for this are unknown. The 
appearance of a double band upon AMS alkylation of non-reduced Ero1α samples may be 
explained by incomplete alkylation, resulting in a heterogeneous population of Ero1α 
molecules. 
Characterisation of the sulphenic acid probe dimedone was carried out using peroxiredoxin 
IV as a model system. The assay depicted in Figure 3.5 successfully showed that dimedone 
reacts specifically with cysteine sulphenic acid. It also highlights the reactivity of PrxIV 
with hydrogen peroxide, as significant sulphenylation occurred in the absence of added 
hydrogen peroxide. Dimedone reactivity is confirmed to be sulphenic acid specific as 
increased hyperoxidation of PrxIV was coupled to decreased dimedone labelling. 
The labelling of Ero1α with dimedone paints a somewhat confusing picture. Under the 
conditions tested, Ero1α was clearly labelled with dimedone (Figure 3.6). At high 
concentrations of hydrogen peroxide (60 μM), dimedone-labelling of Ero1α decreases. 
This is presumably due to hyperoxidation of the cysteines and so dimedone can no longer 
react, as seen in Figure 3.5B.  However, dimedone reactivity does not interfere with Ero1α 
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regulation as Ero1α was not trapped in an active, or reduced, form by dimedone (Figure 
3.7). This would suggest that Ero1α is sulphenylated on one or more cysteine residues 
uninvolved in regulation of activity or formation of Ox1 or Ox2. The fact that activity is 
not inhibited suggests that catalytic residues (cyteines 94, 99, 394 and 397) are not 
sulphenylated. It is possible that sulphenylation occurs on one or more of cysteines 35, 37, 
46, 48, 166, 208 or 241. There may be a slight delay in the completion of Trx oxidation 
when compared to activity of Ero1α in the absence of dimedone (Figure 3.4), however it 
can be concluded that the regulatory disulphides are not modified by dimedone thus 
unlikely to be sulphenylated as part of the regulatory inactivation mechanism. 
In contrast to the data presented in Figure 3.4, Figure 3.8 clearly shows that hydrogen 
peroxide induces disulphide formation. 100 µM hydrogen peroxide induces oxidation more 
quickly than 10 µM, however the oxidised band appears smeared. This may indicate the 
formation of non-native disulphides or the incomplete formation of disulphides due to thiol 
hyperoxidation. Disulphide formation in Ero1p by 100 μM hydrogen peroxide does not 
occur, nor does the inclusion of catalase slow oxidation (Kim et al., 2012). Ero1p does not 
display peroxidase activity (Gross et al., 2006). There is currently no data which quantifies 
physiological cellular concentration of hydrogen peroxide, either at steady state or under 
stress conditions. The concentrations of hydrogen peroxide used in this study, therefore, 
are thought to be roughly physiological; 100 µM is thought to be excessive (Song et al., 
2007). 
The fact that 100 µM hydrogen peroxide induces Ero1α re-oxidation in this assay is 
interesting, as the Ero1α-thioredoxin assay (Figure 3.4) would theoretically produce 100 
µM hydrogen peroxide. This, however, does not induce Ero1α re-oxidation, possibly due 
to the gradual build up of hydrogen peroxide. The fact that Ero1α shifts from Ox1 to Ox2 
suggests that the disulphides formed are regulatory in nature as the C94-C131 disulphide is 
formed during the Ox1-Ox2 transition (Appenzeller-Herzog et al., 2008). In conclusion, 
sulphenic acid may play a role in Ero1α re-oxidation and inactivation but this mechanism 
may produce non-natively folded intermediates which would require isomerisation by the 
PDI family. 
It is interesting to note that DTT treatment is not sufficient to completely reduce Ero1α as a 
mixture of Ox1 and reduced forms can be seen (Figure 3.8 and Figure 3.10). This may be 
explained by the fact that DTT can be used as a substrate by Ero1α, thus generating 
disulphides within the Ero1α molecule.  
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The techniques used in this study to investigate the process of intramolecular disulphide 
exchange within Ero1α cannot exclude the contribution of autonomous oxidation, which 
has been described in Ero1p (Kim et al., 2012). 
The ability of Ero1α to utilise exogenous FAD was tested using an SDS-PAGE based 
assay performed under anaerobic conditions to prevent de novo disulphide formation 
(Figure 3.9). The fact that thioredoxin oxidation reaches approximately 54% is puzzling; 
theoretically if 2 μM Ero1α is present then only 14 μM Trx should be oxidised during the 
assay if there are 7 disulphides reduced in each molecule of Ero1α. A small concentration 
of oxygen may be present which could drive a limited amount of oxidation. FAD clearly 
cannot act as a terminal electron acceptor for Ero1α, directly contrasting work carried out 
on Ero1p (Gross et al., 2006) but complementing results witnessed with Ero1α (Wang et 
al., 2009). 
Addition of molecular oxygen to the anaerobic assay restores the ability of Ero1α to 
generate disulphides. Oxygen is able to induce Ero1α re-oxidation, although no increase in 
oxidation is witnessed when comparing physiological and excessive oxygen concentrations 
(Figure 3.10). Oxidation driven by oxygen is slow and incomplete compared to hydrogen 
peroxide-driven oxidation, although the oxidised Ero1α bands appear sharper. This data 
suggests that Ero1α re-oxidation and inactivation by intramolecular disulphide exchange is 
possible, but is slow and incomplete. 
Taken together, the data presented in this chapter show that Ero1α has been successfully 
expressed and purified using a bacterial expression system. Ero1α is active towards the 
substrates DTT, thioredoxin and PDI, and displays key characteristics unique to the Ero1 
family of enzymes. Ero1α is sulphenylated and reacts with dimedone. After developing a 
system where Ero1α could be stabilised in the reduced form, it was shown to be oxidised 
and inactivated by hydrogen peroxide, and slowly and incompletely oxidised by an 
intramolecular disulphide exchange mechanism. Furthermore, exogenous FAD is 
determined to be a poor terminal electron acceptor for Ero1α. 
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Chapter 4.0 
Dithiol disulphide exchange between Ero1α and ER oxidoreductases 
 
4.1 Introduction. 
4.1.1 The PDI domain structure and active sites. 
The redox activity of PDI is mediated by four thioredoxin-like domains, two of which 
contain the redox active CxxC motif. The remaining two thioredoxin-like domains are 
redox inactive but are thought to contribute to binding of substrate proteins and interacting 
partners. The PDI thioredoxin-like domains are arranged in the fashion a-b-b′-a′, where the 
a and a' domains contain a CGHC motif. The PDI active site disulphides are thought to be 
relatively unstable within the ER and are found in the reduced form at steady state. 
Dictating disulphide stability is the chemical properties of the two residues positioned 
between the active site cysteines. In PDI these residues are glycine and histidine; glycine is 
the smallest amino acid with only a hydrogen molecule sidechain, histidine has a bulky 
sidechain with delocalised electrons. These delocalised electrons are thought to disfavour 
an electron rich disulphide bond from forming, compared to other amino acids such as 
proline. The measure of the propensity for a disulphide to form is known as the reduction 
potential, where an increased reduction potential denotes a decreased stability for the 
disulphide, or a more stable dithiol. A histidine to proline mutation within the PDI CGHC 
motif lowers the reduction potential of the disulphide, which has been confirmed as PDI 
CGPC mutants are better substrates for Ero1α during oxidative protein folding (Chambers 
et al., 2010). 
4.1.2 Diversity within the PDI family. 
While PDI exclusively contains CGHC active site motifs, many other PDI family members 
have variations of this sequence, giving rise to a family of oxidoreductases with diverse 
functions. There are four main properties that differentiate between the PDI family 
members and their enzymatic activity: (i) the active site CxxC motif sequence, (ii) the pKa 
of the active site cysteines which is governed by neighbouring residues, (iii) the presence 
or absence of a glutamate-lysine charged pair for proton transfer reactions, (iv) and the 
presence of a binding site and its affinity for substrates. The CGHC is a motif found in 
many oxidoreductases, including PDI, ERdj5, PDIr, ERp57, ERp72, P5 and ERp46. ERdj5 
contains three CxPC active sites (Cunnea et al., 2003). Other active site motifs include 
CSMC in PDIr, CPAC in TMX and CPSC in TMX4. The specific functions and 
characteristics of these motifs are yet to be confirmed. Further diversity within the active 
sites includes the replacement of either the first or second cysteine within the active site for 
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a serine, as in SNDC in TMX2, CRFS in ERp44 and SKQS or SKKC in PDILT. Although 
these sequences cannot harbour a disulphide, these proteins are known to be redox active 
due to the remaining cysteine residues. ERp44 lacks the second ‘resolving cysteine’ and 
forms more stable, less transient mixed disulphides with other cysteine containing proteins 
(Anelli et al., 2003, Anelli et al., 2002). 
Further diversity within the PDI family stems from the catalytically inactive domains 
within the PDI family. PDI contains two redox inactive domains, as do ERp57, ERp72 and 
ERp27 amongst others. PDIr and ERp28 have one redox inactive domain, while ERp18, 
ERp44, ERdj5 and others lack a homologous binding domain. The significance of the 
binding domain is currently unknown but may provide a means of ensuring the PDI family 
can interact with the variety of client proteins entering the ER. 
Further structural diversity within the PDI family arises from the presence or absence of a 
fairly well conserved argninine residue which can move into the proximity of the active 
site (Lappi et al., 2004).This modulates the pKa of the active site cysteines, stabilising the 
active site N-terminal cysteine thiolate ion and destabilising the active site C-terminal 
cysteine thiolate ion. N-terminal cysteines, therefore, have a lower pKa value than C-
terminal cysteines, ensuring that nucleophilic attack by the N-terminal cysteine forms 
mixed disulphides. These mixes disulphides are then resolved by the C-terminal cysteine. 
Several factors, therefore, influence the activity and specificity of the PDI family, ensuring 
that a wide range of substrates can be oxidised or isomerised efficiently. This contributes 
to oxidative protein folding and ensures the health and fidelity of the cell. 
4.1.3 Ero1α – PDI interactions. 
The interaction between Ero1α and PDI was first described by Benham et al. in 2000 
where PDI co-immunoprecipitated with Ero1α.  This study described the Ero1α OX2-
dependent nature of the interaction, suggesting the Ero1α-PDI complex occurs specifically 
during oxidative protein folding and not during the oxidative folding steps of Ero1α 
maturation (Benham et al., 2000). Ero1α-PDI interactions are dependent on Ero1α Cys94 
(Bertoli et al., 2004). Ero1α preferentially oxidises the a′ domain of PDI (Baker et al., 
2008), similar to the oxidation witnessed in PDIp by Ero1p (Kulp et al., 2006). In cells, 
Ero1α oxidation of PDI was confirmed as oxidation of both PDI active sites increases with 
overexpression of deregulated Ero1α (Appenzeller-Herzog et al., 2008). 
The reduction potential of the PDI active site disulphides is crucial to their Ero1α-mediated 
oxidation. PDI mutants with lowered reduction potentials are oxidised more readily than 
wild type PDI (Chambers et al., 2010). 
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The PDI binding pocket is located on the b′ domain and contains a negatively charged 
surface which binds Ero1α more efficiently than the same domain from the closely related 
ERp57, suggesting specificity among the PDI family (Inaba et al., 2010). In addition, 
mutation of a cluster of positively charged residues positioned near the shuttle cysteine-
containing loop of Ero1α has an inhibitory effect on disulphide transfer with PDI. High 
concentrations of sodium chloride enhance binding of Ero1α to PDI and Triton X-100 
inhibits binding (Inaba et al., 2010). A PDI mutant containing no cysteine residues was 
able to bind Ero1α with near wild type kinetics, further evidence to suggest that non-
covalent interactions may mediate this interaction (Inaba et al., 2010). 
Docking simulations predicted that a β-hairpin structure protruding from Ero1α binds to 
the PDI hydrophobic b′ domain binding pocket. Experimental data confirmed this, as 
interactions between the two molecules were impaired upon deletion of the β-hairpin 
residues (Masui et al., 2011). Mutation of hydrophobic phenylalanine residues within the 
PDI binding pocket impaired interactions and compromised disulphide transfer between 
Ero1α and PDI, and disrupted folding of JcM in cells. 
Interactions between Ero1α and PDI have therefore been well studied and documented. 
Binding occurs exclusively between the b′ domain of PDI and Ero1α, facilitating 
disulphide transfer between the shuttle cysteines and the PDI a′ active site. These previous 
studies have investigated the binding of oxidised Ero1α and the reduced form of PDI, 
however, and so do not necessarily represent the mechanisms governing the potential 
oxidation of Ero1α by PDI. 
4.1.4 Autonomous and PDI-mediated oxidation of Ero1p. 
While the regulatory disulphides of Ero1p are known to be reduced by substrate enzymes, 
the mechanism of re-oxidation of the disulphides and subsequent inactivation of Ero1p is 
less well understood. However, PDIp and autonomous oxidation are emerging as potential 
regulators of Ero1p activity. Ero1p is capable of autonomous oxidation, where one Ero1p 
molecule oxidises another via the C100-C105 shuttle disulphide (Kim et al., 2012). PDIp-
mediated oxidation is more efficient, however, and provides a means of feedback 
regulation of Ero1p by linking Ero1p oxidation to the glutathione balance (Kim et al., 
2012). The implications of this finding are that Ero1p activity can be regulated by these 
molecules to prevent the formation of a hyperoxidising environment, which can impair 
protein folding in the ER and stress cells (Chapters 1.2.7 and 1.2.8). PDIp will be reduced 
due to the availability of nascent client proteins and the relative abundance of reduced 
glutathione – which keeps Ero1p in an active state. Ero1p works to oxidise PDIp and GSH 
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indirectly until the redox balance becomes more oxidising and Ero1p is subsequently 
inactivated through the re-oxidation of its regulatory disulphides. Regulation of Ero1α 
activity by PDI has not yet been studied. 
4.2 In vitro Ero1α re-oxidation and inactivation is carried out by specific ER 
oxidoreductases. 
With over 20 PDI family members discovered so far, many acting as oxidases to transfer 
disulphides to reduced proteins, it is possible that one or more function to regulate the 
activity of Ero1α by re-oxidising and inactivating it. This hypothesis was tested using an 
SDS-PAGE based approach, where DTT-reduced Ero1α was incubated with various 
oxidants and PDI family members at the indicated concentrations for 300 s. This was done 
under anaerobic conditions, ensuring that oxidation of Ero1α was a result of oxidation by 
the indicated oxidants or PDI enzymes. Samples from the time courses were NEM 
alkylated at the given time points and analysed by SDS-PAGE before silver staining or 
Western blotting with an α-Ero1 antibody. The Ero1α redox state was then visualised 
(Figure 4.1A). 
Ero1α remained reduced under anaerobic conditions over the duration of the assay. The 
inclusion of oxidised glutathione (10 mM) induced some oxidation of Ero1α, as did Trx 
(100 μM). ERp18 (50 μM) and PDIr (10 μM) were both able to oxidise Ero1α almost 
completely within 300 s. PDI (10 μM) and ERp46 (10 μM) were relatively more efficient 
at oxidising Ero1α, however. PDI (10 μM) oxidised Ero1α almost completely within 30 s, 
while ERp46 (10 μM) was able to oxidise it almost completely within 10 s. 
Densitometry analysis of the oxidation of Ero1α by the ER oxidoreductases PDI and 
ERp46 was carried out to quantify the percentage of Ero1α oxidised at each time point 
(Figure 4.1B). Each experiment was carried out three times independently. ERp46 oxidised 
75 ± 11% (standard deviation, n=3) of the Ero1α within 10 s, 84 ± 15% within 60 s and 91 
± 8% of the Ero1α after 300s. In comparison, PDI oxidised approximately 28 ± 15% of the 
Ero1α within 10 s, 81 ± 12% after 60 s and 89 ± 8% after 300 s. Specific oxidoreductases 
therefore can act to shut down Ero1α activity in vitro. In comparison, PDIr oxidised only 
13 ± 3% of Ero1α within 10 s, 40 ± 4% after 60 s and 72 ± 7% after 300 s. 
4.3 Investigating the PDI mediated oxidation of Ero1α.  
Interactions between Ero1α and PDI have not been studied with regards to regulation of 
Ero1α activity. Interactions during oxidative protein folding involve reduction of Ero1α by 
the PDI a′ active site and the subsequent oxidation of the PDI a′ active site. During Ero1α 
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Figure 4.1 - Ero1α is oxidised completely and rapidly by the oxidised forms of PDI and 
ERp46. A - Ero1α was reduced with DTT before removal of the reducing agent. 2μM 
reduced Ero1α was then incubated alone or with oxidised glutathione (GSSG), Trx, ERp18, 
PDI, PDIr or ERp46. Incubations were carried out under anaerobic conditions with 
samples taken at the given time points and alkylated with NEM to freeze the redox states 
of the enzymes. Analysis was carried out via SDS-PAGE with gels either silver stained or 
Western blotted. B – The redox state of various PDI family members were analysed after 
15 min incubation with 20 mM GSSG. Samples were AMS alkylated before analysing via 
non-reducing SDS-PAGE. Gels were Coomassie stained to visualise. C – Assays in A were 
repeated independently and gels were subject to densitometry quantification. Total 
oxidised Ero1α was calculated as a percentage of oxidised material/ total material and 
results were plotted against time. PDI and ERp46 oxidation of Ero1α is compared to PDIr 
and the Ero1α control assay. Error bars represent standard deviation (n=3). 
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regulation, oxidised PDI must interact with the reduced form of Ero1α; an interaction 
thought unfavourable due to the reduction potentials of the Ero1α and PDI disulphides (-
275 mV and -180 mV, respectively) (Baker et al., 2008). In favour of the regulatory 
interaction is the affinity of PDI for reduced substrates, driven by hydrophobic and 
electrostatic interactions (Masui et al., 2011). It was therefore necessary to investigate the 
mechanism of interaction between the two molecules to determine if interaction was 
mediated by the PDI b′ binding domain (Masui et al., 2011) and the a′ active site 
(Chambers et al., 2010). 
4.3.1 Ero1α oxidation by PDI active site mutants. 
By eliminating one PDI active site, any disulphide transfer between PDI and Ero1α must 
occur due to dithiol disulphide exchange with the remaining active site. Two PDI active 
site mutants, prepared previously (Chambers et al., 2010), were utilised to determine 
whether Ero1α is oxidised specifically by either domain. ΔS1 PDI has the a domain active 
site mutated from CGHC to AGHA, while ΔS2 PDI has the a′ active site mutated to 
AGHA (Figure 4.2A). Each mutated active site can no longer form the active site 
disulphide. Under anaerobic conditions, oxidised forms of both ΔS1 and ΔS2 PDI were 
incubated with reduced Ero1α and the redox state of Ero1α was monitored over time 
(Figure 4.2B). The ΔS2 mutant was able to oxidise 18 ± 0.6% (standard deviation, n=3) of 
Ero1α after 10 s, 60 ± 1% of Ero1α after 60 s, and 82 ± 12% after 300 s. The ΔS1 PDI 
mutant was able to oxidise 18 ± 10% (standard deviation, n=3) of Ero1α after 10 s, 67 ± 
10% after 60 s and 87 ± 10% after 300 s.  
To study the effect of lowering the reduction potential of the PDI active sites on the 
interaction with Ero1α, two further mutants were used. Lowering the reduction potential 
makes the disulphide more stable, thus the mutants are less likely to act as oxidases. The 
ΔS1 HP and ΔS2 HP mutants have the remaining CGHC active site histidine mutated to a 
proline (Figure 4.3A). Reduced Ero1α was incubated with oxidised ΔS1 HP or ΔS2 HP 
PDI and the redox state of Ero1α was monitored over 300 s (Figure 4.3B). Densitometry 
analysis was performed to quantify the levels of Ero1α oxidised over the time course. 
Assays were performed independently at least twice and the mean value of oxidised Ero1α, 
as a percentage of the total Ero1α per lane, was plotted against time (Figure 4.4).  
The ΔS1 HP mutant was able to oxidise 16 ± 3% (standard deviation, n=4) of Ero1α within 
10s , 57 ± 10% within 60 s and 84 ± 12% after 300 s. The ΔS2 HP mutant was able to 
oxidise 13 ± 4% (range, n=2) of Ero1α after 10 s, 13 ± 18% after 60 s and 23 ± 
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Figure 4.2 – Ero1α is preferentially oxidised by the PDI a′ active site domain. A – 
Schematic diagram showing the PDI domain structure and the cysteine to alanine 
mutations within the active sites in each of the ΔS1 and ΔS2 PDI mutants. B – Reduced 
Ero1α was incubated with oxidised PDI ΔS1 or ΔS2 mutants for 300 s under anaerobic 
conditions. Samples were taken at the given time points and alkylated with NEM to freeze 
the redox states of the enzymes. Samples were then analysed via SDS-PAGE and Western 
blot, probing with the α-Ero1α antibody. Ero1α re-oxidation by wild type PDI is included 
for comparison. 
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Figure 4.3 – Lowering the reduction potential of the PDI active sites lowers oxidase 
activity thus slowing oxidation of Ero1α. A – Schematic diagram of the PDI domain 
structure and the histidine to proline mutations in the remaining intact active sites of ΔS1 
HP and ΔS2 HP PDI. B - Reduced Ero1α was incubated with oxidised PDI ΔS1 or ΔS2 
mutants for 300 s under anaerobic conditions. Samples were taken at the given time 
points and alkylated with NEM to freeze the redox state of the enzymes. Samples were 
then analysed via SDS-PAGE and Western blot, probing with the α-Ero1α antibody. Ero1α 
re-oxidation by the ΔS1 and ΔS2 PDI mutants is included for comparison.  
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Figure 4.4 – Quantification of Ero1α re-oxidation by the PDI mutants. Densitometry 
analysis of the results presented in Figures 4.2 and 4.3 was performed to quantify 
oxidation of Ero1α as a percentage of the total, per lane, and plotted against time. The 
assays were performed and repeated independently. Error bars represent standard 
deviation (n=3) except DS2 HP mutant where error bars represent the range (n=2). 
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18% after 300 s. 
4.3.2 The role of the PDI b′ domain in Ero1α re-oxidation. 
Ero1α binds to the PDI b′ domain prior to PDI oxidation. To explore the binding 
mechanism during the regulatory interaction between Ero1α and PDI, an oxidised PDI 
binding mutant (Appendix 2) was incubated with reduced Ero1α. Samples were taken at 
the given time points, NEM alkylated and the Ero1α redox state was analysed by SDS-
PAGE and Western blot (Figure 4.5A). Densitometry analysis was performed on the 
resultant blots to quantify the oxidation of Ero1α during the time course. Oxidised Ero1α 
was calculated as a percentage of the total, per lane, and plotted against time (Figure 4.5B). 
The PDI binding mutant (BM) was able to oxidise 10 ± 6.5% (standard deviation, n=6) of 
Ero1α after 10 s, 33 ± 12% after 60 s and 67 ± 18% after 300 s.  
4.4 In vivo investigation of Ero1α re-oxidation. 
Having analysed the data from Chapters 3 and 4, it seemed that the most likely mechanism 
of Ero1α re-oxidation and inactivation would be enzymatic oxidation by members of the 
PDI family, particularly PDI and ERp46. These two enzymes rapidly and completely 
oxidised Ero1α in vitro while intramolecular disulphide exchange and sulphenylation 
mechanisms are not as efficient. This conclusion warranted the progression of investigation 
into living cells. 
4.4.1 Ero1α recovery from a DTT challenge.  
An investigation into the in vivo re-oxidation of Ero1α by several ER oxidoreductases was 
carried out. The presence of PrxIV and the Gpx7/8 enzymes within the ER should 
theoretically remove hydrogen peroxide, thus hydrogen peroxide should not affect Ero1α 
re-oxidation. The contribution of intramolecular disulphide exchange to Ero1α inactivation 
cannot be eliminated due to the availability of oxygen. It was hypothesised that Ero1α and 
the ER proteins would be reduced by treatment with DTT (10 mM). Ero1α would then re-
establish the redox balance by generating disulphide bonds de novo prior to returning to its 
OX2 conformation. It was hypothesised that overexpression of PDI and ERp46 would 
accelerate the re-oxidation of Ero1α. Cells overexpressing ERp18 were included for 
comparison, as oxidation of Ero1α by ERp18 was slow in vitro (Figure 4.1). Cells were 
treated with DTT before washing and allowing recovery over 60 min. At the appropriate 
time points, cells were washed with NEM and lysed. The Ero1α redox state was analysed 
by SDS-PAGE and Western blot (Figure 4.6). 
The results show that in untreated HT1080 cells (UNT), Ero1α existed in its fully oxidised 
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Figure 4.5 – The PDI b′ domain influences the oxidation of Ero1α. A – Reduced Ero1α was 
incubated under anaerobic conditions with an oxidised PDI mutant containing three point 
mutations which abolish binding of Ero1α. At the given time points, samples were 
alkylated with NEM before SDS-PAGE analysis and Western blotting using an α-Ero1α 
antibody. Results of Ero1α incubation alone and with wild type PDI are included for 
comparison. B – Densitometry analysis was performed on the results of the PDI binding 
mutant incubation with Ero1α. The results shown are representative of three 
independently performed assays. The percentage of Ero1α re-oxidised during the binding 
mutant assay (green) is compared to the results of wild type PDI (red) and Ero1α control 
(blue) assays. Error bars represent standard deviation (n=3). 
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Figure 4.6 – Overexpression of PDI and ERp46 do not improve Ero1α recovery from a DTT 
challenge. A – HT1080 cells or HT1080 cells overexpressing ERp46, PDI or ERp18 were 
treated with DTT (10 mM) for 5 min before washing out the DTT for the given time. 
Untreated cells (UNT) or cells treated with DPS (1mM) were included as controls. At each 
time point, cells were washed in PBS containing NEM (20 mM) to prevent further 
disulphide transfer. Cells were lysed and the supernatant resuspended in SDS sample 
buffer before analysis by non-reducing SDS-PAGE and Western blot using an α-Ero1α 
antibody (* = cross reactive band). Representative results are shown.  B – Densitometry 
analysis was performed on the results in A. Oxidised Ero1α was calculated as a 
percentage of total Ero1α, per lane, and plotted against time for each cell line tested. 
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form and ran with mobility comparable to Ero1α in DPS-treated cells. After DTT 
treatment, Ero1α ran with a decreased mobility through the gel. Within 5 min Ero1α began 
to recover back to its oxidised form and within 20 to 30 min Ero1α had recovered to its 
untreated state. Densitometry analysis of the results was performed to quantify oxidised 
Ero1α as a percentage of the total Ero1α in each lane. The percentage of oxidised Ero1α 
was plotted against time and representative values are shown for each cell line (Figure 
4.6B).  
4.4.2 Ero1α recovery from DTT in PDI, ERp46 and PrxIV knockdown cells. 
The effect of knocking down ERp46 and PDI on Ero1α recovery from DTT challenge was 
investigated to determine whether the absence of the main source of Ero1α oxidation may 
prevent or impair this process. PDI and ERp46 knockdown cells were created by 
transfecting HT1080 cells with specifically targeted shRNA constructs; the resultant 
expression levels 5 days post-transfection were quantified after lysing cells and analysing 
samples by SDS-PAGE and Western blot. Expression of each target protein was compared 
with mock transfected cells (cells transfected using scrambled shRNA, sh13). GAPDH was 
used as a loading control (Figure 4.7). Bands were quantified by densitometry analysis. 
PDI expression levels in the PDI shRNA transfected cells were 48% of control levels 
(Figure 4.7A). In cells transfected with ERp46 targeted shRNA, ERp46 expression was 
lowered to 21% of control levels (Figure 4.7B). 
In an additional knockdown assay, cells stably transfected with shRNA targeted at PrxIV 
previously prepared by Dr. Timothy Tavender were tested for PrxIV expression levels 
(Figure 4.7C). PrxIV expression in PrxIV knockdown cells were 18% of that in control 
cells. PrxIV knockdown cells were used as PDI and ERp46 rapidly reduce PrxIV in vitro 
and in cells, therefore PrxIV may be a major source of disulphides for PDI and ERp46 
(Tavender et al., 2010, Zito et al., 2010). Disrupting this disulphide source may prevent re-
oxidation and inactivation of Ero1α by these oxidoreductases. 
To address the potential issue of functional degeneracy within the PDI and ERp46 
knockdown cells, a PDI-ERp46 shRNA co-transfection was carried out. This produced 
cells with PDI expression levels of 29.5 ± 4% of control levels, and ERp46 expression 
levels between 30 ± 3% when using GAPDH as a reference (Figure 4.7D). 
Having successfully produced cells expressing lower levels of PDI, ERp46, PrxIV and 
ERp46-PDI compared to the scrambled shRNA control, these cells could be used in the 
DTT-recovery assay to determine whether or not lowered levels of these enzymes 
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Figure 4.7 – Knockdown of PDI, ERp46 and PrxIV expression in HT1080 cells. Knockown of 
A – PDI and B – Erp46 by shRNA transfection. HT1080 cells were grown to approximately 
80% confluence prior to transfection with shRNA. Cells were grown for 5 days under 
antibiotic selection to eliminate untransfected cells. Post-selection, cells were lysed and 
analysed by SDS-PAGE and Western blot probing with αPDI, αERp46 or αGAPDH 
antibodies. Densitometry analysis was performed to determine relative expression levels 
using GAPDH as a reference. C – A PrxIV stable knockdown cell line created previously 
was analysed to determine expression levels of PrxIV using similar methods to those in A 
and B. D – A PDI-ERp46 double knock down cell line was created by co-transfecting shRNA 
targeted to both oxidoreductases. Antibiotic selection was applied for 5 days post-
transfection then cell lysates were analysed as in A, B and C. Knockdown was tested and 
expressed as a percentage of expression in control cells ± standard deviation (n=3). (* = 
cross reactive band). Control cells were transfected with sh13 vector containing a 
scrambled, non-specific shRNA construct. 
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Figure 4.8 – Knockdown of PDI and ERp46 expression does not significantly affect Ero1α 
re-oxidation after a DTT challenge. A - Knockdown cells prepared as previously described 
were grown to approximately 80% confluence before a 5 min treatment with media 
containing DTT (10 mM). DTT-media was washed out with fresh media for the indicated 
time before washing for 5 min with PBS containing 20 mM NEM. Cell lysate was analysed 
via SDS-PAGE and Western blot, probing with αEro1α antibody (* = cross reactive band). 
B – Assays in A were independently repeated and densitometry analysis was performed 
to quantify levels of Ero1α oxidation. The percentage of Ero1α oxidised was plotted 
against time for each shRNA knockdown cell line. Error bars represent standard deviation 
(shPDI, n=3; shERp46, n=3; shPDI-ERp46, n=3) or range (mock, n=2; shPrxIV, n=2). C – 
Ero1α DTT-resistance in shRNA transfected cells. The mean absolute percentage of Ero1α 
remaining oxidised during DTT treatment was calculated as a percentage of the total 
Ero1α from A. Error bars represent standard deviation (shPDI, n=3; shERp46, n=3; shPDI-
ERp46, n=3) or range (mock, n=2; shPrxIV, n=2). 
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influence re-oxidation of Ero1α. Knockdown cells were treated with DTT before washing 
with media for up to 60 min. At each given time point, cells were washed with PBS 
containing NEM to freeze the redox state of Ero1α before SDS-PAGE and Western blot 
analysis. Blots were probed with αEro1α antibody (Figure 4.8A). Densitometry analysis 
was performed to quantify oxidised Ero1α as a percentage of the total in each lane, and 
values were plotted against time (4.8B). 
Results from the mock transfection show that Ero1α existed almost exclusively in the Ox1 
state at the 0 time point, with only a small fraction remaining oxidised. Re-oxidation 
reached 46 ± 4% (range, n=2) after 10 min and 85 ± 5% after 60 min. The same assay 
performed in shERp46 treated cells resulted in Ero1α oxidation reaching 39 ± 7.5 % 
(standard deviation, n=3) after 10 min and 76 ± 11% after 60 min. In PDI knockdown 
cells, 39 ± 13% (n=3) of Ero1α was oxidised after 10 min and 79 ± 28% after 60 min. 
Ero1α oxidation in PDI-ERp46 double knockdown cells reached 55 ± 15% (n=3) after 10 
min and 65.5 ± 6% after 60 min. In PrxIV knockdown cells, 38 ± 17% (n=2) of Ero1α was 
oxidised after 10 min, and 84 ± 3% after 60 min. 
One interesting result visible in Figure 4.8A was the significant portion of Ero1α, 33 ± 
13%, which remained oxidised during DTT treatment (t=0) of PDI knockdown cells 
(Figure 4.8C). The DTT-resistant band could also been seen at the 0 time point in the PDI-
ERp46 shRNA co-transfected (shDouble) cell assay; 19.8 ± 3.7% remained reduced.  In 
ERp46 knockdown cells, 6.8 ± 1.1% of Ero1α was DTT-resistant, in PrxIV knockdown 
cells 2.8 ± 2.6% and in mock transfected cells 2.8 ± 2.1%.  
4.5 Discussion. 
Enzymatic re-oxidation of Ero1α is quicker and more complete than the intramolecular 
disulphide exchange mechanism and oxidation by hydrogen peroxide (Figures 3.8 and 3.9). 
Enzymatic oxidation of Ero1α results in well-resolved bands. Ero1α is preferentially 
oxidised by PDI and ERp46 (Figure 4.1) suggestive of a specific function for these 
enzymes. High concentrations of oxidised glutathione have no direct effect on Ero1α 
activity regulation. The results imply that there may be a feedback system; Ero1α will 
oxidise PDI to drive oxidative protein folding, but PDI will oxidise Ero1α to prevent 
hyperoxidising conditions. ERp46 seems to be a more efficient oxidase of Ero1α than PDI, 
however the reasons for this are unknown given the similarities in the CxxC motifs 
between the two oxidoreductases. Furthermore, the CGHC motif is shared by ERp18 and 
PDIr and so the reason that these PDI family members are poor oxidases of Ero1α remains 
to be determined. Binding and interactions between Ero1α and the oxidases may prove 
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crucial. In the reduced state, the region of cys94-131 is unstructured in Ero1α which would 
facilitate interaction with PDI and therefore oxidation, changing redox state of Ero1a from 
OX1 to OX2 (Inaba et al., 2010). 
Interestingly, the rapid and complete oxidation of Ero1α by PDI mirrors the oxidation of 
Ero1p by PDIp (Kim et al., 2012). Aside from the differences in isoforms used during the 
studies, Kim et al. use PDIp concentrations of 20 to 50 times that of Ero1p. This study 
shows that PDI oxidation of Ero1α occurs at concentrations only 5 times higher, thus 
proving that Ero1α re-oxidation is more sensitive than previously thought. 
It is interesting to note the two separate Ero1α bands clearly visible after re-oxidation in 
the ERp18 and PDI assays (Figure 4.1, also witnessed in Figures 4.5, 4.3 and 4.2). This 
may be two separate Ero1α redox species, the identities of which could be determined by 
mass spectrometry.  
The fact that Ero1α is oxidised differentially by the PDI active site mutants (Figure 4.5) is 
somewhat expected given recent studies exposing the preferential interactions between 
Ero1α and the a′-b′ domains. Ero1α has been shown to oxidise the a′ active site of PDI 
(Baker et al., 2008, Chambers et al., 2010) during the process of oxidative protein folding. 
This study reveals a similar interaction occurs during Ero1α activity regulation, as the a′ 
active site oxidises Ero1α as well as the wild type. Oxidation of Ero1α by the a domain 
active site is slightly slower. The binding of PDI to Ero1α occurs via a protruding Ero1α β-
hairpin structure and a hydrophobic binding pocket within the PDI b′ domain (Masui et al., 
2011); the same is true during Ero1α activity regulation. It can therefore be concluded that 
a similar interaction occurs during the oxidation of Ero1α by PDI (Figure 4.1). Oxidation 
of Ero1α by the PDI binding mutant is not completely impaired, however, and so the b′ 
domain is important but not essential for regulation of Ero1α. 
Previous work has showed that lowering the reduction potential of the PDI active site, by 
mutating the sequence from CGHC to CGPC, stabilises the disulphide and enhances PDI 
oxidation by Ero1α (Chambers et al., 2010). The data presented in Figures 4.2 and 4.3 
confirm this effect, as the PDI histidine to proline mutants display impaired oxidase 
activity; the active site disulphide has been stabilised thus is less likely to be reduced by 
Ero1α. Although the data in Figure 4.4 shows small differences in the oxidase activity of 
these PDI mutants, the differences are consistent and reproducible. Interestingly, the ΔS1 
HP mutant was more able to oxidise Ero1α than the ΔS2 HP mutant, confirming that the a′ 
domain active site is more active in this respect. Taken together, this suggests that lowering 
the reduction potential of the PDI active sites results in their impaired ability to oxidise 
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Ero1α. The b′ domain of PDI seems to bind both the oxidised and reduced forms of Ero1α, 
and the a′ domain of PDI then participates in a dithiol-disulphide exchange reaction. 
Ero1α recovery from a DTT challenge was investigated in cells and generated interesting 
results (Figure 4.6). The Ero1α recovery rate is much slower in vivo than in vitro. This is 
most likely due to the large ER proteome which has been reduced during DTT treatment. 
Ero1α can only recover once its substrate proteins and the glutathione balance has been 
restored. This could also explain why there is no increased Ero1α recovery rate in the PDI 
and ERp46 overexpressing cell lines when compared to the HT1080 and ERp18 
overexpressing cell lines. 
One problem with the knockdown approach used in Figures 4.7 and 4.8 is that functional 
degeneracy exists within the ER oxidoreductases; phenotypic traits can be masked due to 
the compensatory actions of other ER proteins. Although PDI and ERp46 expression levels 
were successfully lowered, other oxidoreductases may compensate for this lowered 
expression. Previous knockdown studies on PDI have yielded variable results – from 55% 
knockdown using a similar shRNA approach (Tavender and Bulleid, 2010) to 100% 
knockdown using siRNA (Rutkevich et al., 2010), although this is questionable given the 
suggestion that the PDI gene is essential in yeast (LaMantia and Lennarz, 1993). Further 
studies suggest PDI knockdown is limited to approximately 40-50% using siRNA (Gilbert 
et al., 2006, Tian et al., 2009). Knockdown of ERp46 expression has previously been 
reported at 77% (Tavender and Bulleid, 2010); the knockdown described in this study is 
therefore comparable. Production of a PDI-ERp46 double knockdown shows that PDI 
expression is 29.5 ± 4% of mock transfected cells, while ERp46 expression is 30 ± 3%. 
The reason for slighty lower PDI expression in the double knockdown compared to the 
PDI single knockdown is unknown. ERp46 expression in the double knockdown was 
slightly higher than in the ERp46 single knockdown, which could possibly be as a result of 
compensation for the lowered PDI levels. 
After carrying out the DTT recovery assay on PDI, ERp46 and PDI-ERp46 knockdown 
cells, it became apparent that there is no significant difference in Ero1α recovery between 
transfected and mock transfected cells (Figure 4.8). This may be due to functional 
degeneracy within ER oxidoreductases or may be due to additional mechanisms acting to 
oxidise Ero1α such as hydrogen peroxide or internal disulphide exchange. A failsafe 
mechanism may be in place to prevent excessive Ero1α activity in the absence of its two 
principle oxidases. Ero1α recovery in PrxIV knockdown cells is unaffected, compared to 
mock transfected cells, and could possibly be due to the fact that PrxIV oxidation of PDI 
and ERp46 is relatively slow, occurring on the minute scale (Tavender and Bulleid, 2010), 
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and so would be unlikely to impact upon Ero1α regulation. Alternatively, the lack of 
oxidising equivalents being introduced into PDI and ERp46 by PrxIV may again be 
masked by functional degeneracy. 
Recent evidence has questioned the role of Ero1α as the main source of oxidising 
equivalents within the ER, implicating PrxIV in this process as it can drive oxidative 
folding of RNAse and is reduced by several PDI enzymes (Tavender et al., 2010, Zito et 
al., 2010). The PrxIV-PDI pathway could constitute a feedback regulation system where 
the hydrogen peroxide generated by Ero1α could be utilised by PrxIV to generate de novo 
disulphide bonds. Excessive Ero1α activity, leading to increased hydrogen peroxide 
concentrations, results in disulphide formation within PrxIV before reduction by PDI, 
ERp46 or P5. From here the disulphides could be used to re-oxidise Ero1α and prevent 
hyperoxidation of the ER environment. 
One potentially important result can be seen in Figure 4.8 and relates to the apparent partial 
DTT-resistance of Ero1α in PDI knockdown and PDI-ERp46 double knockdown cells. 
Ero1α displays lowered sensitivity to DTT reduction in cells expressing lowered levels of 
PDI, as has been suggested in yeast (Kim et al., 2012). Hydrogen peroxide-mediated or 
autonomous oxidation of Ero1α cannot be ruled out in cells and so may mask effectsof 
ERp46 and PDI knockdown on Ero1α re-oxidation. Furthermore, levels of PDI and ERp46 
may not be low enough in each of the knockdowns to see an effect; it is possible that these 
low levels of PDI and ERp46 expression are sufficient to carry out the function of re-
oxidising Ero1α. Ero1α re-oxidation in PrxIV knockdown cells does not differ significantly 
from re-oxidation in control cells. This could suggest that knockdown of PrxIV increases 
Ero1α sensitivity to sulphenylation, or more likely PrxIV involvement in this pathway is 
not significant. 
There are a number of potential caveats associated with the overexpression and knockdown 
assays carried out in Figures 4.6 – 4.8. The cell lines overexpressing ERp18, PDI, ERp46 
were not confirmed as overexpressing the relevant PDI family member, which could be 
done by Western blot. In using shRNA to carry out a transient transfection, the individual 
cells may be affected in different ways and some may express lower levels of the target 
protein than others. Furthermore, the cells may compensate for the lowered expression 
levels of specific PDI family members by upregulating expression of others. Transfection 
of the cells with shRNA could also potentially result in off-target effects such as the 
unwanted knockdown of other related PDI family members. These factors could 
potentially mask any effect during the DTT recovery assay or could produce an artefactual 
effect. 
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Taken together, the data in this chapter suggests strongly that the oxidation and 
inactivation of Ero1α is catalysed efficiently by PDI and ERp46 in vitro. Interactions 
between reduced Ero1α and oxidised PDI have been characterised and shown to be 
mediated by interactions with the PDI b′ binding domain and the a′ active site. These 
interactions can be impaired by lowering the reduction potential of the active site 
disulphides. Unfortunately the inactivation of Ero1α by PDI and ERp46 is more difficult to 
investigate in cells, as overexpression and knockdown of PDI and ERp46 did not generate 
significant acceleration or deceleration of Ero1α re-oxidation following DTT challenge. 
The results may, however, implicate PDI further in the regulation of the Ero1α redox state 
as Ero1α is less sensitive to DTT in cells with lowered PDI expression. 
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Chapter 5.0 
The roles of Ero1α and glutathione in ER redox homeostasis 
 
5.1 Introduction. 
After the landmark study by Hwang et al. in 1992, glutathione was thought to provide the 
source of oxidising equivalents for disulphide bond generation within the ER due to the 
skewed ratio of GSSG: GSH (approximately 1:10) in comparison with the cytosol (1:100). 
With a relative abundance of GSSG, it was thought that this could support oxidative 
protein folding. However, evidence is now mounting that glutathione actually provides a 
buffer not to facilitate oxidative processes, but to facilitate the reduction of the oxidative 
protein folding enzymes enabling the reduction and isomerisation of non-native 
disulphides. Glutathione has been shown to support the reduced redox states of PDI family 
members and acts to counter the oxidative power of Ero1 and hydrogen peroxide, thus 
preventing ER hyperoxidation. 
5.1.1 Glutathione provides a reducing pathway within the ER to support 
isomerisation of non-native disulphides. 
Yeast cells are able to re-establish the balance of glutathione after reductive challenge with 
DTT. This balance is dependent on the activity of Ero1 which regenerates GSSG via the 
oxidation of GSH (Cuozzo and Kaiser, 1999). Mutations in the glutathione synthesis gene, 
GSH1, complement the ero1-1 thermosensitive yeast mutant. This suggests that 
glutathione acts as a net reductant and that preventing yeast from generating GSH could 
protect the cells from the effects of a compromised oxidative pathway. Glutathione seems 
to exert an extra load on the oxidative pathway as ero1-1: gsh1 double mutant cells are 
more able to facilitate oxidative folding of CPY compared to ero1-1 cells. Removing this 
extra load allows a compromised oxidative pathway to cope. Overexpression of GSH1 
does not impair the oxidative folding of CPY, although the UPR is induced in GSH1 
overexpressing cells indicating an accumulation of unfolded proteins within the ER. 
Disrupting the GSH1 gene in ero1-1 cells results in the decreased activation of the UPR, 
while the inclusion of GSH in the growth medium of ero1-1: gsh1 cells results in an 
increased UPR induction. Glutathione therefore acts as a reductant in the yeast ER and 
opposes the oxidative activity of Ero1p. 
The reductive function of glutathione has been investigated in mammalian cells. Oxidative 
protein folding and subsequent secretion of tissue type plasminogen activator (tPa) is 
accelerated in cells overexpressing Ero1α. In glutathione-depleted buthionine 
sulphoximine (BSO) treated cells, where γ-glutamylcysteine synthetase is inhibited, 
96 
 
disulphide formation within tPa is accelerated but secretion is impaired due to the 
formation of non-native disulphides. Secretion is coupled to the resolution of these non-
native disulphides (Chakravarthi and Bulleid, 2004). Furthermore, disulphide formation 
within the JcM is accelerated in SP cells compared to intact cells. Restoring glutathione to 
the SP cell system has an inhibitory effect on folding in a concentration-dependent manner. 
Disruption of the glutathione balance with GSH-synthesis inhibitors also results in 
accelerated JcM folding although this leads to the formation of high-molecular weight 
aggregates (Molteni et al., 2004). Lower levels of glutathione therefore impair 
isomerisation and result in the hyperoxidation of the ER. This effect is likely due to the 
lack of reduction of the ER oxidoreductases required to carry out isomerisation reactions. 
GSH within the cytosol opposes the oxidative folding pathway within the ER, although this 
system can be saturated as GSH added to intact cells has no effect on JcM folding. Without 
glutathione, cells are susceptible to the powerful oxidative activity of Ero1α. 
5.1.2 Glutathione maintains ERp57 in a reduced state. 
Direct evidence of the reduction of ER oxidoreductases by glutathione has been shown 
with ERp57. Numerous oxidoreductases were confirmed to exist in a reduced state in cells, 
while ERp57 specifically was shown to recover from an oxidative challenge. This recovery 
is not seen in microsomes thus the reductive pathway is not functional within the closed 
microsomal system (Jessop and Bulleid, 2004). Recovery is restored, however, when 
microsomes are incubated in the presence of cytosolic glutathione. Carmustine-inhibition 
of glutathione reductase, thus GSSG reduction, prevents the reduction of ERp57. A similar 
effect is seen with BSO treatment, strongly suggesting that cytosolic GSH is a major 
reductant within the ER. However, this does not imply that glutathione directly reduces 
ERp57. 
Complementary data showed that ERp57 reduction is accelerated in the presence of 
glutathione, in a concentration-dependent manner. Purified recombinant ERp57 was 
oxidised using DPS and was sensitive to GSH treatment. Interaction between GSH and 
ERp57 was confirmed in vivo, thus GSH can directly reduce ERp57. Maintaining the 
intracellular glutathione pool and balance is essential, therefore, to keep members of the 
oxidoreductase family in the reduced state. Glutathione provides a reductive pathway 
within the ER which is essential to the reduction and isomerisation of disulphides during 
oxidative protein folding. 
5.1.3 The dynamic relationship between glutathione, Ero1 and PDI. 
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While glutathione contributes to the regulation of the ERp57 redox state, its influence on 
the Ero1-PDI pathway has been widely studied due to the central role of this pathway in 
oxidative protein folding. Glutathione has an indirect effect on Ero1α activity by 
modulating the redox state of PDI. Glutathione therefore acts as a redox buffer that 
governs ER oxidative capacity. Hyperoxidation of the glutathione equilibrium pushes Ero1 
towards its inactive Ox2 state, while Ero1 is pushed towards the reduced, active form when 
the glutathione balance is reducing. 
Ero1p drives oxidative protein folding in the presence of GSH, generating GSSG through 
the oxidation of PDI by Ero1p and the subsequent reduction of PDI by glutathione (Tu et 
al., 2000). Regulatory disulphides within Ero1p are reduced more slowly in BSO treated 
cells following DTT treatment, compared to untreated cells, suggesting that the presence of 
a pool of GSH can accelerate the reduction of Ero1p regulatory disulphides (Kim et al., 
2012). Glutathione, therefore, can influence the activity of Ero1p through PDI. 
Incubation of Ero1p with both PDIp and GSH enhances Ero1p reduction and activation, 
suggesting that the pool of reduced PDIp required to activate Ero1p is maintained by GSH 
(Kim et al., 2012, Sevier et al., 2007). This reaction generates GSSG in an Ero1p-
dependent fashion, as no GSSG is produced in the presence of an inactive Ero1p mutant 
(Kim et al., 2012). Furthermore, PDIp oxidation by Ero1p is fastest in a GSSG free 
environment, compared to oxidation in the presence of various ratios of GSH: GSSG. The 
initially quick rate of PDIp oxidation decreases as GSSG is produced, again suggesting this 
can influence Ero1p activity (Kim et al., 2012). The ratio of GSH: GSSG where Ero1p is 
oxidised has been estimated at 3: 1, above which Ero1p would be reduced and activated. 
The glutathione ratio therefore controls Ero1p activity through regulation of the PDIp 
redox state. The glutathione ratio at which Ero1α is oxidised has yet to be determined. 
There is a growing body of evidence to suggest that Ero1α activity is modulated by 
glutathione. After DTT treatment, Ero1α is stable in the OX1 form in cells. In the absence 
of cytosolic GSH, in SP cells, the OX2 form of Ero1α is rapidly generated. GSH addition 
to SP cells results in the slowing of OX2 formation in a dose-dependent manner. Oxidation 
of Ero1 α is due to the oxidised state of PDI in SP cells, which is counteracted by the 
presence, or addition, of GSH (Molteni et al., 2004). In BSO-treated cells expressing the 
hyperactive C131A Ero1α mutant, the hyperoxidised phenotype is exacerbated and ER 
oxidoreductases ERp57 and TMX3 exist in the oxidised form (Appenzeller-Herzog et al., 
2008). Upregulation of GSH has been described in cells expressing the Ero1α C131A 
mutant, however there is currently contradictory evidence regarding this phenomenon in 
Ero1α-overexpressing cells (Appenzeller-Herzog et al., 2008, Molteni et al., 2004). 
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Expression of a deregulated Ero1α mutant, C104/131A, leads to increased ER 
oxidoreductase oxidation which is alleviated by treatment with the glutathione precursor 
N-acetylcysteine (NAC), or aggravated by treatment with BSO (Hansen et al., 2012). The 
same result is seen in yeast cells (Cuozzo and Kaiser, 1999). GSH, therefore, buffers the 
ER oxidoreductases from Ero1α-mediated oxidation. GSH, PDI and Ero1α are involved in 
a close, elegant relationship which influences redox regulation within the ER. 
5.2 Removal of the cytosol induces PDI and ERp57 oxidation. 
5.2.1 Depletion of cellular glutathione following digitonin permeabilisation of the 
plasma membrane. 
Semi-permeabilisation of cells has been described previously and widely adopted to 
investigate the functions of glutathione and cytosolic components. Digitonin, a cholesterol-
specific detergent, acts to permeabilise cholesterol-rich membranes while leaving others 
intact. The ER and nuclear envelope both surivive digitonin treatment while the plasma 
membrane is permeabilised. By subsequently washing the semi-permeabilised cells, the 
cytosolic components can be removed, including proteins and glutathione. To confirm that 
treatment of cells with digitonin caused a release of cytosolic glutathione content, the 
glutathione content of cells was quantified in cells treated with digitonin or left untreated. 
To assay this, protein was precipitated from cell lysate before adding the soluble fraction to 
DTNB, NADPH and glutathione reductase in buffer. DTNB is reduced by GSH resulting 
in the release of 2-nitro-5-thiobenzoate which absorbs at 405 nm, thus its production can 
be followed spectrophotometrically. Glutathione reductase turns over oxidised glutathione 
thus providing a means of quantifying the total glutathione content. The initial rate of 
change in absorption at 405 nm can be compared to standard samples of known glutathione 
content, allowing quantifaction of the content in cell samples. After plotting the initial rate 
of change in absorption against glutathione content standards in nmol, a line of best fit was 
drawn (Figure 5.1). This line had the equation y = 0.3496x + 0.3113, where y is the rate of 
change in absorption and x is the glutathione content in nmol. After assaying 3 million 
cells for glutathione content, glutathione content was determined to be 7.16 ± 2.41 nmol 
(standard deviation). Assaying 3 million digitonin-treated cells resulted in a glutathione 
content of 0.77 ± 0.16 nmol, while 8 million digitonin-treated cells contained 1.50 ± 0.61 
nmol glutathione. Thus digitonin treatment of cells greatly depletes glutathione content. 
5.2.2 ERp57 and PDI are oxidised after digitonin treatment. 
The use of microsomal vesicles has been described previously to specifically investigate 
the role of glutathione in the redox maintenance of the ER oxidoreductase ERp57 
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Figure 5.1 – Glutathione content standard curve. SP cells were lysed in 1% 5-sulfosalicyclic 
acid and proteins were removed by centrifugation. Supernatant was added to a reaction 
mixture of 0.2 mM NADPH, 0.6 mM Ellman’s reagent and 1 unit glutathione reductase in 
150 mM sodium phosphate buffer. Absorbance at 405 nm was recorded and the rate of 
change of absorbance was plotted against standard glutathione content. This assay was 
carried out twice and error bars show standard deviation. The line of best fit was used to 
determine glutathione content in cells and SP cells. 
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(Jessop and Bulleid, 2004). In this study, the SP cell preparation technique was used to 
consolidate and contribute to this knowledge with the investigation of PDI and ERp57 
redox states. SP cells were created and the remaining intact ER was treated with DTT (10 
mM), DPS (1 mM) or left untreated for 10 min. Thiols were alkylated in buffer containing 
NEM (20 mM). Differential alkylation was carried out after lysing the cells, treating with 
the reducing agent TCEP and AMS. This results in the AMS modification of thiols which 
were originally in an oxidised state, and produces a greater shift in mobility between the 
oxidised and reduced forms of ERp57 and PDI. These samples were compared to the 
equivalent treatments in intact cells which were incubated in the absence of digitonin 
(Figure 5.2A). 
In DTT treated samples, both PDI and ERp57 ran faster through the gel than DPS-treated 
samples in both SP cells and in intact cells. The difference in mobility reflects either the 
absence or presence of disulphides following treatement with DTT or DPS respectively.  
PDI was approximately 36 ± 6% (standard deviation, n=3) oxidised in untreated, intact 
cells, or 79 ± 4.6% oxidised in untreated SP cells. ERp57 also displayed an oxidative shift 
between intact cells and SP cells. ERp57 was 23 ± 1% (range, n=2) oxidised in untreated, 
intact cells, or 61 ± 5.5% oxidised in untreated SP cells. The redox states of PDI and 
ERp57, therefore, shifted from reduced to oxidised during the SP cell preparation. 
The SP cell preparation contained a number of steps with several washes, therefore the 
oxidation of PDI and ERp57 could occur at a specific stage within the protocol. To 
determine at which stage the oxidation of these enzymes occurred, samples were taken at 
several time points throughout the preparation and NEM alkylated to freeze the redox state. 
They were then differentially alkylated with AMS to produce the necessary gel shift and 
analysed by SDS-PAGE and Western blotting (Figure 5.2B).  
Upon addition of digitonin, ERp57 existed in the reduced form while PDI existed as a 
mixture of reduced and oxidised species. The reason for this is unknown; however it seems 
unlikely that the PDI redox state would be altered immediately upon plasma membrane 
permeabilisation. After 5 min of incubation with digitonin, both ERp57 and PDI were 
slightly more oxidised. ERp57 and PDI were both oxidised further between the digitonin 
treatment step and the HEPES wash. ERp57 was further oxidised over the course of this 
wash step, whereas PDI seemed to be almost completely oxidised between these steps. It is 
possible to conclude that PDI and ERp57 were oxidised during the course of the SP cell 
preparation with much of the oxidation occurring between the digitonin treatment and the 
HEPES wash.  These findings were confirmed by densitometry analysis. This observation 
is interesting as the cytosolic components, which would be released during the digitonin 
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Figure 5.2 – PDI and ERp57 are oxidised during the SP cell preparation. A – SP cells or 
intact cells were treated with either DTT, DPS or left untreated for 10 min. All cells were 
then alkylated in 10 mM NEM, washed and lysed in NEM-free lysis buffer. Samples were 
then added to SDS sample buffer, treated with 10 mM TCEP and incubated with 20 mM 
AMS for 20 min. Samples were analysed by SDS-PAGE and Western blotted using α-PDI or 
α-ERp57 antibodies. Densitometry analysis was carried out and oxidised protein was 
calculated as a percentage of the total in each lane; shown as a histogram with error bars 
representing standard deviation (PDI, n=3) or range (ERp57, n=2). B – To determine at 
which point oxidation occurred during the SP cell preparation, samples were taken 
immediately upon addition of digitonin and after 5 min incubation. Samples were also 
taken during incubation with HEPES buffer at 0, 1, 2, 5 and 10 min. Samples were 
alkylated immediately in NEM before washing, differentially alkylating with AMS and 
analysing via SDS-PAGE and Western blot as above. Densitometry analysis was performed 
on the blots in B and represent oxidised PDI or ERp57 as a percentage of the total 
material in each lane. 
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treatment, are removed at this point - including glutathione which was shown previously to 
affect the ERp57 redox state (Jessop and Bulleid, 2004). We subsequently hypothesised 
that the increased oxidation of PDI and ERp57 was due to one or both of the following; the 
removal of reduced glutathione from the cytosol or oxidation directly or indirectly by 
Ero1α. 
5.3 Ero1α knockdown impairs PDI and ERp57 oxidation in SP cells. 
To test the hypothesis that Ero1α could drive oxidation of PDI and ERp57 during the SP 
cell preparation, an Ero1 knockdown cell line previously used to investigate the ER redox 
state  was used (van Lith et al., 2011). This cell line expresses only 5% of endogenous 
levels of Ero1α and so any oxidation of PDI and ERp57 will likely be from another source 
i.e. PrxIV-mediated oxidation, although the contribution of the remaining Ero1α cannot be 
ruled out. The redox states of PDI and ERp57 were investigated in SP cells, created from 
Ero1α knockdown cells, or intact Ero1α knockdown cells (Figure 5.3).  
In intact cells and SP cells treated with DPS, ERp57 and PDI both existed in an oxidised 
state indicated by their reduced mobility through the gel due to AMS alkylation. In intact 
cells and SP cells treated with DTT, both ERp57 and PDI existed as reduced species and 
ran comparatively slowly through the gel. In untreated intact cells PDI and ERp57 were 18 
± 9.7% and 10 ± 6% oxidised, respectively, however in untreated SP cells PDI was 49 ± 
4.5% oxidised and ERp57 was 26 ± 7.6% oxidised. Knocking down Ero1 expression, 
therefore, results in a decreased level of oxidation of PDI and ERp57 in SP cells. 
5.4 PDI and ERp57 redox state after cell lysis. 
Having shown that Ero1α oxidised PDI and ERp57 during the SP cell preparation, it was 
necessary to confirm that this process was enzymatic and occured on a much quicker scale 
than it would do by air oxidation. SP cells were therefore lysed immediately upon their 
preparation (after digitonin treatment and HEPES wash step) and the oxidation state of PDI 
and ERp57 was monitored over the course of 60 min. The redox state after cell lysis was 
compared to that of intact cells, SP cells after 2 min of incubation with digitonin and after2 
min of incubation in HEPES buffer. Samples were analysed via SDS-PAGE as above 
(Figure 5.4). 
The blots reveal that the redox states of both PDI and ERp57 did not shift during the assay, 
remaining reduced in each sample. This finding confirmed that oxidation of these enzymes 
was catalytic rather than being driven by air oxidation as ERp57 and PDI were both stable 
in the reduced state after cell lysis. 
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Figure 5.3 – Oxidation of ERp57 and PDI during the SP cell preparation is highly 
dependent on Ero1α. SP cells were generated using Ero1 knockdown cells. These were 
treated with DTT, DPS or left untreated for 10 min and compared to intact Ero1 
knockdown cells. All cells were alkylated with 20 mM NEM after treatment before 
differential alkylation using TCEP and AMS for 20 min. Samples were analysed via SDS-
PAGE and Western blotted using α-PDI or α-ERp57 antibodies. Densitometry analysis was 
carried out and oxidised protein was calculated as a percentage of the total in each lane; 
shown as a histogram. Error bars represent standard error (ERp57, n=3) or range (PDI, 
n=2). 
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Figure 5.4 – PDI and ERp57 are not oxidised after lysis of SP cells; confirmation that 
oxidation of the SP cell ER environment is an enzymatic process. Samples were taken 
after 2 min of digitonin treatment, after 2 min of incubation with HEPES buffer, or from 
intact cells and NEM alkylated. Samples were also NEM alkylated at 0, 5, 10, 30 and 60 
min from cells post-lysis. Alkylated samples were precipitated in 10% TCA, resuspended in 
SDS sample buffer, reduced with TCEP and differentially alkylated with AMS. Samples 
were then analysed by SDS-PAGE and Western blotted with α-PDI or α-ERp57 antibodies.  
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Figure 5.5 – PDI and ERp57 both remain in the reduced state in microsomes. Microsomes 
were prepared from HT1080 cells. Microsomes were treated with DTT, DPS or left 
untreated for 10 min before alkylating samples with 20 mM NEM. Microsomes were 
washed, treated with TCEP and differentially alkylated with AMS for 20 min. Samples 
were analysed via SDS-PAGE and Western blot using α-PDI and α-ERp57 antibodies. 
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5.5 Microsomal redox state comparison with cells and SP cells. 
Microsomes have been used in a number of previous studies to investigate the impact of 
glutathione on the ER redox state. Previous studies have suggested that ERp57 remains in 
the reduced state in microsomes, contrary to the redox state of ERp57 in SP cells. To 
clarify the redox state of ERp57 and PDI in microsomes, a similar differential alkylation 
assay to that used above was adopted. Microsomes were gifted by Greg Poet (PhD student, 
University of Glasgow), having been isolated from dog pancreas. Microsomes were treated 
with DTT, DPS or left untreated for 10 min before alkylating with NEM. Samples were 
then precipitated in 10% TCA before resuspending the protein pellet in SDS sample buffer. 
Samples were reduced with TCEP and alkylated with AMS and analysed via SDS-PAGE 
and Western blot (Figure 5.5). 
The PDI blotted samples show a marginal shift between oxidised and reduced species as 
the gel was not run as long as with previous samples. The DPS treated microsomes show 
that PDI existed in the oxidised form as it ran slightly higher than PDI in the DTT treated 
sample. In untreated microsomes, PDI ran alongside the DTT treated sample, suggesting 
that it was reduced in microsomes. The shift between the reduced and oxidised form of 
ERp57 was more pronounced and clearly shows the slower migration of ERp57 in the DPS 
treated microsomes compared to the DTT treated microsome sample. In untreaded 
microsomes, ERp57 existed in a mainly reduced state. PDI and ERp57 therefore exist in 
the reduced state in microsomes, unlike in SP cells where they are oxidised. 
5.6 Discussion. 
The data presented in Chapter 5 both confirm and contribute to knowledge surrounding the 
role of glutathione and Ero1α in ER redox homeostasis. This study confirms that treatment 
of cells with digitonin and subsequent washing with buffer strips the cells of cytosolic 
glutathione. This treatment removes approximately 90% of cellular glutathione (0.77 nmol 
in 3 million SP cells compared to 7.16 nmol in 3 million untreated cells). This is 
comparable to the glutathione content found in other cell types (Hwang et al., 1992, Ramos 
et al., 2005). This method therefore provides a system where the influence of cytosolic 
glutathione, or other cytosolic factors, on ER redox homeostasis can be investigated. 
The redox state of PDI shifts from reduced to oxidised in a glutathione-depleted 
environment (Mezghrani et al., 2001), as glutathione maintains ER oxidoreductases in a 
reduced state (Jessop and Bulleid, 2004, Molteni et al., 2004). There are a number of 
studies describing potential glutathione transport proteins and systems (Banhegyi et al., 
2003, Banhegyi et al., 1999) although a definitive report remains elusive. It is currently 
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unknown, therefore, why cytosolic glutathione alters redox states within the ER. In this 
study, the redox states of PDI and ERp57 are both confirmed to be sensitive to cytosolic 
glutathione and are oxidised in SP cells. In addition to this, the time course presented in 
Figure 5.2B shows for the first time that oxidation occurs almost immediately upon 
digitonin treatment, presumably as the plasma membrane is permeabilised and cytosolic 
glutathione is diluted into the buffer. Interestingly, this treatment alone is not sufficient to 
cause complete oxidation, as oxidation continues during the HEPES buffer incubation. PDI 
and ERp57 oxidation is therefore highly sensitive to the presence of glutathione. 
ERp57 is known to be sensitive to glutathione removal and not the removal of other 
cytosolic factors (Jessop and Bulleid, 2004). The same cannot be concluded for PDI, which 
could be further investigated by adding back cytosolic factors and monitoring their 
influence on PDI redox state. 
ERp57 seems to be slightly more resistant to oxidation than PDI during the SP cell 
preparation. This may be due to the fact that ERp57 is a poor substrate for Ero1α 
(Mezghrani et al., 2001). 
To identify the source of oxidation during the SP cell preparation, SP cells were created 
using Ero1 knockdown cells. Recent studies have questioned the contribution of Ero1α in 
ER redox homeostasis, suggesting that PrxIV may play an equal or greater role (Tavender 
et al., 2010, Zito et al., 2010). Furthermore, the fact that Ero1α is not an essential gene 
(Zito et al., 2010) would suggest that it is not such a significant source of oxidising 
equivalents. Oxidation of ERp57 and PDI in Ero1 knockdown SP cells, however, was less 
than that in HT1080 SP cells, indicating that Ero1 is a major source of oxidation during 
this process. ERp57 is approximately 35% less oxidised in Ero1 knockdown SP cells 
compared to HT1080 SP cells. PDI is approximately 30% less oxidised under the same 
conditions. These significant effects are seen in cells expressing 5% of endogenous Ero1α 
levels, thus it would be interesting to investigate the effects of an Ero1α knockout which 
may have a more profound effect on PDI and ERp57 oxidation in SP cells. These findings 
agree with, and contribute to, results previously obtained on the effects of Ero1α 
knockdown (van Lith et al., 2011).  
The results shown in Figure 5.4 confirm that PDI and ERp57 oxidation is a result of 
enzymatic activity rather than an artefactual effect of cell lysis or air oxidation. PDI and 
ERp57 are stable in the reduced state and resistant to air oxidation for over 60 min. There 
are discrepancies in the data as both PDI and ERp57 exist almost completely reduced 
throughout the time course. After 2 min of HEPES buffer incubation in Figure 5.2B, 
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ERp57 is approximately 50% oxidised, while PDI is almost fully oxidised. This is different 
from what is witnessed in Figure 5.4. An oxidised control would confirm the oxidative 
shift in mobility. This raises the question of the source of the oxidative power in cells and 
in Ero1α knockdown cells – it may be provided by the remaining Ero1α, PrxIV or by some 
other mechanism. This could be investigated by repeating the same assay in PrxIV 
knockdown or knockout cells, or in Ero1α-PrxIV double knockdown or knockout cells. 
The results in Figure 5.5 confirm data previously presented, showing that ER 
oxidoreductases exist in the reduced state in microsomes; contradicting their SP-cell redox 
state. ERp57 has previously been shown to exist in the reduced state in microsomes 
(Jessop and Bulleid, 2004). The reasons for this are likely due to the methods of 
preparation; microsomes are isolated by ultracentrifugation, whereas SP cells are 
mechanically disrupted by digitonin. The ER membrane may be affected by the detergent, 
thus producing a slightly ‘leaky’ system which could lead to differences in glutathione 
content between the two. Unfortunately separation of the PDI redox states in this assay was 
poor due to incomplete electrophoresis. 
The results presented in this chapter provide a significant insight into the influence of 
glutathione and Ero1α on ER redox homeostasis. At a time when the contribution of Ero1α 
has been questioned, it is clear that it is a source of significant oxidation within SP cells. 
Oxidation of ER oxidoreductases is shown to be a catalytic process occurring upon 
removal of cytosolic factors, most importantly glutathione. This implies that cytosolic 
glutathione may ultimately influence the oxidative protein folding of nascent proteins 
within the ER. The results also highlight the fact that microsomes and SP cells, although 
both glutathione-depleted, differ significantly with regards to ER oxidoreductase redox 
states. 
108 
 
Chapter 6.0 
Conclusions and future work 
 
6.1 General discussion. 
This novel study aimed to investigate the mechanism of Ero1α re-oxidation and 
inactivation. Having tested the three hypotheses, listed in chapter 1.4, it is clear that 
although hydrogen peroxide and internal disulphide exchange can catalyse the oxidation of 
Ero1α, the most rapid and efficient mechanism is oxidation by specific ER 
oxidoreductases. At equimolar concentrations of the potential oxidant molecules, internal 
disulphide exchange seems to be the least favourable mechanism of oxidation, while 
oxidation by PDI and ERp46 is most favourable. It is interesting to note that, in vitro, 
Ero1α is more sensitive to regulation by PDI than has been previously reported (Kim et al., 
2012). This study reveals that Ero1α is completely and rapidly oxidised by PDI at a ratio of 
2 μM Ero1α: 10 μM PDI, a much more physiological ratio than that tested on Ero1p (2 
μM; 50 μM). As Ero1α oxidation by hydrogen peroxide and internal disulphide exchange 
is shown to be possible, contribution of these mechanisms to the in vivo regulation of 
Ero1α activity cannot be ruled out under the conditions tested in this study. Furthermore, 
autonomous oxidation by Ero1α cannot be discounted by the findings of this study. PDI, 
ERp46, hydrogen peroxide and internal disulphide exchange may work together to prevent 
excessive Ero1α activity, however PDI and ERp46 would likely drive the vast majority of 
oxidation. This would explain, in part, the lack of effect of PDI and ERp46 knockdown on 
Ero1α re-oxidation. 
As PDI is a known isomerase, it may be possible that non-native disulphides formed by 
sulphenylation of Ero1α regulatory cysteines could be isomerised by PDI, thus 
contributing to the overall goal of preventing Ero1α activity. Alternatively, hydrogen 
peroxide may cause oxidation of the glutathione pool throught the glutathione peroxidase 
enzymes. An increased ratio of oxidised: reduced glutathione would influence the PDI 
redox state, thus preventing Ero1α activity through a lack of substrate or by directly 
oxidising the regulatory disulphides. It is entirely possible, and indeed sensible, that more 
than one mechanism exists to regulate Ero1α activity, considering the potentially dire 
consequences of hyperactivity. Glutathione is likely the ‘master governer’, as glutathione 
influences the redox state of PDI which can ultimately reduce or oxidise Ero1α. 
This study also raises the question of a possible feedback loop existing between ERp46, 
PDI and PrxIV. This feedback loop would involve the hydrogen peroxide produced by 
Ero1α acting as an oxidant to create disulphide bonds within PrxIV. As PDI and ERp46 are 
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known to reduce PrxIV (Tavender et al., 2010), the dislphides could be passed from PrxIV 
to PDI or ERp46 and on to Ero1α, thus preventing further hydrogen peroxide production. 
The 2000 Benham et al. study suggested that PDI prefers to bind a fully folded Ero1α, and 
did not bind well to a C391A mutant which migrated as a diffuse smear during SDS-
PAGE. This data would contradict the findings of this study; however there are important 
differences in the redox states of Ero1α and PDI which should be taken into account. 
Crucially, in cells, PDI would be reduced and would interact with oxidised Ero1α, unlike 
the conditions tested during this study. Furthermore, PDI is known to interact with C94 
which could potentially be obscured or inaccessible in the smeared, potentially misfolded 
C391A mutant. 
Interestingly, in addition to the investigations of Ero1α oxidation by PDI, this study adds 
further evidence that glutathione, Ero1α and PDI are inextricably linked. Lowering PDI 
expression by shRNA knockdown decreases Ero1α sensitivity to DTT; Ero1α is not 
reduced as efficiently in PDI deficient cells. Although knockdown of PDI in this study was 
limited to between 50 and 70%, a significant effect on Ero1α reduction by DTT was 
witnessed; Ero1α was only approximately 80% reduced by DTT. This is in agreement with 
the hypothesis that Ero1α redox state is controlled by glutathione via PDI. 
Another interesting result from this study is the fact that Ero1α contributes significantly to 
ER redox homeostasis. Combining results from the oxygen consumption assay (Figure 3.3) 
and the ERp57 and PDI redox state assay in Ero1 knockdown cells (Figure 5.3), it is clear 
that Ero1α influences the oxidised: reduced glutathione ratio, via oxidation and recycling 
of PDI, until the glutathione ratio approaches approximately 1: 20. This is approximately 
half of the predicted ER glutathione ratio of 1: 10. Furthermore, Ero1α accounts for at least 
approximately 35% of ERp57 oxidation and 39% of PDI oxidation in SP cells. It can be 
concluded, therefore, that Ero1α accounts for between 35% and 50% of the oxidation of 
PDI, ERp57 and glutathione within the ER. This may suggest why Ero1α is necessary for 
cells to recover from DTT treatment (van Lith et al., 2011). 
This study contributes significantly to the field of ER homeostasis and oxidative protein 
folding as it provides novel data to suggest that Ero1α activity can be rapidly and 
efficiently controlled specifically by PDI and ERp46. It also provides evidence to suggest 
that hydrogen peroxide and internal disulphide exchange, or autonomous oxidation, may 
also play a role. Furthermore, the data provides a novel insight into the interaction between 
oxidised PDI and reduced Ero1α, an interaction that has never been studied previously in a 
published article. This study implicates the a′ and b′ domains of PDI in this interaction. 
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The contribution of Ero1α to redox homeostasis in cells and in SP cells has been partially 
quantified, and found to be significant with respect to the redox state of important ER 
oxidoreductases. This study also highlights the differences in the redox states of PDI and 
ERp57 between microsomes and SP cells – the reasons or which are yet to be discovered. 
6.2 Future work. 
A number of experiments could be performed to further investigate the findings of this 
study. With relation to the hydrogen peroxide induced sulphenylation of Ero1α, it may be 
possible to determine which regulatory cysteines, if any, are particularly susceptible to 
sulphenylation. This could be done by titrating increasing concentrations of hydrogen 
peroxide then using mass spectrometry to define the redox state of Ero1α. Low 
concentrations of hydrogen peroxide may induce specific regulatory disulphide formation. 
Likewise, a similar approach could be used to determine if any of the regulatory 
disulphides are particularly susceptible to oxidation by PDI or ERp46, or by internal 
disulphide exchange or autonomous oxidation. 
Mass spectrometry would be a useful approach to determining the disulphide patterns in 
Ero1α during the activity assay with Trx. This could be used to characterise the reductive 
and oxidative steps that occur during the activity cycle, in a similar manner to that carried 
out on Ero1p (Heldman et al., 2010). 
It would perhaps be beneficial to determine the concentrations of hydrogen peroxide 
produced in the assays using the oxygen electrode. If equal concentrations of hydrogen 
peroxide are generated and recovered, this would be a strong indication that sulphenylation 
does or does not play a role in Ero1α oxidation. 
As an additional control to confirm that cytosolic factors are removed during the SP cell 
preparation, the removal of well known and characterised cytosolic proteins could be 
followed by Western blotting samples before and after digitonin treatment and HEPES 
buffer wash. A more global approach could be adopted by measuring protein content with 
Bradford’s reagent before and after the SP cell preparation. 
To investigate the contribution of other oxidative processes during the SP cell preparation, 
it would be beneficial to determine the redox states of PDI and ERp57 in SP cells 
generated from, for example, PrxIV knockdown or knockout cells. A similar assay could 
be carried out in Ero1-PrxIV double knockdown cells to quantify the contribution of both 
oxidative pathways. 
To determine whether autonomous oxidation occurs with Ero1α, a C394/397A active site 
mutant could be used in conjunction with a myc-tagged Ero1α, similar to the assay carried 
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out with Ero1p (Kim et al., 2012). The redox state of the C394/397A mutant could be 
followed during incubation with the myc-tagged version, having selectively removed the 
myc-tagged version by immunoprecipitation prior to Western blot. 
Another potentially interesting assay could be done with a C94A Ero1α mutant, where its 
interaction with the oxidised form of PDI would indicate whether PDI oxidises the shuttle 
cysteines which then distribute disulphides to the regulatory cysteines, or whether PDI 
directly oxidises the regulatory cysteines. 
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Appendix 1 . 
Size exclusion gel filtration calibration curve. 
Before analysing Ero1α by size exclusion gel filtration chromatography, a calibration 
curve was calculated using proteins of known molecular weight. Cytochrome C (12.3 
kDa), ribonuclease A (13.7 kDa), ovalbumin (43 kDa), bovine serum albumin (67 kDa) 
and thyroglobulin (669 kDa) were loaded onto the column and their elution volumes 
recorded. Blue dextran was loaded onto the column to calculate the void volume of 7.8 ml. 
The column volume is 24 ml.The Kav value for each elution volume was calculated using 
the equation: 
Kav  = Volume of elution – Void volume 
             Column volume – Void volume 
The Kav value was plotted against the log of the molecular weight for each protein and the 
line of best fit was drawn (Appendix 1), with the equation: 
 y = -0.3106x + 1.8825 
where y is the Kav value and x is the log value of the molecular weight. This equation was 
then used to calculate the molecular weight of Ero1α after obtaining its elution volume. 
y = -0.3106x + 1.8825
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Appendix 2. 
PDI wild type and binding mutant purification. 
Wild type PDI was expressed and purified as described in Chapter 2.4.2. Analysis of 
samples taken before and after induction show that PDI expression is induced by IPTG 
(Appendix 2A, Lanes 1 & 2) as PDI can be seen as a band running at approximately 55 
kDa. Cells were lysed and centrifuged at high speed to remove insoluble matter (Lane 3). 
This clarified lysate was then loaded onto a HisTrap column, and a sample of unbound 
material from the flowthrough was taken (Lane 4). Comparatively little PDI remains 
unbound, whereas the majority of E. coli proteins are unbound. After a linear gradient 
elution with up to 500 mM imidazole, bound material is released and contains PDI. Lanes 
5 and 6 correspond to protein containing fractions which were eluted. 
 In addition to the wild type PDI enzyme, a PDI binding mutant used in previous studies 
(Nguyen et al., 2008) was purified from a plasmid vector kindly gifted by Prof. Lloyd 
Ruddock. This binding mutant contains a His-tag and three point mutations that abolish 
binding of PDI to substrates (I272A, D346A, D348A). The plasmid was expressed in 
Origami B (DE3) pLysS E. coli cells. The 55 kDa band that appears post-induction 
(comparing Appendix 2B, lanes 1 and 2) corresponds to the molecular weight of PDI. Cells 
were lysed (lane 3) and clarified by centrifugation (lane 4). After washing the column, A 
number of contaminating bands persisted after HisTrap elution (lanes 6 – 8). Size 
exclusion gel filtration was able to remove a number of these contaminants although one 
contaminating band exists at approximately 26 kDa (Appendix 2C). This may be a 
cleavage product or a remaining E. coli protein. 
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Appendix 2 – SDS-PAGE analysis of the expression and purification of wild type PDI and 
PDI binding mutant. A – Wild type PDI was expressed in Origami E. coli bacteria with 
samples taken before and after induction with IPTG (lanes 1 and 2). Cells were lysed and 
clarified (lane 3) before loading onto a HisTrap column. Unbound material (lane 4) 
contained little PDI; PDI was eluted in imidazole-containing buffer (lanes 5 & 6). B – 
Expression and purification of the PDI binding mutant by nickel affinity. The PDI binding 
mutant was purified using a HisTrap column. Samples were taken before and after 
induction (lanes 1 & 2), and clarifying the cell lysate (lane 3). Material remaining unbound 
to the nickel-agarose column contained little PDI (lane 4). The column was washed (lane 
5) prior to elution with imidazole-containing buffer. Protein-containing fractions were run 
to determine which contained the PDI mutant (lanes 6, 7 & 8). C – Removal of 
contaminants from the PDI binding mutant preparation by size-exclusion gel filtration. 
Fractions containing PDI from the HisTrap purification were pooled and concentrated 
(lane 1) before passing through the gel filtration column. Samples from the protein 
containing fractions were analysed by SDS-PAGE (lanes 2 – 7). 
 
 
